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The primary aims of this thesis were to 1) identify the modality of exercise which is 
most effective for improving glycaemic control in women at risk and diagnosed with 
gestational diabetes mellitus (GDM); 2) to determine the influence of maternal obesity 
and degree of glucose intolerance on neonatal hypoglycaemia and birth-weight over 
the 90th percentile; 3) to design a reliable non-invasive and non-time-consuming 
technique of measuring abdominal visceral and subcutaneous tissue in early pregnancy; 
4) investigate the use of parameters of body composition as an early detector or risk 
stratification tool for GDM. 
A systematic literature review was undertaken to identify modality of exercise in the 
blood glucose control of women with or at risk of GDM. Initially, 428 journal articles 
were considered, with 12 included in the final synthesis. Interventions in women at risk 
of GDM were overall more successful in improving blood-glucose parameters, these 
lasted a duration of 10-24 weeks.  
As part of a retrospective study in a GDM cohort, data pertaining to pregnancy risk, 
biochemistry results from 75g-oral glucose tolerance test (OGTT), as well as other 
maternal and neonatal pregnancy outcomes were abstracted from patient medical 
records retrospectively (n=303). Maternal obesity, but not degree of glucose 
intolerance increased occurrence of neonatal hypoglycaemia. Multiparous women had 
greater risk of neonates born large for gestational age. 
In a prospective observational trial, anthropometric measures including 8-point 
skinfold measurements and abdominal subcutaneous and visceral fat measured via 
ultrasound were collected (n=234). As part of this, repeated measures of abdominal 
adipose tissue and its constituent components were measured via ultrasound to develop 
and define reliability and reproducibility of a technique to be utilized in practice (n=30). 
The results from this prospective study, found that parameters of maternal body 
composition early in pregnancy, in particular abdominal visceral adiposity could be 
used as a tool to stratify women at risk of developing GDM. This can be used to identify 
women at risk of GDM early in pregnancy to apply targeted preventative lifestyle 
interventions. The findings from this thesis can inform future studies in the 
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Gestational diabetes mellitus (GDM) is hyperglycaemia with its first onset (or 
detection) during gestation without prior diabetes diagnosis and normally resolves 
postpartum, as defined by the World Health Organisation (Alberti and Zimmet 1998). 
It is detected through risk-based selection for diagnostic testing at week 30 gestation in 
pregnancy. Diagnosis involves ingestion of 75g of glucose by the pregnant women, and 
blood glucose samples taken in the fasted state, followed by one and two hours post 
ingestion. Where the response of the blood plasma glucose levels are out-with the 
normal range, then GDM is considered established and treatment begins for this patient.  
Medical therapy from diagnosis consists of nutritional therapy and pharmacological 
intervention to obtain and maintain glycaemic control. Treatment has been shown to 
have positive results in the management of this condition, evidences by the attenuation 
of complications (Tieu et al. 2014). The importance of prenatal glycaemic control and 
weight management engaging in exercise and nutrition manipulation is recognised in 
practice too. The ‘Royal College of Obstetricians and Gynaecologists’ (RCOG), as well 
as the ‘American College of Obstetricians and Gynaecologist’ (ACOG), both endorse 
the participation of pregnant women in aerobic and strength-conditioning (resistance) 
exercise,  with the goal of maintaining a good fitness level, as part of a healthy lifestyle 
during pregnancy (ACOG 2015, RCOG 2019). Despite multiple interventions over the 
last decade, the most effective form of lifestyle management of dietary and physical 
activity behaviours for the prevention of GDM remains undetermined (Bain et al. 2015, 
Shepherd et al. 2017, Griffith et al. 2019). 
The cause of GDM is still not known, however early detection is important in order to 
manage the condition and reduce the risks associated with excursions of blood glucose 
levels. It is known that lifestyle factors have a large influence on the likelihood of a 
person to develop GDM during their pregnancy. In fact, women who are non-
Caucasian, have a family history of diabetes, advancing age, and obesity all have a 
higher risk of developing this disorder.  
Maternal obesity has been linked to increased morbidity and mortality in pregnancy 
placing both the mother and infant at risk in the short and long term (Cedergren 2004, 
Dodd et al. 2011). Large population studies examining pregnancy outcomes, based on 
the World Health Organisation BMI sub-classifications (WHO, 2013) of obesity, found 
a direct relationship with increasing risk of adverse outcomes. These included GDM, 
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hypertensive disorders, caesarean section, macrosomia, admission to neonatal intensive 
care unit and neonatal hypoglycaemia (Catalano and Hauguel-De Mouzon 2011, Dodd 
et al. 2011, Catalano et al. 2012, Scott-Pillai et al. 2013). In addition, women in the 
highest obesity group are at risk of additional adverse outcomes, including stillbirth, a 
longer postnatal hospital stay, and wound problems following caesarean delivery 
(Wloch et al. 2012). Maternal obesity has also been linked to negative perinatal 
outcomes in glucose tolerant, as well as glucose intolerant pregnancies. Thus, 
establishing it as an independent risk factor (Catalano et al. 2012, Wahabi et al. 2014).  
These studies are especially relevant as worldwide rates of obesity are increasing 
(Gallus et al. 2015), with this trend exists amongst the pregnant population too (Griffin 
et al. 2000). This rise in obesity is presenting with a concurrent increase in prevalence 
of pregnancies complicated with gestational diabetes mellitus (GDM), with a reported 
prevalence of 17.8% globally (Sacks et al. 2012a), and 13.2% in Ireland (Ali et al. 
2013). These figures are of concern, as obesity and GDM are independently associated 
with an increased risk of complications in both mother and foetus (Metzger et al. 2008, 
Catalano 2010, Catalano et al. 2012).  
In addition, both obesity and GDM have been shown to increase insulin resistance 
(Catalano 2010). The glucose intolerance that develops in pregnancy resulting in GDM 
is a combination of metabolic defects via a decreased tissue insulin sensitivity, together 
with an inadequate insulin response (Buchanan and Xiang 2005). The Pederson 
hypothesis (Pedersen 1952) suggests that this insulin resistance produces high maternal 
blood glucose, which subsequently crosses the placenta, stimulating excess foetal 
insulin production resulting in excess foetal growth. Obesity and the accumulation of 
adipose tissue associated with pregnancy is thought to contribute to the development 
of GDM through various pathways (Buchanan and Xiang 2005). During pregnancy, 
both adipose and muscle mass play an antagonistic role in insulin sensitivity (Wolfe 
2006, Srikanthan and Karlamangla 2011, Xiang et al. 2015). Body fat and muscle tissue 
in the body play an important role in how well glucose is utilized in the body. 
Subcutaneous and visceral adipose and its distribution around the body may play a role 
in the level of risk constituted. Despite BMI being criticised due to its inability to 
provide information on components of body composition, it is used as a risk-
stratification tool in pregnancy to identify women at risk of developing GDM (Farah et 
al. 2011, Farah et al. 2012, Most et al. 2018). Quantifying these parameters may 
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provide a more accurate risk factor than the currently used BMI, and therefore 
potentially be an early identification tool for risk stratification of GDM early in 
pregnancy. 
In addition to body composition, engaging in exercise is also known to play a role in 
insulin sensitivity. Exercise improves insulin sensitivity and insulin-stimulated muscle 
glucose uptake, both of which improve glycaemic control (Ruchat and Mottola 2013). 
It lowers blood glucose concentration via two distinct mechanisms: the contraction-
mediated pathway, and the insulin-stimulated pathway (Hawley and Lessard 2008). 
The physiological mechanisms involved in increasing insulin sensitivity include 
increased number of insulin-sensitive glucose transporters (GLUT-4), enhanced 
response of GLUT-4 to insulin and increased glycogen synthase activity, all within 
skeletal muscle. These work in combination to lower capillary glucose concentrations. 
The underlying mechanisms surrounding this are described in-depth elsewhere 
(Golbidi and Laher 2013). 
Modality, frequency, and duration of exercise are important components of exercise 
prescription and need to be defined in order to be of practical use to be prescribed in 
pregnancies both ‘at risk’ and those with a clear diagnosis of GDM. As skeletal muscle 
is the major source for insulin-stimulated glucose uptake, any treatment targeted to 
improve glucose uptake in this tissue will improve whole-body insulin sensitivity.  
The metabolic benefits of exercise, specifically during GDM pregnancy, are thought to 
be due to changes affecting pathways which influence insulin sensitivity, adipokines 
and reduction-oxidation reactions (Golbidi and Laher 2013). Aerobic and resistance 
exercise trigger various metabolic pathways to elicit metabolic benefits when 
performed prior to pregnancy (Bain et al. 2015) and as part of medical therapy for 
glycaemic management in type II diabetic patients (Thomas et al. 2006). Some research 
has shown that the metabolic benefits and protective effects are dose-dependent 
(Warburton et al. 2006) leading some studies to turn their focus to energy expenditure 
(Callaway et al. 2010, Kumareswaran et al. 2013). However, studies investigating the 
effects of differing modality of exercise on several metabolic markers and 
compartmental changes in body composition show that the metabolic benefits are 
specific and diverse according to modality (Ibanez et al. 2005, Dreyer et al. 2006, 
Rattarasarn 2006, Dreyer et al. 2010, Ku et al. 2010).  
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Aerobic exercise may work best for increased uptake of glucose into the muscle and 
reducing fat mass (reduced adipokine and leptin production). However, resistance 
exercise may be more effective at increasing lean muscle, and thus basal metabolic rate, 
and therefore may have its place in the management of GDM pregnancies, in terms of 
long-term maternal outcomes and their risk of developing type II diabetes mellitus 
(Kim et al. 2002). Previous studies have suggested that the maternal environment, in 
particular reduction in maternal insulin sensitivity, contributes significantly to foetal 
growth (Scholl et al. 2001). Regular aerobic exercise, through an effect on maternal 
insulin sensitivity, may influence offspring size by regulating nutrient supply to the 
foetus. Given the importance of exercise highlighted above, in this thesis, exercise is 
considered throughout this thesis. Initially, it is considered in the systematic review 
(chapter 3), posing the question of which modality might be best for women with or at 
risk of GDM, and later (chapter 6) as a potential confounder when exploring the 





1.2 Thesis aims 
1. To determine which modality of exercise is best for controlling blood glucose 
parameters in women at risk of GDM and diagnosed with GDM. 
2. To understand the relationship between maternal obesity and degree of glucose 
intolerance on occurrence of neonatal hypoglycaemia and birth weight within a 
GDM cohort. 
3. To design a reliable, non-invasive and non-time-consuming technique of 
measuring abdominal visceral and subcutaneous tissue in pregnancy. 
4. To investigate the use of parameters of body composition as an early detector 
or risk stratification tool for GDM. 
1.3 Thesis Objectives 
1. To conduct a systematic review on the different exercise modalities to 
determine their effect on blood glucose parameters in women at risk of GDM 
and diagnosed with GDM. 
2. To determine the pregnancy risk and outcomes in a GDM cohort. 
3. To examine the relationship between risk of neonatal hypoglycaemia between 
women with obesity (BMI≥30kg/m2) versus non-obese (BMI<30kg/m2) 
women, in a GDM cohort. 
4. To examine the relationship of maternal BMI to glucose intolerance (PGAUC 
of OGTT) in a pregnant cohort with GDM. 
5. To examine the relationship between maternal BMI, and maternal glucose 
intolerance (PGAUC of OGTT), to neonatal percentile birth weight in a 
pregnant cohort with GDM. 
6. To test the inter-tester and intra-tester reliability of measuring abdominal 
subcutaneous and visceral fat via ultrasound. 
7. To describe the anthropometrics and activity levels of pregnant women at ~12 
weeks gestation. 
8. To explore the association between measures of body composition in early 
gestation, on maternal glucose intolerance level later in gestation and neonatal 
weight at birth. 
9. To determine a prediction model built with body composition parameters to be 
used as an early risk identification tool for GDM. 
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1.4 Thesis structure 
This thesis explores the use of body composition measurements as a risk stratification 
tool in early pregnancy. Each chapter informs subsequent chapters and therefore the 
direction of the thesis. A brief introduction to the topic was provided in this chapter. A 
broad overview of the current literature is presented in Chapter 2; outlining the 
pathophysiology underpinning GDM, diagnostic criteria, management, changes in 
body composition, and methods as well as challenges of quantifying body composition 
during pregnancy and early predictors of GDM. Chapter 3 contains a focused piece of 
writing on the effect of exercise on blood glucose control in a pregnant population 
identified to be at risk and diagnosed with GDM. This was published in Obesity Science 
in Practice (Appendix J) and presented at the DIP2017 Diabetes in Pregnancy, 
Barcelona. Chapter 4 presents data from a retrospective cohort study on pregnancies 
affected by GDM (n=303). In this chapter, maternal obesity and degree of glucose 
intolerance are examined in relation to their association with neonatal pregnancy 
outcomes, namely the occurrence of neonatal hypoglycaemia and infants born large for 
gestational age (LGA). This chapter has been published in the European Journal of 
Paediatrics (Appendix K). Chapter 5 delves into the components of abdominal fat 
(subcutaneous and visceral adipose) and their relationship to metabolic health, and tests 
the intra-tester and inter-tester reliability of a specific methodology for the 
measurement of abdominal adipose tissue in a pregnant cohort at 12 weeks gestation 
(n=30). This technique was employed in chapter 6. These findings have been published 
in BMC Medical Imaging (Appendix L). Findings from both chapters 4 & 5 have been 
presented at DIP2019 Diabetes in Pregnancy, Florence. Chapter 6 presents data from 
a large prospective observational study in pregnancy (n=235). This chapter explores 
the relationship between measures of body composition and physical activity with 
degree of glucose intolerance and adjusted birth percentile initially, and subsequently 
using binary classifier of GDM diagnosis and infant born LGA. A further analysis with 
a prediction model built with known risk factors and parameters of body composition 
for the prediction of GDM is presented. This work will be presented at the 22nd 
European Congress of Endocrinology (ECE 2020). Finally, Chapter 7 concludes the 
thesis with a summary of the research presented, tackling study limitations, and 








2.1 Overview of pathophysiology of Gestational Diabetes Mellitus  
Gestational diabetes mellitus (GDM) is hyperglycaemia with its first onset (or 
detection) during gestation without prior diabetes diagnosis and normally resolves 
postpartum, as defined by the World Health Organisation (Alberti and Zimmet 1998). 
The placenta is the foetal organ which connects mother and foetus and serves as a 
source of life for the unborn baby during its development by transporting maternal 
nutrients for foetal growth, providing an immunological barrier and thermoregulation 
for the foetus by dissipating energy resulting from foetal metabolism (Hiden and 
Desoye 2010). The placenta also exerts its influence on the mother, by synthesizing 
hormones and growth factors to facilitate maternal adaptation to pregnancy. The 
position and role of this organ implies that it will influence and be influenced by 
hormones, growth factors and metabolites present in both circulations (Hiden and 
Desoye 2010)  
Pregnancy induces decreased insulin sensitivity of tissues through diabetogenic effects 
of placental hormones- mainly cortisol and progesterone- that interfere with post-
insulin receptor signalling pathways. However, during normal pregnancy, research 
demonstrates that there is an increase in insulin resistance which starts from mid-
gestation and increases throughout the third trimester (Buchanan and Xiang 2005). The 
increase in insulin resistance is thought to be as a result of increased maternal adiposity 
(adipokines), as well as the insulin de-sensitizing effects of placental products- these 
being human placental lactogen, placental growth hormone and TNF- α  (Buchanan 
and Xiang 2005). To compensate for this, β-cells -specialised cells located in the 
pancreas- display an element of plasticity by increasing the production of insulin to 
counteract these effects resulting in small changes in circulating blood glucose relating 
to the large changes in insulin sensitivity (Buchanan and Xiang 2005). In pregnancies 
affected by GDM, excess maternal adiposity contributes to more adipokine production 
by adipocytes, as well as increased placental hormones contributing to increased insulin 
resistance, which is already present in a normal pregnant physiological state. The β-
cells will compensate for this up to a certain extent, at which point insulin resistance 
outweighs the β-cell compensation, resulting in increased blood glucose in the mother.  
The stress on these β-cells over a long period causes them to exhibit a loss of function, 
resulting in weight gain. The weight gain further exacerbates the now persistent insulin 
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resistance. If this vicious cycle is not broken through pharmacological or lifestyle 
intervention to reduce post-partum weight retention, eventually the β-cells lose as much 
function resulting in the development of type II diabetes (Buchanan and Xiang 2005). 
The process is illustrated in Figures 2.1 and 2.2.
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Figure 2.1 Schematic comparison of contributors to β-cell compensation in normal pregnancies and those affected by GDM in 
response to insulin resistance as explained by Buchanan and Xiang (2005)  
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Figure 2.2 Diagrammatic representation of euglycaemia throughout normal pregnancy and dysglycaemia resultant of 
insufficient β-cell compensation during GDM pregnancy 
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2.2 The diabetic intrauterine environment: Short and long-term adverse 
maternal and foetal outcomes in pregnancies complicated by GDM  
Overt diabetes mellitus during pregnancy is associated with significantly increased 
risks of adverse perinatal and maternal outcomes (Savona-Ventura and Chircop 2003, 
Metzger et al. 2008, Metzger et al. 2009, Hod 2011, Kessous et al. 2013, Scifres et al. 
2015).  
It is thought that the excess glucose in the mother’s blood stream (hyperglycaemia) 
crosses the placenta entering the foetal circulation (Catalano and Hauguel-De Mouzon 
2011) promoting thrifty gene inter-generationally (Edwards 2017). The foetal 
compartment is insulinotrophic and therefore produces insulin in response to the 
presence of glucose in the blood. This hyperinsulinaemia in the foetal compartment 
alters placental development resulting in deranged gene expression and metabolism 
(Hiden and Desoye 2010, Edwards 2017). 
The expansive HAPO study performed in the US took place between July 2000 and 
April 2006 in order to examine the adverse outcomes associated with GDM for both 
infant and mother. The International Association of Diabetes in Pregnancy Study 
Groups (IADPSG, www.iadpsg.org ) is a working group analysing the results from this, 
which is shedding light on clarifying current unanswered questions concerning 
diagnosis and adverse effects of hyperglycaemia throughout pregnancy. 
In one study looking at the adverse pregnancy outcomes relating to hyperglycaemia 
during pregnancy, the four primary outcomes looked at were birth weight above the 
90th percentile for gestational age, primary caesarean delivery, clinical neonatal 
hypoglycaemia, and cord-blood serum C-peptide level above the 90th percentile (a 
marker of foetal hyperinsulinemia). Secondary outcomes were premature delivery 
(before 37 weeks of gestation), shoulder dystocia or birth injury, low APGAR1 scores 
at five minutes post birth with need for intensive neonatal care, hyperbilirubinemia, 
and preeclampsia (Metzger et al. 2008).  
                                                 
1 APGAR score is a score derived from a quick test performed by the doctor, midwife or health provide 
at 1 and 5 minutes after birth. The 1 minute score determines how well the infant tolerated the birthing 
process and the score taken at 5 minutes indicates how well the infant is coping to conditions outside 
the mothers womb. The categories scored are breathing effort, heart rate, muscle tone, reflexes and 
skin colour (Apgar, V. (1953) 'A proposal for a new method of evaluation of the newborn infant', Curr 
Res Anesth Analg, 32(4), 260-7.) 
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The HAPO study demonstrated a graded relationship between maternal glucose and 
the primary outcomes of the study, including foetal insulin (as expressed by cord C-
peptide at birth) and macrosomia (Metzger et al. 2008). Later, the same HAPO Study 
Cooperative Research Group (Metzger et al. 2009) showed strong statistically 
significant gradients across increasing levels of maternal glucose and cord serum C-
peptide against measures of neonatal adiposity (either by skinfolds or derived percent 
body fat at birth), which persisted after adjustment for potential confounders (Metzger 
et al. 2009).  
GDM is not associated with an increase in congenital anomalies, but is linked to a 
variety of pregnancy complications, including macrosomia, increased prenatal and 
perinatal mortality, and perinatal complications (Ornoy et al. 2001). The adverse 
outcomes measured relate closely to their clinical significance of obstetric and neonatal 
complications in the short and long term, the latter of which warrant further attention 
(Catalano et al. 2012). Macrosomia -indicated by a neonatal weight of ≥4kg at birth- 
may cause complications relating to the size of the infant. This can cause obstructed 
labour, whereby the delivery of the head, the anterior shoulder of the infant, cannot (or 
requires significant manipulation) pass below the pubic symphysis. This type of 
obstructed labour is termed shoulder dystocia and is diagnosed when the shoulders fail 
to deliver shortly after the foetal head. A large for gestational age (LGA) infant may 
also be at risk of complications in the short term, including perinatal death, which may 
require obstetric intervention (for example induction of labour, or caesarean section) 
or admission to the neonatal intensive care unit (Metzger et al. 2008). 
Complications also extend to the mother, where incidence of pre-eclampsia- a 
pregnancy complication characterized by high blood pressure and signs of damage to 
another organ system, often the kidneys, resulting in proteinuria- is higher in mothers 
with obesity and GDM (Dennedy and Dunne 2010).  
Long-term complications also pose a threat to these mothers and their infants. Mothers 
have a higher risk of developing type II diabetes following their GDM pregnancy, with 
reported prevalence being double for obese women as it is for lean women with 60 and 
30% respectively shown by original studies in this area by O'Sullivan (1982). This has 
implications for the mothers own health and implications for any subsequent 
pregnancies, as the complications and major anomalies of pregnancy affected by type 
II diabetes mellitus are well known (Ornoy et al. 2015). These include anomalies 
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pertaining to the central nervous system and those of the cardiovascular system. Those 
of the central nervous system include: anencephaly, acrania, meningomyelocele, 
arrhinencephaly, microcephaly, exencephaly, holoprosencephaly and spina bifida; the 
cardiovascular system: hypo plastic right or left heart syndrome, AVSD and VSD, 
tricuspid atresia and mitrial atresia, double inlet left ventricle, double outlet right 
ventricle, transposition of great arteries, tetralogy of Fallot; and anomalies of 
craniofacial structures such as: hemifacial spasm macrosomia, cleft lip/palate, microtia, 
micrognathia, microophtalmia, frontal nasal dysplasia and lens opacity (Ornoy et al. 
2015). 
Foetal origins of adult disease is on the agenda of many health related conferences 
(Nolan 2011), with growing strong epidemiological evidence linking intrauterine 
growth restriction with later adult diseases such as obesity, hypertension, type II 
diabetes mellitus and cardiovascular disease (Barker et al. 1993, Mi et al. 2000, 
Simmons 2011). The link between childhood obesity and later chronic disease is 
difficult to establish, however epidemiological studies have indicated that foetal 
hyperglycaemia poses a risk for later infancy and adolescence obesity risk with higher 
adiposity early in life (Gillman et al. 2003, Hillier et al. 2007, Boerschmann et al. 2010, 
Thaware et al. 2015). In addition, there is evidence that the environmental milieu in 
pregnancy can influence the phenotype of the infant due to GDM, presenting with or 
without obesity (Silverman et al. 1998). This work correlated amniotic fluid insulin 
levels and increased body mass index in adolescents aged 14-17y, postulating an 
association between islet cell activation in utero and development of childhood obesity. 
Indeed, Catalano et al. (2003b) showed that infants of mothers with GDM have 
increased fat mass when compared to weight-matched infants. The increased birth 
weight of these infants tends to normalize by 12 months before increasing again during 
early childhood. This obesity during childhood tracks into adulthood predisposing, thus 




2.3 Diagnostic test and current criteria of disease  
The clinical detection of GDM is generally accomplished by a combination of criteria 
from aspects of clinical risk assessment, glucose tolerance screening (such as 
urinalysis) or formal glucose tolerance testing with the means of a fasted 75g Oral 
Glucose Tolerance Test (OGTT). Universal screening for GDM remains controversial 
(Gillespie et al. 2012, Neelakandan and Shankar Sethu 2014, Salmeen 2016). To date 
the American Diabetes Association (ADA), the International Diabetes Federation 
(IDF) and the National Institute for Health and Clinical Excellence (NICE) recommend 
selective screening for GDM between 24-30 weeks gestation based on one or more risk 
factors (Rani et al., 2016). However, the case for Universal screening to be applied has 
been made by various research centres based on discrepancies between detection and 
true prevalence (Griffin et al. 2000, O'Sullivan et al. 2012). 
In addition to the problem surrounding screening, developing diagnostic cut-offs for 
GDM diagnosis has been an issue of considerable controversy over the past three 
decades (Salmeen 2016). Many national bodies have derived their own criteria based 
on local experience and their healthcare delivery systems (HSE, 2010). This lack of 
consensus has recently been addressed by recommendations arising from the 
International Association of Diabetes in Pregnancy Study Groups (IADPSG), a 
working group analysing the results of the Hyperglycaemia and Adverse Pregnancy 
Outcome (HAPO) study. The recommendations from this group form the basis of the 
updated guidelines by the World Health Organisation (WHO, 2013) are therefore 
considered by relevant national bodies and incorporated into local health care service 
pathways. 
The diagnostic test, which takes place, is a two hour 75g oral glucose tolerance test 
(OGTT). Women are asked to consume their usual diet for 3-days prior to test without 
altering their current diet during this period. Twelve hours prior to the test, woman fast 
(no flood or fluids except water) for 12 hours prior to the test. The woman receives a 
75g oral glucose solution to ingest over a 10-15 minute period whilst at rest and without 
smoking. A venous sample of blood is collected and blood glucose measured at one 
and two hours from the commencement of the test. A diagnosis of GDM is made when 
one or more of values set out for each time-point are met, or exceeded, according to the 
updated clinical guidelines (WHO, 2013). WHO (2013) indicate that the diagnosis of 
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GDM at any time during pregnancy should be based on any one of the following values 
resulting from a 75g Oral Glucose Tolerance Test (OGTT): Fasting plasma glucose = 
5.1-6.9 mmol/L; 1-h post 75g oral glucose load ≥10.0 mmol/L or 2-h post 75g oral 
glucose load ≥8.5 – 11.0 mmol/L. 
Recommendations on diagnostic guidelines were recently updated in response to 
findings from a five-year prospective single-blinded observational study, which 
investigated pregnant women during their third trimester, to examine the adverse 
outcomes associated with varying degrees of hyperglycaemia (Metzger et al. 2008).  
Results from the HAPO study were analysed and recommendations derived from these 
findings (Metzger et al. 2008). The International Association of Diabetes in Pregnancy 
Study Groups (IADPSG) Consensus Panel defined diagnostic values for dichotomous 
classification of hyperglycaemia, which occurs on a continuum. This was based on 
odds ratio for adverse outcomes compared with mean values for fasting plasma 
glucose, 1-h and 2-h OGTT plasma glucose concentrations and selected an odds ratio 
relative to the mean glucose of 1.75. The recommended diagnostic thresholds for 
fasting plasma glucose, 1-h, and 2-h plasma glucose concentration, are the average 
glucose values at which odds for birth weight (≥90th percentile), cord C- peptide( ≥90th 
percentile), and neonatal percent body fat (≥90th percentile) reached 1.75 times the 
estimated odds of these outcomes at mean glucose values. These were based on fully 
adjusted logistic regression models (Metzger et al. 2008). The WHO then disseminated 
these in 2013 to be implemented in practice globally (WHO, 2013). 
These criteria are implemented with the intention that timely diagnosis allows health 
providers to optimise interventions and therefore pregnancy outcomes. A recent 
Cochrane collaboration by Tieu et al. (2014) synthesized data from four trials involving 
3972 women concluded that not enough evidence was present to determine which 
current methods of screening provided the best pregnancy outcomes. Despite the 
HAPO study shedding light and insights into this area, there is still a need to establish 
diagnostic criteria in order to maximise effects pregnancy outcomes, as the earlier one 
is diagnosed the more time available for referral management of GDM for lifestyle and 




2.4 Lifestyle management as part of medical therapy in management  
Patients with this diagnosis are provided with appropriate dietary modification, and this 
is followed with insulin therapy if adequate glycaemic control is not achieved, as 
evidenced by two or more failed glucose target levels (fasting blood glucose >5.3 
mmol/l or postprandial > 7.0 mmol/l, following a minimum of two weeks of dietary 
therapy).  
It is agreed that dietary management is the cornerstone of care in pregnancies 
complicated by GDM (Tieu et al. 2014, Duarte-Gardea et al. 2018). Medical nutrition 
therapy is an integral component of lifestyle treatment for GDM to improve maternal 
and foetal outcomes. Through nutrition therapy, dietitians assist patients in obtaining 
blood glucose and weight gain targets and adequate foetal growth while meeting 
pregnancy requirements for essential nutrients. Guidelines for health practitioners 
indicate that all women with GDM should receive individualised nutritional advice by 
a dietitian who is trained to take into consideration all components of diabetes and 
pregnancy, as well as any co-morbidities or complications they may present with 
(Duarte-Gardea et al. 2018). Despite this, a recent systematic review comparing 
international GDM-specific medical nutrition therapy clinical practice guidelines 
revealed high heterogeneity in terms of structure and content of guidelines (Tsirou et 
al. 2019). Stakeholder involvement, rigor, transparency, and applicability are among 
the domains that have to be improved when developing medical nutrition therapy 
clinical practice guidelines for patients with GDM. Patients and dietitians were not 
involved in the development of the majority of clinical practice guidelines and this 
presents an important area for improvement.  
In a study of pregnant women with GDM, those receiving dietetic intervention had a 
decreased likelihood of infant admission to a neonatal intensive care unit compared to 
those who did not receive dietetic intervention [aOR = 0.41, 95% CI= 0.22–0.75; p = 
0.004). Women requiring pharmacotherapy were more likely to experience maternal 
complications (aOR = 3.13, 95% CI = 2.23–4.41; p < 0.001) and had a greater number 
of dietetic consultations (β-coefficient = 0.28, 95% CI = 0.17–0.39; p < 0.001) 
compared to women managed through diet (Absalom et al. 2019). 
Dietetic intervention plays a key role in optimising maternal and neonatal health 
outcomes for women with GDM (Absalom et al. 2019). The focus of nutrition in this 
group remains in the pursuit to achieve normoglycaemia through monitoring of 
19 
 
carbohydrate intake, whilst avoiding starvation ketosis. Adequate energy intake should 
be recommended which is aimed at achieving weight gain based on the 
recommendations for appropriate weight gain according to pre-pregnancy BMI as 
advised by the Institute of Medicine (IOM 2009). 
Good clinical practice through evidence synthesis by the Academy of Nutrition and 
Dietetics indicate the all women with GDM should be referred to a dietitian to receive 
personalized medical nutrition therapy (Duarte-Gardea et al. 2018). The recent 
guidelines recommend the nutrition care process should commence with a nutrition 
assessment to determine nutrition diagnosis and formulate a nutrition plan that is 
individualized. Adjustments should be made through ongoing dietetic counselling. This 
input should be regular and frequent throughout the index pregnancy. Medical nutrition 
therapy by a dietitian as part of a comprehensive nutrition intervention that includes 
individualization of medical nutrition therapy is effective in improving blood glucose 
control and neonatal and maternal outcomes in women with GDM. The goal of this 
dietetic input is to promote adequate foetal and maternal health, through achieving 
glycaemic control goals, maintaining appropriate gestational weight gain, and reduce 
the risk for adverse outcomes. Specifically, adequate amounts of calories, 
macronutrients, and micronutrients to support pregnancy should be provided, with 
guidance from the reference intake guideline for example in Ireland guidelines from 
the European Food Safety Authority (EFSA). Dietitians should individualize the 
nutrition prescription based on thorough nutrition assessment; the patient’s blood 
glucose parameters and response to treatment goals; physical activity; medication, if 
any (e.g., insulin); and patient needs. The amount and type of carbohydrates at meals 
and snacks should be individualized and distributed into three meals and two or more 
snacks per day to reduce postprandial blood glucose excursions. In the case that a 
patient continues to experience elevated post-prandial hyperglycaemia after breakfast, 
further modification to the amount or the type of carbohydrate (glycaemic index) at 
breakfast may be incorporated to achieve therapeutic targets (Duarte-Gardea et al. 
2018). On top of this, dietitians should encourage women with GDM to make healthy 
food choices and consume a variety of foods to meet the increased micronutrient 
requirements related to pregnancy. In some cases a dietary supplement within the 
reference ranges for pregnancy may be considered in the case that a patient is unable 
to meet micronutrient needs through diet.  
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Other dietetic considerations in a GDM pregnancy are the use of artificial sweeteners 
and alcohol. In the case that high intensity sweeteners are considered, dietitians should 
only encourage selection of those approved or generally recognized as safe by 
regulating bodies and to limit intake within a known safe range. Abstinence from 
alcohol during pregnancy should be reinforced at nutrition therapy visits. Unless 
contraindicated, daily moderate exercise of 30 minutes or more should be encouraged 
to help improve glycaemic control and facilitate achieving weight gain 
recommendations (Duarte-Gardea et al. 2018). Benefits of physical activity for 
glycaemic management have been long known and recent strong evidence showing 
physical activity is beneficial in prevention and management of GDM through 
improved weight management and blood glucose control, diet prescription remains a 
larger part of lifestyle management in this population in practice (ACOG 2015, Duarte-
Gardea et al. 2018). 
Lifestyle management during pregnancy complicated by GDM is effective, however 
considerably research has been done in preventing the onset of GDM through lifestyle 
interventions prenatally (Bain et al. 2015). These interventions focus on educating 
mothers to reduce weight to a health BMI prior to conceiving. A large Cochrane 
collaboration looking at the role of diet and exercise interventions in preventing GDM 
is ongoing and is regularly updated (Bain et al. 2015). 
 
2.5 Quantification of burden on a Global and National level 
Frequency of gestational diabetes was reported for the sites participating in the  HAPO 
study across the globe (Sacks et al. 2012a). The overall frequency across sites was 
17.8%, with substantial centre-to-centre variation ranging from 9.3 to 25.5%. Adjusting 
the results for maternal age, BMI, height, chronic hypertension, frequency of family 
history of diabetes and hypertension accounted for some of these differences; however, 
it did not eliminate centre-to-centre differences entirely. Table 2.1 overleaf shows the 
location of the centre, number of participants per centre and percentage sample 
diagnosed with gestational diabetes according to the International Association of 




Table 2.1 Location of HAPO centres and figures for number of participants 
diagnosed with GDM according to IADPSG criteria, as well as percentage.  
Adapted from Sacks et al., (2012a). 
 
Centre No. of 
participants in 
centre 
No. of participants  
diagnosed with GDM 
% GDM 
HAPO overall 23,957 4,264 17.8 
Bellflower, CA 1,981 505 25.5 
Singapore, Singapore 1,787 449 25.1 
Cleveland, OH 797 199 25.0 
Manchester, U.K. 2,376 577 24.3 
Bangkok, Thailand 2,499 575 23.0 
Chicago, IL 753 130 17.3 
Belfast, U.K. 1,671 286 17.1 
Toronto, Canada 2,028 314 15.5 
Providence, RI 757 117 15.5 
Newcastle, Australia 668 102 15.3 
Hong Kong, PRC 1,654 238 14.4 
Brisbane, Australia 1,444 179 12.4 
Bridgetown, Barbados 2,093 249 11.9 
Petah-Tiqva, Israel 1,818 184 10.1 
Beersheba, Israel 1,631 152 9.3 
*HAPO Hyperglycaemia and Adverse Pregnancy Outcomes; IADPSG International Association of the Diabetes and Pregnancy 
Study Groups; GDM Gestational Diabetes Mellitus 
 
The reasons for the centre-to centre differences observed are not clear and may partially 
relate to frequencies of obesity and degree of abnormal glucose metabolism in the 
general populations where HAPO centres were located. However, data on population 
characteristics are not available for many of the HAPO centres, therefore conclusions 
on this cannot be made (Sacks et al. 2012a). The implications of such varying rates 
signifies that specific centres may choose to construct their referral pathway 
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accordingly due to resources, as the cost of GDM screening and management is 
becoming an increasing economic burden (Gillespie et al. 2012) 
The prevalence of GDM in Ireland was quantified using the new diagnostic criteria set 
out by the IADPSG, which were based on the results from the HAPO study (Metzger 
et al. 2010). As part of a 5-year research programme, the Atlantic DiP research team 
aimed to improve outcomes for diabetes during pregnancy. Initially, they quantified 
the prevalence in Ireland by applying Universal screening for GDM in pregnancy at 
24-28 weeks gestation, with the 75g-OGTT protocol and criteria set out by IADPSG 
(WHO, 2013). They found the prevalence of GDM to be 12.4%, or one in 10 women 
(O'Sullivan et al. 2012). This is much greater than the 2.7% previously reported (Griffin 
et al. 2000), as the latter study was limited by a sample from one site and used the 
previously set out by the less stringent WHO criteria for diagnosing GDM. Based on 
this finding (O'Sullivan et al. 2012) they recommended Universal screening should be 
adopted.  Subsequently, Khalifeh et al. (2014)  showed a rise in incidence of GDM in 
a cohort of over 180k deliveries in Ireland over a 10-year period, and reported a rise in 
prevalence of GDM without a concomitant rise in pre-existing diabetes. These studies 
illustrate the extent of the issue and medical burden of GDM in Ireland and globally. 
2.6 Healthy changes in body composition during pregnancy 
There is significant physiological change during pregnancy, which are accompanied by 
changes in body composition to support foetal growth and development. Changes in 
total body water (TBW) accretion, protein accretion (i.e. Fat-free mass (FFM)) and fat 
mass (FM) accretion. There is unique patterns of accretion during pregnancy with 
varying effects on foetal outcomes (Most et al. 2018). Figure 2.3 depicts the accretion 
of various tissues in maternal and foetal compartments throughout pregnancy (Pitkin 
1976). The Institute of Medicine (IOM), makes recommendations on weight gain in 
women during pregnancy based on maternal prenatal BMI, and  have been developed 





Figure 2.3 Components of gestational weight gain throughout pregnancy. LMP: 





2.6.1 TBW accretion in pregnancy 
Total body water accretion is highly variable throughout pregnancy, and mainly under 
hormonal control. Across several studies, TBW accretion measured by deuterium 
showed an increase of 7-8L on average in healthy pregnancies (Hytten and 
Chamberlain 1991). Maternal plasma volume expands during pregnancy, 
approximately 2L in the blood and a further 2L in extracellular fluid. Expansion of the 
extracellular fluid (ECF) measured using the tracer sodium thiocyanate is estimated to 
be about 6-7 L. For example, a 12.5kg gestational-weight-gain would consist of a total 
water gain at term distributed between several compartments. These being the foetus 
(2,414 g); placenta (540 g); amniotic fluid (792 g); blood-free uterus (800 g); breast 
tissue (304 g), blood (1,267 g), and ECF (1,496 g) with no oedema or leg oedema and 




2.6.2 Protein accretion in pregnancy 
Protein accretion is estimated at ~1kg by the 28th week of gestation, with an additional 
~2.5kg accumulating in the following 12 weeks. The protein accrued predominantly 
distributes itself in the foetus (42%), but also in the uterus (17%), blood (14%), placenta 
(10%), and breasts (8%) (Hytten and Chamberlain 1991). Protein accrual occurs 
predominantly in late pregnancy. Protein deposition has been estimated from 
measurements of total body potassium (TBK) accretion derived by whole-body 
counting in a number of studies of pregnant women (Pipe et al. 1979, Forsum et al. 
1988, Butte et al. 2003).  
2.6.3 FM accretion 
Maternal FM is the most variable component of gestational weight gain in pregnancy. 
A wide range of FM change has been reported from net changes of -9.5 to +13.9kg 
from 14 to 37 weeks gestation (Lederman et al. 1999). There is limited data on the 
timing of FM changes in pregnancy due to paucity of data in the literature examining 
pregnancy at multiple points (Most et al. 2018). Studies have shown a linear increase 
in FM throughout pregnancy at a rate ranging from 0.5kg reported by Butte et al. (2003) 
and 2kg per trimesters (Kopp-Hoolihan et al. 1999) in healthy pregnancies, with larger 
increases in higher pre-gravid BMI ranges (Butte et al. 2003). The average FM of infant 
at birth is 350g, most of which is accrued in the third trimester. GWG and infant 
adiposity have been shown to have a linear relationship (Hull et al. 2011), with 
excessive FM gain in the mother resulting in obesity in the neonate (Catalano et al. 
2003b, Hull et al. 2011). However, a more recent study found maternal pre-gravid 
weight status to be correlated to DNA methylation not GWG, indicating an intra-
uterine environmental affect propagating obesity trans-generationally not mediated by 




2.7 Models of assessing maternal body composition in pregnancy  
Models of body composition classify all body tissue in compartments of similar tissues. 
These models are based on categorization from human dissection studies carried out in 
the 19th century (Fidanza 1987, Clarys et al. 1999). Figures 2.4 and 2.5 reproduced 
from Wang et al. (1992) and Fosbøl and Zerahn (2015) respectively, illustrates the 
tissues contributing to the various component models. At its simplest form, the 2-
component (2C) model distinguishes between fat mass (FM) and fat free mass (FFM), 
whereas a 3-component (3C) model further compartmentalizes FFM into lean tissue 
and bone. 4-component (4C) models further compartmentalizes lean mass into its 
constituent protein and water. Ideally, 4C models are ideal when measuring body 
composition; however, each technique of measuring body composition has its uses and 
limitation. These techniques are described in the following sections.  
 
 




Figure 2.5 Main components of the molecular level of body composition and the 
relationship between lipid and fat (molecular level) and the tissue-organ-level 
component adipose tissue. Reproduced from Fosbøl and Zerahn (2015)  
 
 
2.7.1 Two-Compartment models (2C) of body composition in pregnancy 
The use of this model in pregnancy has been criticised extensively in the literature 
(Hopkinson et al. 1997, Kopp-Hoolihan et al. 1999). The model is based on the 
assumption that the hydration of FFM is constant, therefore calculation of FM, 
followed by deduction from total body weight to calculate FFM. This assumption 
would require a stable hydration constant of hydrated tissue, however, during 
pregnancy there is an average increase of 6L of water due to maternal plasma 
expansion, in the uterus, amniotic fluid, placenta and foetus (Pitkin 1976). Hydration 
of tissues changes drastically from 73% to 90% in the FFM component throughout the 
pregnancy. In addition, predicting the extent of hydration for an individual person is 
not possible due to variability in hydration, which increases in late pregnancy due to 




2.7.2 Three-Compartment models (3C) of body composition in pregnancy 
The 3C model divides the body into water, protein and fat. This is achieved via 
measurement of water using stable radiolabelled tracer tritiated water (3H2O), 
deuterium water (2H20) or H2
180 labelled water administered orally. This water 
distributes within the body rapidly reaching equilibrium in about 3-4 hour. Dilution is 
measured via urine of blood plasma, in which the concentration of the stable element 
and the labelled one is measured. Naturally occurring isotope 40K decay to 39K is 
measured using a whole body γ-radiation counter and total K subsequently calculated. 
The use of stable isotopes in pregnancy and measuring endogenous decay of K is 
considered safe and without risk in pregnancy (McCarthy et al. 2004). Cell mass and 
therefore protein is then calculated using this figure. Once protein and water 
contributions are calculated, these are deducted from overall body weight to quantify 
FM. TBW determination employing the dilution technique is time-consuming and 
requires adequate laboratory facilities, which makes this method less applicable in 
large-scale studies or in field settings where the necessary equipment is unavailable 
(Fosbøl and Zerahn 2015). 
 
2.7.3 Four-Compartment models (4C) of body composition in pregnancy 
Four component models distinguish and quantify water, fat mass, osseous mass (bone) 
and protein. It accounts for biological variability in both TBW and osseous mass, 
however assumes a fixed ratio of osseous to non-osseous mineral of 0.8191:0.1809 
(Hopkinson et al. 1997). The 4C model has been validated against multi-compartment 




2.7.4 Measuring hydration of FFM in pregnancy via Total Body Water 
(TBW) 
Distribution of water in the body is traced using isotopes of the stable element H20 such 
as deuterium oxide (H2
18O or 2H2O). The isotope-labelled water will distribute evenly 
in tissue fluid, and eventually reach equilibrium. Time to equilibrate has been 
calculated to be five hours in various bodily fluids: urine (Kopp-Hoolihan et al. 1999), 
saliva (Forsum et al. 1988) and venous blood (Huston Presley et al. 2000) samples. As 
the hydration of FM is assumed to be zero (Huston Presley et al. 2000), the dilution of 
the isotope-labelled water (tracer) over the time for disappearance of tracer equates to 
an estimate of FFM. 
As described earlier, there is expansion of hydrated tissues during gestation in both the 
foetal and maternal unit, e.g blood volume and amniotic fluid. This means the tracer is 
more dilute as it equilibrates across all bodily tissue. This results in an overestimation 
of FFM and underestimation of FM in pregnant women due to the assumption that all 
lean tissue mass (LTM) has the same level of hydration. This overestimation has been 
calculated to be up to 50% in women gaining three to four kg of fat. Adjustments for 
expected gestational water gain has been calculated (van Raaij et al. 1988, Catalano et 
al. 1995). 
This technique is safe in pregnancy however, it is expensive, required specialized skill 




Figure 2.6 Illustration of published values for FFM hydration and density throughout 
pregnancy. Reproduced in its entirety from Most et al. (2018).  
Hydration (a) and density (b) of FFM (fat free mass) are shown for specific time points in pregnancy as published by the 
presented studies. Individual values are calculated by using body weight, body volume, and total body water (3C models). 
Published values are used as estimates/reference when individually measured values are not available (2C models). The 
exponential regression lines are only based on the data by van Raaij et al. (1988) which are most commonly used in 2C models, 
and allow for estimation of FFM hydration/density for any given time throughout gestation.  
Hydration FFM (L/kg) = 0.724 + 0.00008484 * GA (weeks) + 0.00001435 * GA (weeks) 2  
(Where GA = gestational age; R2=0.998, p<0.001, and 
Density FFM (kg/L) = 1.1 − 0.00002988 * GA (weeks) ‐0.00000731 * GA (weeks) 2 




2.8 Measurement of body composition in pregnancy 
2.8.1 Densitometry: Underwater Weighing (UWW)/ Hydrostatic weighing 
and Air-displacement Plethysmography (ADP) use in pregnancy 
Measurement of density using hydrostatic weighing or air-displacement 
plethysmography (ADP) is based on the 2C model of body composition. In these 
techniques, the displacement of air or water is used to calculate volume using 
Archimedes principle and Boyle’s Law respectively. Body density is calculated from 
body volume and weight.  These are subsequently used to estimate fat mass from 
equations derived from cadaver studies (Siri 1956, Brozek et al. 1963). Maximal 
expiration and calculation of residual volume in lungs is accounted for in the 
measurement of body volume. Air-displacement plethysmography and 
hydrodensitometry have shown narrow Limits of Agreement in reliability studies in 
populations of normal weight adults, obese adults (Ginde et al. 2005, Noreen and 
Lemon 2006).  
Densitometry methods are not suitable during pregnancy due to lack of distinguishing 
from maternal and foetal unit. In addition, estimates of body components with these 
methods is affected as a result of shifts in the density and composition of FFM over the 
course of the pregnancy. In addition, specialized equipment is required making it 
difficult to use extensively. However, the technique is non-invasive and if further 
research is undertaken in this area to validate the technique by combining with other 
methodologies for the assessment of TBW (with assessment in various population 
groups and amongst various ethnicities), it could potentially be used as a tool in this 
field. This has been suggested in a recent review by Widen and Gallagher (2014). ADP 
is more likely to be tolerated than hydrodensitometry due to the methodological 
requirement of being submerged underwater, with expelled breath for an extended 




2.8.2 Bio-impedance analysis (BIA) use in pregnancy 
Bio-impedance analysis (BIA) is used in various formats, either single-frequency, 
multi-frequency or bioelectric impedance spectroscopy (BIS). In essence, each of these 
techniques passes a small alternating electrical current with low amperage throughout 
the body via electrodes. This current uses the water content of the body as a conductor. 
The impedance of the electrical flow via tissues estimates the TBW, from which FM 
and FFM is derived.  
Validation of BIA techniques in pregnancy is contentious, due to estimates of TBW, 
which the BIA uses to compute FM and FFM as these are influenced by the ratio of 
intracellular (ICW) to extracellular water (ECW), which changes substantially during 
gestation compared to non-pregnant females (Deurenberg et al. 1989, McCarthy et al. 
2004).  
BIS uses extrapolated resistance values at zero and infinite frequency (i.e. varying 
frequencies) via the Cole-Cole model (Ward et al. 2006). The model assumes a parallel 
arrangement of the ECW and ICW, and provides resistance values for each of these. 
Regression equations are used to calculate fluid compartments. Therefore, BIS may not 
be suitable for pregnancy, as greater water is located in the trunk region compared with 
non-pregnant populations violating the underpinning assumptions to the estimates. A 
new model for BIS assessment of TBW in pregnancy has not been developed yet (Lof 
and Forsum 2004).  
Due to the inter-variability of TBW between women of 5-8L increase in TBW over the 
course of pregnancy (Lederman et al. 1997, Kopp-Hoolihan et al. 1999), coupled with 
the sensitivity of TBW to gestational stage (Lof and Forsum 2004), validating BIA in 




2.8.3 Dual Energy X-Ray Absorptiometry (DXA) use in pregnancy 
DXA is a 4C model for the measurement of body composition, accurately quantifying 
whole body and regional estimates of FM, LTM and bone mass. Despite DXA gaining 
wide acceptance as a body composition reference method (Williams et al. 2006, Marra 
et al. 2019), it is not suitable during pregnancy as DXA works by generating X-rays, 
and using a detector to measure the attenuation of the radio-wave which is then 
modelled into images via the software. The doses of radiation the person being 
measured are small (1–7 μSv) (Marra et al. 2019), is equivalent to one to 10% of 
radiation from an X-ray (Lee and Gallagher 2008). Due to DXA’s advantages in terms 
of accuracy, simplicity, availability, and relatively low expense as compared to 
procedures like TBK, MRI or CT scan, and low radiation exposure, DXA measurement 
is becoming increasingly important, emerging as reference assessment technique also 
in muscle mass evaluation (Heymsfield et al. 2015). This technique has been used in 
intensive studies of women postpartum (Butte et al. 1997). 
 
2.8.4 Imaging: Computed Tomography (CT) Magnetic Resonance Imaging 
(MRI) use in pregnancy 
Imaging methods are considered the most accurate methods for quantification of body 
composition at the tissue level. CT and MRI both measure adipose tissue, and its 
constituents: subcutaneous, visceral and interstitial tissue. Skeletal muscle is measured 
and its segmental distribution can be compartmentalized. This level of specificity in 
tissue composition is only possible with CT or MRI scans (Fosbøl and Zerahn 2015). 
CT studies in paediatric and adult populations outwit pregnancy are common (Ashwell 
et al. 1985), and utilize the ability of determining visceral fat to determine metabolic 
risk associated with obesity (Lindsay et al. 1997). The radiation dose for a whole body 
CT is substantial making it a hazard in pregnancy. 
MRI estimate of fat mass have been validated against phantoms (Donnelly et al. 2003) 
devised from cadaver dissection studies (Abate et al. 1994). MRI does not involve 
exposure to ionizing radiation and is therefore is not contra-indicated in pregnancy. 
The technique is based on the interaction between the hydrogen nuclei within the body. 
The machine produces a powerful magnetic field; the hydrogen nuclei align themselves 
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with the magnetic field in a known direction. A radio frequency (RF) pulse is then 
applied causing the hydrogen nuclei to absorb energy. This energy is released as the 
nuclei return to the aligned state in the form of a RF signal. This signal is then used to 
generate the magnetic resonance images (Fosbøl and Zerahn 2015). There are no 
specific concerns of the use of MRI imaging in pregnancy, however unfortunately this 
is an expensive specialised equipment, which is not readily available and likely why it 
has rarely been used to study maternal body composition so far (McCarthy et al. 2004). 
2.8.5 Ultrasound use in pregnancy  
Ultrasound in not a technical procedure and is non-invasive. It involves the production 
of sound waves at varying frequencies to measure adipose tissue thickness during 
pregnancy. Ultrasound technique has been used extensively outside of pregnancy to 
quantify abdominal fat and its constituents (Armellini et al. 1990, Suzuki et al. 1993), 
with validation against CT (Suzuki et al. 1993). Techniques used in studies in a 
pregnant population have lacked use of standardized protocols. Further research into 
the validity and reliability of body composition measurement via ultrasound, requires 
development and is warranted (Most et al. 2018). Cross-sectional (Bartha et al. 2007) 
and longitudinal (Stevens-Simon et al. 2001, Kinoshita and Itoh 2006) studies have 
used ultrasound measurements in pregnancy. 
Foetal ultrasonography is widely used to assess foetal size and adiposity 
(Papageorghiou et al. 2014, Ikenoue et al. 2017). In addition, predication of newborn 
adiposity assessed by US at 30 weeks gestation where validated against DXA and ADP 




2.9 Summary of challenges and limitations in quantifying body composition 
in pregnancy 
All the methods described in detail can be applied in pregnancy however each have 
their limitations during pregnancy due to estimates based on assumptions of various 
tissue properties relative to each other (Heymsfield et al. 1990). In pregnancy and in 
the postpartum phase, these tissue changes in properties are very dynamic throughout 
pregnancy and indeed postpartum (IOMPWG 2009, Most et al. 2018). The main 
limitation of application of these techniques is the large proportion of water 
accumulation relative to the gestational weight gain, which leads to an increase in 
relative hydration of the FFM throughout pregnancy (Taggart et al. 1967, van Raaij et 
al. 1988). This accumulation of fluid is highly variable throughout gestation and 
amongst individual women, ranging from 67-80% of FFM. Limitations of other 
methods include exposure to radiation, which has known teratogenic effects, such as in 
CT scan and DXA; cost and use of specialist equipment for MRI, and technique for 
TBW and TBK methodology; difficult procedure such as UWW; and more use of 
expensive equipment with ADP.  
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2.10 Anthropometric techniques in pregnancy 
2.10.1 Skinfold thickness (SFT) 
The use of SFT measurements in pregnancy has been widely used over the past four 
decades (Taggart et al. 1967, Pipe et al. 1979, Durnin 1991, Villar et al. 1992, Catalano 
et al. 1998, Paxton et al. 1998, Huston Presley et al. 2000, Soltani and Fraser 2000, 
Sidebottom et al. 2001, Ehrenberg et al. 2003). There is some research attempting to 
validate this method with UWW, ADP, TBW and TBK (Pipe et al. 1979, Catalano et 
al. 1998). Despite this, pregnancy-related hydration changes result in varying 
compressibility of tissue. As hydration increases in pregnancy, the distribution and 
compression of subcutaneous tissues could be distorted. This has been shown to result 
in overestimating subcutaneous fat as the pregnancy progresses and introduces bias in 
the postpartum phase when identifying rate of weight loss, as shown by studies 
comparing agreeability between MRI, US and SFT in a pregnant population (Sohlstrom 
and Forsum 1997, Stevens-Simon et al. 2001).  The agreement between changes in 
total body fat measured via MRI and SFT with TBW measures differed significantly 
during different times in the prenatal and post-partum phase. This was significantly 
(1.5-4kg) influenced by the amount of FM gained or lost. There is therefore a risk for 
bias when measuring changes in total body fat during reproduction when body 
composition is estimated via SFT together with TBW by isotope dilution (Stevens-
Simon et al. 2001). 
SFT measurements typically include measurements from 4-8 anatomical sites (See 
Table 2.2). The summation of these skinfold thickness measurements at specifically 
identified anatomical landmarks are used to approximate total body subcutaneous fat 
(Durnin and Womersley 1974). SFT measurements together with other anthropometric 
measurements (e.g weight, height, mid-upper arm circumference (MUAC) and waist 
circumference), have been utilized in multiple regression predictive equations to 
formulate equations which convert the crude SFT measurements from mm to 
percentage body fat (Paxton et al. 1998, Huston Presley et al. 2000). These predictive 
equations are specific to rigid time-points during gestation and are specific to maternal 
age and race. These equations are dated and are not validated in obese population 
therefore their applicability in pregnancy with obesity is yet to be clarified (Paxton et 
al. 1998, Most et al. 2018).  
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Paxton et al. (1998) group undertook a large study of 200 pregnant women and 
developed anthropometric equations predicting fat mass from gestational week 14 to 
37, validated against the 4C model of UWW combined with TBW by isotope dilution 
previously developed (Heymsfield et al. 1990, Friedl et al. 1992). These findings were 
followed-up and in line with a study by Huston Presley et al. (2000), where UWW and 
18O abundances measured by gas-isotope-ratio mass spectrometry to measure TBW 
were used to develop equation model built from  weight and four SFT measurements 
(n=20). The proposed model explained 91% of variance in FM via UWW and TBW 
using maternal weight, triceps, subscapular and suprailiac skinfolds with no statistical 
significance in estimation of FM via the two methods (reporting a CI of -2.476 to 
+2.748 kg of fat mass), thus validating the technique in later gestation (30 weeks). To 
this day, these remain the landmark studies to date for equations developed in a 
pregnant population, accounting for changes in hydration of tissue components in the 
body that occur in the pregnant state (Most et al. 2018).  
SFT techniques are widely used and accepted by women and researchers due to its low-
cost, portability and no requirement for expensive material (relative to other 
techniques). Despite this ease of use, most measurement arises from inter-variability 
amongst researchers. Hence, there is a need for standardised training to consistently 
measure within a relative technical error of measurement  (TEM) of 5% for intra- 
evaluator skinfold measurements and 7.5% inter-evaluator SFT measurements (Perini 
et al. 2005), such as the specific techniques developed by the International Society of 
Anthropometrics and Kinanthropometry (ISAK) (Stewart and Marfell-Jones 2011). 
Limitations to this technique include the requirement of extensive training to ensure 
inter and intra reliability of measurements (Perini et al. 2005, Stewart and Marfell-
Jones 2011). Even in cases of extensive training, it has been reported that it has been 
difficult to maintain consistency amongst different weight (Ehrenberg et al. 2003) and 
parity (Taggart et al. 1967). Despite all these limitation, SFT measured with precision 
could be useful both for clinical use and for the purpose of research (Most et al. 2018). 
Work by (Kannieappan et al. 2013) developed a tool for obtaining maternal SFT 
measurement and assessing inter-observer variability among pregnant women who are 
overweight and obese. They developed and validated an equation, which is described 




Table 2.2 Anthropometric equations for estimating body FM (fat mass), 
expression of body (%FM), and density in pregnancy 
Source Measurement Anthropometric equation 
Paxton et al. 
(1998) 
FM ∆ from 14-37w 
gestation 
∆FM(kg)=0.77(∆weight (kg) + 0.07 
(∆thigh SFT (mm))-6.13  
Paxton et al. 
(1998) 
FM at 37w 
gestation 
FM(kg)=0.40(weight(kg) at 37w gestation) 
+ 0.16 (bicep SFT at 37w (mm))-0.15 
(thigh SFT at 37w (mm))- 0.09 (wrist 
circumference at 37w (mm))+0.10 (pre-
pregnancy weight (kg))-6.5 
Huston 
Presley et al. 
(2000) 
FM at 30w  
gestation 
FM (kg)=0.33529(weight (kg))+0.65664 
(tricep SFT(mm)) – 0.4373 (subscapular 




Total upper arm 
area (TUAA) 
TUAA= MUAC2 / (4*π) 
Arm fat area (AFA) AFA(cm2)=MUAC-(tricep SFT x π)2 /4 π - 
AMA 
Arm muscle area 
(AMA) 
AMA(cm2)=[MUAC-(tricep SFT x π)] 2 /4 
π 
Arm fat index 
(AFI) 
AFI (%) = (AFA / TUA)*100 
Siri (1993) % body fat (BF) %BF= ([4.950 / BD (kg.m-3) – 
4.500] x 100) 
Kannieappan 
et al. (2013) 
%FM at 10-20w 
gestation 
BF% = 12.7+0.457 x tricep SFT(mm) 
+0.352 x subscapular SFT (mm) + 0.103 x 
bicep SFT(mm) -0.057 x ht(cm) +0.265 x 
MUAC(cm) 
van Raaij et 
al. (1988) 
%FM FM = W/100 (497/BD–452.3) 
Jackson et al. 
(1980) 
Body Density (BD) BD = 1.0994921 – (0.0009929 x Σ tricep, 
thigh and suprailiac SFT) + (0.0000023 x  
(Σ (triceps, thigh & suprailiac SFT)2) - 
(0.0001392 x age) 
*FM Fat mass; BD Body density; SFT Skinfold thickness; TUAA Total upper arm area; AMA arm muscle area; AFI Arm fat 




2.10.2 Arm anthropometry 
Arm anthropometry is used as an indirect measurement of body composition (FFM and 
FM) by assessing the shape of the upper arm in both clinical and field settings. The 
measurements used are upper-arm length, mid-upper arm circumference (MUAC) and 
tricep SFT. Derivations of body mass indices can then be computed from these (see 
Table 2.2). This measurement relies on the assumption that the arm is a cylindrical 
shape, and the subcutaneous fat layer is evenly distributed around a circular core of 
muscle. When using tricep SFT in conjunction with MUAC, it also assumes that triceps 
skinfold separates subcutaneous adipose and muscle tissue components of the arm 
accurately and the SFT is twice the thickness of subcutaneous fat in the arm. In order 
to reduce observer variability, the technique relies on the testers’ ability to wrap the 
tape at the correct tension, without it being too loose or too tight, and in parallel to the 
arm. Population standards are available for healthy adults however have not been 
validated in a pregnant population, therefore the cut-offs should not be applied in 
pregnancy. 
MUAC in isolation is commonly used in nutrition surveillance and screening programs 
as it quickly assesses nutritional status. Typically, it is used for the detection and 
referral of individuals with acute malnutrition. However, it has been used extensively 
as a research measurement in the field of pregnancy (Friis et al. 2002, Friis et al. 2004, 
Okereke et al. 2013). MUAC is also implemented to predict BMI categories, and has 
been proposed as a surrogate measure for BMI in pregnancy (Fakier et al. 2017). 
MUAC can be used in combination with other arm anthropometry such as triceps SFT 
to derive the arm anthropometric indices arm muscle area (AMA), arm fat area (AFA), 
and arm fat index (AFI) which are proxies for lean and fat mass (Heymsfield et al. 
1982). These are uses for the assessment of regional and total fat mass and fat free mass 
in resource-limited settings, and in the field research settings, where current reference 
methods of body composition are not feasible, such as in pregnancy (Most et al. 2018). 
Arm anthropometry is quick, inexpensive, non-invasive, and requires no input by 
participant and has such no risk of respondent biases. There is good agreement (despite 
over- or underestimation) between anthropometric arm muscle and fat area and the 
cross-sectional area measured by CT and ultrasound in a non-pregnant population 
(Chiba et al. 1989, Jordao et al. 2004). 
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2.10.3 Body Mass Index (BMI) 
BMI is defined as weight (kg) divided by height (m), squared. It has been used by the 
World Health Organisation (WHO) to categorize individuals as normal (18.5-24.9 
kg/m2), overweight (25-29.9 kg/m2), stage I obese (30-34.9 kg/m2), stage II obesity 
(35-39.9 kg/m2) or stage III obesity (≥40 kg/m2). The main limitation of BMI to classify 
obesity is that it is only a surrogate measure of adiposity and does not provide 
information on the distribution and components of adiposity, which is known to elicit 
varying hormonal affects in the body (Brisson et al. 2013, Balani et al. 2014).   
In addition, there are challenges when classifying obesity in pregnancy (Turner 2011), 
as has been shown by Farah et al. (2011), body composition changes relating to 
ethnicity may influence the BMI cut-offs in different ethnicities. This raises questions 
regarding the suitability of BMI cut-offs in pregnancy.  
The use of BMI as a surrogate measure of body fat percentage (BF%) is justified on 
the observation that BMI correlates well with BF% and is hardly dependant on height. 
The suggested cut-off points for overweight (BMI≥ 25 kg/m2) and obesity (BMI≥ 30 
kg/m2) are based on observational studies in Europe and the USA on the relationship 
between morbidity and mortality with BMI in a Caucasian population. The cut-off 
arises due to corresponding BMI of BMI≥ 30 kg/m2corresponding to BF% of about 
35% in young female adults. Various authors have criticized the validity of these cut-
offs in various ethnic groups (Deurenberg 2001, Ko et al. 2001). Later studies based 
on comparison of BMI to predicted BF% were undertaken. They developed more 
suitable cut-offs of ≥23 kg/m2 for overweight ≥27 kg/m2 for obesity in Singaporean 
women (Deurenberg et al. 2002); ≥24 kg/m2 for overweight and ≥28 kg/m2for obesity 
in Chinese women (Zhou 2002); and ≥27.5 kg/m2for obesity in Indian women  (Farah 
et al. 2011). Despite difficulties in measuring body composition in pregnancy, Fattah 
et al. (2010) has shown that BMI and body composition do not change during the first 
trimester of pregnancy, therefore these cut-offs could be applied in clinical practice as 
well as research however, unfortunately are not (Turner 2011). 
Despite this, pre-pregnancy BMI remains an important risk factor for GDM, both 
because of its increase in prevalence over recent years (O'Sullivan et al. 2012), and also 
as a modifiable risk factor compared to other established risk factors (e.g parity, family 
history of diabetes, age and ethnicity) (Kim et al. 2010, Nelson et al. 2010, Giannakou 
et al. 2019). 
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2.11 Risk factors and early predictors of GDM 
Early prediction of GDM is a pertinent topic at this time, as prevalence of GDM is on 
the rise, resulting in associated economic implications (Gillespie et al. 2013, Poon et 
al. 2018). Prediction models have been tested based on maternal characteristics 
(modifiable and non-modifiable risk factors), blood borne biomarkers and a 
combination of the two.  
Women with GDM may exhibit metabolic alterations in recognized pathophysiological 
pathways early in pregnancy, as evidenced by the association between elevated first 
trimester fasting glucose levels, within the non-diabetic range, and increased risk of 
GDM diagnosis later in pregnancy and adverse pregnancy outcomes (Sweeting et al. 
2015).  Donovan et al. (2018) postulated that measurement of first trimester biomarkers 
representative of these metabolic changes may allow for early detection and 
management of GDM, improved understanding of GDM pathogenesis and enhanced 
targeted intervention   
Observational studies have identified a variety of both modifiable and non-modifiable 
risk factors associated with GDM. These include advanced maternal age (Farrar et al. 
2017), increasing parity (Farrar et al. 2017), ethnicity (Li et al. 2020), maternal obesity 
(Morisset et al. 2010), high gestational weight gain  (MacDonald et al. 2017, Hashim 
et al. 2019), physical inactivity (Zhang et al. 2006b, Chasan-Taber et al. 2008), low-
fibre high-glycaemic-load diets (Zhang et al. 2006a), history of previous macrosomia 
or GDM (Petry 2010), family history of diabetes mellitus, and history of polycystic 
ovarian syndrome (PCOS). A history of previous GDM appears to be the strongest 
predictor of subsequent GDM (associated with a 16-fold increased risk); however, 
Teede et al. (2011) postulated that the increasing prevalence of primiparity and 
increased advanced maternal age in current pregnancy cohorts underscores the 
limitations of the current risk factor approach to GDM prediction available. 
Studies assessing the predictive value of traditional clinical risk factor models show 
variable success in sensitivity with poor specificity and low positive predictive value 
(Teede et al. 2011). Models using maternal characteristics have had some success in 
detecting women at risk of GDM later in pregnancy. Most recently, a computerized 
prediction of GDM using information pertaining to diabetes in first degree relative, 
BMI, maternal age, parity and previous GDM was validated and showed high accuracy 
in predicting GDM even at the start of gestation (area under the receiver operating 
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curve (auROC) = 0.85), substantially out-performing a baseline risk score 
(auROC = 0.68) (Artzi et al. 2020). This identified women at low risk that might not 
be otherwise identified from risk-stratification for OGTT screening used in Ireland 
(HSE, 2010). 
Other studies looked at multivariate algorithms, which included maternal 
characteristics in addition to blood borne biomarkers such as placental proteins PAPP-
A and PLGF and found little improvements in their predictive model (Nanda et al. 2011, 
Syngelaki et al. 2015b). This is in contrast to Sweeting et al. (2017) that found inclusion 
of placental protein PAPP-A in the algorithm improved screening efficacy, although 
other commonly used first trimester markers were of little added value. This work shed 
light on the possibility that different markers may be of use in different settings with 
varying results achieved when stratified for ethnicity (Farina et al. 2017). Syngelaki et 
al. (2015a) also found that inflammatory markers (hs-CRP and TNFa) only improved 
sensitivity by 1% in the model. Adiponectin and sex hormone binding globulin are both 
reduced in pregnancies that continue to develop GDM and these markers improve 
screening sensitivity by 6% compared to maternal history alone.  Glycosylation and/or 
glycation of proteins such as fibronectin and CD59 have recently been shown to have 
high auROC scores. Poon et al. (2018) postulated that further work is needed to see if 
these can be combined with other maternal characteristics and investigational tools 
(Rasanen et al. 2013, Ghosh et al. 2017). Recent systematic reviews of these 
biomarkers and prediction models are available in the literature (Donovan et al. 2018, 
Sweeting et al. 2019). 
As detailed in section 2.10.3, BMI is an important risk-stratification tool in pregnancy 
used to identify women at risk of developing GDM (Farah et al. 2011, Farah et al. 2012 
and Most et al. 2018). Excessive accumulation of adipose tissue into the viscera has 
been implicated in increased risk of cardio-metabolic risk (Ribeiro-Filho et al. 2001, 
Bartha et al. 2007, Vlachos et al. 2007) and diabetes mellitus (Bartha et al. 2007, 
Vlachos et al. 2007, Bray et al. 2008, Neeland et al. 2012). Further to this, some studies 
have investigated measures of abdominal adipose tissue in early pregnancy, and 
established its ability to predict glucose intolerance and gestational diabetes in later 
pregnancy (Martin et al. 2009, De Souza et al. 2014, Gur et al. 2014, Yang et al. 2017, 
Bourdages et al. 2018, D'Ambrosi et al. 2018). These research investigations give 
insight into how measures of body composition in early pregnancy play an important 
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role in earlier diagnosis and/or intervention, at a time when there is established contact 
with healthcare professional (Poon et al. 2018). Some recent studies have looked at 
maternal anthropometrics in relation to development of GDM later in pregnancy. 
MacDonald et al. (2017) looked specifically at patterns of gestational weight gain in 
early pregnancy. They modelled trajectories in the first and second trimesters of 
pregnancy using conditional weight-gain percentiles and used multivariable logistic 
regression to assess independent associations of the trajectory with GDM. They found 
that in normal-weight women, every standard deviation increase in weight gain in the 
first trimester above the maternal predicted gain, was associated with a 23% increase 
in the odds of gestational diabetes [95% CI: 0.2%, 51%]. Similar results were found in 
another geographic population (Hashim et al. 2019). Another study by Takmaz et al. 
(2019) looked at weight gain and waist circumference, finding these to be predictive of 
GDM later in pregnancy. However, these measurements were taken at 20-24 weeks 
gestation. Base on their results in a Turkish population, they determined an optimal 
cut-off points for the best predictive value of GDM were a waist circumference of 100 
cm (sensitivity of 84% and specificity of 70%), pre-pregnancy BMI of 25 kg/m2 
(sensitivity of 81.8% and specificity of 76%), and gestational BMI of 28.3 kg/m2 
(sensitivity 75% and specificity of 77.4%). These studies show the potential of 
anthropometric data in the prediction of GDM. To date there has been no study that 
looked at the predictive ability of body composition on GDM based on the regional 
distribution of subcutaneous adiposity, in conjunction with visceral adipose and 
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Background: Exercise can be used as a strategy to attenuate hyperglycaemia 
experienced during gestational diabetes mellitus (GDM). To maximise its use for 
clinical management, the most effective modality should be identified. The purpose of 
this review is to elucidate the most effective modality of exercise on insulin sensitivity 
and blood glucose control in pregnant women with or at risk of GDM. 
Methods: A search was undertaken in MEDLINE, PUBMED, Scopus, CINAHL, 
Cochrane library, EMBASE and Maternity & Infant Healthcare Database. Inclusion 
criteria were RCT and case-controlled studies, which compared exercise interventions 
to standard care during pregnancy, in women with or at risk of GDM.  
Results: Two interventions using resistance exercise, eight using aerobic-exercise and 
two using a combination of both modalities were included. The interventions showed 
consistently that requirement of insulin therapy; dosage and latency to administration, 
were improved in the exercise groups. Less consistent results were observed for 
capillary blood-glucose measurements; however, both modalities and combination of 
modalities were effective at improving blood-glucose control in already diagnosed 
patients, and pregnant women with obesity. Discrepancies in the timing of intervention, 
GDM diagnostic criteria and the different measures used to assess glucose metabolism 
make it difficult to draw clear recommendations.  
Conclusion: Exercising three times per week for 40-60 min at 65-75% age predicted 
HRmax using cycling, walking or circuit training as a modality improved glycaemic 
control in GDM patients, and reduces incidence of GDM in pregnant women with 
obesity. Further studies looking specifically at the effects of different modalities of 
exercise on glucose metabolism with combined strategies to enhance insulin sensitivity 
should be explored to maximise benefits for GDM pregnancies. Consistency in design 
and delivery of exercise-only interventions is required to make recommendation on 
suitable exercise prescription in this population. In practice, adherence to consensus in 






Gestational diabetes mellitus (GDM) is a carbohydrate intolerance resulting in 
hyperglycaemia of variable severity with onset or first recognition during pregnancy 
and with resolution postpartum (2013). It is recognised that overt diabetes during 
pregnancy is associated with significant levels of perinatal morbidity, such as 
macrosomia, neonatal hypoglycaemia, shoulder dystocia and other birth injuries (Hod 
et al. 1996), as well as more recently: respiratory, neurological, digestive and cardiac 
disorders such as cardiac malformations and  hypertrophic cardiomyopathy (Mitanchez 
et al. 2015).  
In addition, exposure to GDM pregnancy in utero has also been shown to induce long-
term effects in offspring (Dabelea and Crume 2011, Carolan-Olah et al. 2015). These 
included increased incidence of type II diabetes, cardiovascular alterations such as 
hypertension (Simeoni and Barker 2009), metabolic syndrome (Clausen et al. 2009) 
and obesity (Kampmann et al. 2015) in the offspring later in adulthood, as well as 
increased risk of developing long-standing diabetes in the mother (O'Sullivan 1982). 
Complications for pregnancies subsequent to GDM are well-established and carry 
serious consequences (Ornoy et al. 2015).  
Stringent new diagnostic criteria have been adopted as usual practice in centres globally 
following findings from the prominent Hyperglycaemia and Adverse Pregnancy 
Outcomes (HAPO) study (Metzger et al. 2008), which showed that small degrees of 
hyperglycaemia have a significant effects on pregnancy and neonatal outcomes. These 
findings have led to improved uniformity in the diagnosis of GDM internationally. Use 
of the newly established criteria (Sacks et al. 2012b) has also resulted in a rise of 
prevalence of GDM from 2.7% using previous criteria for diagnosis (Griffin et al. 
2000), to figures between 9.3 to 25% across the continents using the newly adopted 
and more stringent diagnostic criteria (O'Sullivan et al. 2011, Sacks et al. 2012a). This 
three-fold increase in prevalence is accompanied by a concurrent rise in specialist 
medical referrals becoming a significant burden on the health-care system.  
Medical therapy during gestation, through nutritional therapy and pharmacological 
intervention to obtain glycaemic control has had positive results in the management of 
this condition and attenuation of complications (Tieu et al. 2014). The importance of 
prenatal glycaemic control and weight management through exercise and nutrition 
manipulation is recognised in practice. The ‘Royal College of Obstetricians and 
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Gynaecologists’ (RCOG), as well as the ‘American College of Obstetricians and 
Gynaecologist’ (ACOG), both endorse the participation of pregnant women in aerobic 
and strength-conditioning exercise,  with the goal of maintaining a good fitness level, 
as part of a healthy lifestyle during pregnancy (ACOG 2015, RCOG 2019). Despite 
multiple interventions over the last decade, the most effective form of lifestyle 
management composed of dietary and physical activity behaviours for the prevention 
of GDM remains undetermined (Bain et al. 2015). A Cochrane review of lifestyle 
interventions for the treatment of GDM reported that women exposed to lifestyle 
interventions were less likely to have postnatal depression and were more likely to 
achieve postpartum weight goals (Brown et al. 2017). Exposure was also associated 
with a decreased risk of the neonate being born LGA and decreased neonatal adiposity. 
Despite these positive findings, the contribution of individual components of lifestyle 
could not be assessed due to limiting study designs goals (Brown et al. 2017). 
Exercise has long been accepted as an adjunctive therapy in the management of type II 
diabetes mellitus in non-pregnant individuals, due to its ability to improve insulin 
sensitivity and insulin-stimulated muscle glucose uptake, both of which improve 
glycaemic control (Ruchat and Mottola 2013). The adaptations to exercise occur at the 
skeletal muscle level, and due to similarities with GDM, the findings may translate to 
this population group (Colberg et al. 2010). Modality, frequency, and duration of 
exercise are important components of exercise prescription and need to be defined in 
order to be of practical use to be prescribed in pregnancies both ‘at risk’ and those with 
a clear diagnosis of GDM.  
The purpose of this literature review was three-fold: 1. To identify exercise intervention 
studies implemented specifically during pregnancies complicated by diagnosed GDM 
or ‘at risk’ of GDM; 2. To determine which exercise modality was the most effective 
at improving insulin sensitivity and glycaemic control; and 3. To make 




3.3 Methods:  
3.3.1 Data sources and search strategy 
The PICO framework was applied to formulate the research question and search 
(Schardt et al. 2007). This specialized framework is endorsed by the Practitioners of 
Evidence-Based Practice (EBP) (Fineout-Overholt and Johnston 2005). 
P (Patient/condition): Women at risk of GDM and diagnosed with GDM 
I (Intervention): Exercise only, unless nutrition is part of standard care. 
C (comparison): Exercise modalities (on multiple occasions, this excludes acute bouts 
of exercise) 
O (Outcome): Measure of insulin sensitivity or blood glucose control 
A systematic search of the literature was performed to identify journals articles that 
examined the insulin and glycaemic effects of exercise intervention during pregnancy, 
on women at risk or diagnosed with GDM. The search strategy ‘gestational diabetes’ 
AND ‘exercise’ AND ‘intervention’ AND ‘glycaemic control’ NOT ‘type II diabetes’ 
was applied to the following seven databases: MEDLINE (Ebsco), PUBMED (NCBI), 
Scopus, CINAHL, Cochrane library, EMBASE and Maternity and Infant Healthcare 
Database (Ovid). No date or limits were set, language limits were set for English. RSS 
notifications were set up for each database. In addition, bibliographies of existing 
reviews, eligible studies, key journals and conference proceedings were manually 
scanned. Scholars of various articles were contacted to enquire about protocol. 
Publications that did not have follow up publications of the corresponding trial results 




3.3.2 Study selection 
All journal articles retrieved from the databases were independently reviewed in a two-
stage process by three reviewers. In the first stage, the titles and abstracts of articles 
from the database search were merged into EndNote™ and duplications removed. 
Studies that met review inclusion criteria and studies where there was uncertainty about 
meeting inclusion criteria were reviewed in full text by the main author. In the second 
stage, the full text of the study was read to determine if the study would be included in 
the review. The eligible studies were then reviewed by a second independent reviewer. 
Ambiguity was resolved by discussion with third reviewer (A.D). Inclusion criteria 
consisted of: (1) study population were women diagnosed with GDM or considered at 
risk, with clearly defined risk factors (2) intervention of exercise (on multiple 
occasions) including any modality (aerobic, resistance, aquatic etc.); (3) comparisons 
of exercise interventions to standard care; (4) outcome measures of insulin sensitivity 
or blood glucose control; (5) study design was a randomized control trial or case-
controlled trial (6). Studies were excluded if they included a dietary aspect to the 
intervention (unless this was part of standard medical therapy); participants presented 
with co-morbidities; or use of medication to control hyperglycamia, and studies which 
investigated the acute response to one bout of exercise. 
3.3.3 Data extraction 
Data from articles were extracted onto an Excel© spreadsheet. Data extracted on the 
details of participants included: number of participants in each intervention and control; 
nature of intervention: timing of intervention, duration and type were included. 
Outcome measures relevant to the review such as glycaemic measures and measures of 
insulin sensitivity were included. Other reported outcomes were listed. Inclusion/ 
exclusion criteria, setting (supervised or home-based), compliance/ adherence methods 
of objectively measuring intensity of exercise where included. 
3.3.4 Assessment of risk of bias, data synthesis and analysis 
The main author and a second assessor independently assessed risk of bias for each 
study using the criteria outlined in The Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins and Green 2011). Any disagreement was resolved by a third 
assessor (A.D). Eligible studies did not have combinable outcomes for meta-analysis; 





3.4.1 Description of the studies 
The initial search yielded 685 abstracts, of which thirteen studies met inclusion and 
exclusion criteria (Figure 3.1). Twelve of these were included in this review after 
reviewing for quality (a summary is shown in S1a and b), two were interventions 
looking at resistance exercise (Brankston et al. 2004, de Barros et al. 2010) and eight 
studies looked at the effect of an aerobic exercise intervention (Avery et al. 1997, 
Davenport et al. 2008, Ong et al. 2009, Callaway et al. 2010, Ruchat et al. 2012, Halse 
et al. 2014, Guelfi et al. 2016, Wang et al. 2017). Two studies utilized a combination 
of aerobic and resistance exercise (Garnaes et al. 2016, Sklempe Kokic et al. 2017). 
One study was omitted due to poor adherence to the intervention, with only 16.4% of 
people attending half the sessions (Oostdam et al. 2012). This study was therefore not 
included, as the results did not reflect the effect of the exercise trial, which was a 
combination of resistance and aerobic training. 
Figure 3.1 PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) flow diagram showing inclusion/exclusion of journal articles 




3.4.2 Risk of Bias 
3.4.2.1 Allocation 
Methods to generate the random sequence were judged adequate in 10 of the 12 
included randomized controlled trials and two were unclear risk (see Table S1a). 
Various techniques were used to randomize participants. These methods included use 
of random number table (Brankston et al. 2004), computer-generated random series 
produced by a person unrelated to the protocol (de Barros et al. 2010) and block 
randomisation (Ruchat et al. 2012). Others stated they randomized participants, 
however did not detail how this was done (Ong et al. 2009, Callaway et al. 2010, Halse 
et al. 2014). 
Five trials were judged to have used adequate methods for allocation concealment 
(Brankston et al. 2004, de Barros et al. 2010, Halse et al. 2014, Sklempe Kokic et al. 
2017, Wang et al. 2017). Of these five trials, three of them used concealed opaque 
envelopes and separate researcher allocated patient according to randomization list, and 
one trial allocation was conducted by a third party at another location outside the 
hospital (Callaway et al. 2010). For the remaining four trials, the risk of bias was judged 
unclear due to inadequate allocation concealment, as no methods were detailed (Avery 
et al. 1997, Ong et al. 2009, Oostdam et al. 2012, Guelfi et al. 2016). 
3.4.2.2 Blinding 
For 10 trials, the risk of performance bias due to inadequate blinding of participants 
and personnel was judged to be high (Avery et al. 1997, Brankston et al. 2004, Ong et 
al. 2009, de Barros et al. 2010, Ruchat et al. 2012, Halse et al. 2014, Garnaes et al. 
2016, Guelfi et al. 2016, Wang et al. 2017). One trial did not state details of blinding 
(Callaway et al. 2010), and one study successfully blinded the personnel (de Barros et 
al. 2010). However, due to the nature of the interventions blinding participants is not 
possible (participants are required to perform exercise). 
All trials were considered at high risk of detection bias due to patient-reported 




3.4.2.3 Outcome data 
All studies were considered at low risk of attrition bias with clearly reported attrition 
rates and all trials had low risk of reporting bias as they included data from these 
participants in their analysis, with the exception of one trial (Brankston et al. 2004). 
Oostdam et al. (2012) had a low adherence of 16.5%, and as a result a lot of follow up 
data were missing. They used a statistical technique, bootstrapping, to analyse 
estimates of missing data.  
3.4.2.4 Case-controlled trial 
One included study was a case-controlled trial (Davenport et al. 2008) which was 
assessed using a tool specific for its design (Higgins and Green 2011). The risk of bias 
was judged minimal. Detailed of this can be seen in table S1b.  
3.4.3 Characteristics of studies and patients included in the systematic 
review 
Table 3.1a summarises the studies selected, showing author, number of participants 
(n), exercise modality utilized, and details of the timing of the intervention. Table 3.1b 
describes the characteristics of the patients included in the systematic review. This table 
includes details on the location where the study took place, nature of the population 
diagnosed or at risk of GDM, maternal age (y) and pre-pregnancy BMI (kg/m2) for both 




Table 3.1a Characteristics of studies meeting inclusion criteria 
Article n 
 
Timing of intervention   
 
Intervention Control Mode (RT*, 
AER**, 
COMB***) 
Start point End point Duration 
(weeks) 
Brankston et al., 2004 16 16 RT From GDM diagnosis (26-32) Till end of gestation ~5 
de Barros et al., 2010 32 32 RT From GDM diagnosis (24-34 
weeks) 
Till end of gestation ~5 
Halse et al., 2014 20 20 AER From GDM diagnosis (week 
28.8± week of gestation) 
Till week 34 gestation ~5 
Ruchat et al., 2012  6 6 AER Between 16-20 weeks 34-36 weeks gestation 14-20 
Davenport et al., 2008 10 20 AER From diagnosis (24-28 weeks) To delivery  ≥6 
Ong et al., 2009 6 6 AER From week 18 gestation 28 weeks gestation 10 
Callaway et al., 2010 25 25 AER From 12 weeks gestation 36 weeks gestation 24 
Avery et al., 1997 16 17 AER From GDM diagnosis (from 34 
weeks or less) 
Till end of gestation 4-6 
Guelfi et al., 2016 85 87 AER Between 13 to 15 weeks 
gestation 
28 weeks gestation 14 
Wang et al., 2017 150 150 AER <12+6 weeks gestation 36 weeks gestation ~24 
Garnaes et al., 2016 46 45 COMB 12-18 weeks gestation 36 weeks gestation 18-24 
Sklempe Kokic et al., 
2017 
20 22 COMB 28 weeks Till end of gestation 6-10 
*RT resistance training, **AER: Aerobic exercise *** COMB Combined resistance and aerobic exercise 
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Table 3.1b Characteristics of patients included in the systematic review 





Intervention group Control group 
 








Brankston et al., 
2004 
Canada X  16 30.5±4.4 28.0±5.7 16 31.3±5.0 25.9±3.4 
de Barros et al., 2010 Brazil X  32 32.4±5.4 25.4±3.8 32 31.8±4.9 25.3±4.2 
Halse et al., 2014 Australia X  20 32.0±3.0 26.4±7.1 20 34.0±5.0 25.2±6.7 
Ruchat et al., 2012  Canada  X 6 31.8±5.7 24.9±5.3 6 30.7±7.3 21.6±1.8 
Davenport et al., 
2008 
Canada X  10 33.4±3.3 32.9±7.1 20 33.3±5.3 32.8±5.9 
Ong et al., 2009 Australia  X 6 30.0±4.0 35.1±3.5 6 30.0±4.0 35.1±3.5 
Callaway et al., 2010 Australia  X 25 30.4±4.8 >30 (36% 
BMI≥35) 
25 30.0±5.9 >30 (36% 
BMI≥35) 
Avery et al., 1997 America X  16 32.2±4.9 28.4±7.6 17 30.4±5.1 25.5±5.5 
Guelfi et al., 2016 Australia  X 85 33.6±4.1 26.3±5.1 87 33.8±3.9 25.7±5.4 
Wang et al., 2017 China  X 150 31.1±4.6 26.8±2.7 150 32.5±4.9 26.8±2.8 
Garnaes et al., 2016 Norway  X 46 31.3±3.8 33.9±3.8 45 31.4±4.7 35.1±4.6 




3.4.3.1 Resistance exercise 
Two studies examining the effects of a resistance exercise program during GDM 
pregnancy were identified (Brankston et al. 2004, de Barros et al. 2010). The 
interventions both took place from diagnosis at circa week 24, until the end of 
gestation, for a period of at least 10 weeks. Details of the design of the intervention, 
outcome measures taken and their main findings are summarized in Table 3.2 below, 
with a more comprehensive table S2a. 
Both studies had similar exercise interventions, each consisting of a circuit format of 
eight exercises working up to 15 repetitions of each exercise using a resistance band, 
three times a week. Both showed positive results, and these differed; Brankston et al. 
(2004) showed that the exercise group required less insulin during gestation (43.8%) 
in comparison to diet alone (56.3%), but this was not statistically significant (p=0.48).  
The amount of insulin required (units/kg) was less in the exercise intervention group 
0.22±0.2 vs. 0.48±0.3 (p<0.05), and women in the intervention group required insulin 
later in pregnancy 3.71±3.1 vs. 1.11±0.8 weeks after diagnosis (p<0.05). No detectable 
difference in blood glucose levels, with the exception of pooled post-meal (2h) glucose, 
which was lower in exercise group 6.0±0.29 vs. 6.4±0.81 mmol/L (p<0.05). de Barros 
et al. (2010) found that fewer patients in the exercise group 21.9% vs. 56.3% required 
insulin during gestation (p=0.005). Moreover, patients in the exercise intervention who 
used insulin continued to present adequate glycaemic control according to the target 
established for a longer percent period of weeks than control patients who used insulin 
(0.63 ± 0.30 vs 0.41± 0.30 (p = .006)). No difference was detected between groups in 
mean glucose levels, amount of insulin required and latency to insulin requirement in 
those patients requiring insulin. Mean glucose levels were observed between patients 
of the two groups who used insulin, however these were not found to be different 





Table 3.2 Abridged summary table for resistance exercise interventions, their 
main outcomes and findings 
 
Article Intervention Main outcome measures 




Brankston et al., 
2004 
Circuit session: 3 x per 
week. 3 rounds of 8 
exercises x 15 
repetitions 
Requirement for insulin ↔ No difference  
Amount of insulin ↓ Improved 
Latency of administration of 
insulin 
↑ improved 
Pooled post meal glucose ↓ improved 
de Barros et al., 
2010 
Circuit session 3 x per 
week: 3 rounds of 8 
exercises x 15 
repetitions 
Requirement for insulin ↓ Improved 
Amount of insulin ↔ No difference  
Latency of administration of 
insulin 
↔ No difference  
Pooled capillary glucose levels ↔ No difference  
 
3.4.3.2 Aerobic exercise 
Eight intervention studies were identified which used aerobic exercise as their exercise 
interventio (Avery et al. 1997, Davenport et al. 2008, Ong et al. 2009, Callaway et al. 
2010, Ruchat et al. 2012, Halse et al. 2014, Guelfi et al. 2016, Wang et al. 2017). The 
details of the design and findings of the outcome measures are summarized in Table 
3.3 with a more comprehensive in table S2b. 
The exercise interventions where completely supervised in some cases (Davenport et 
al. 2008, Ong et al. 2009, Ruchat et al. 2012, Guelfi et al. 2016, Wang et al. 2017) 
partially supervised in others (Avery et al. 1997, Halse et al. 2014) and not supervised 
at all in one study (Callaway et al. 2010). The methods used and outcome measures 
taken vary greatly in each trial making it difficult to compare them directly (see table 
S2b), however there seems to be a positive impact of exercise  in outcome measures of 
insulin sensitivity and glycaemic control across those studies that had at least three 
supervised sessions per week lasting 40-45 minutes. Two studies found no differences 
in various measures of blood glucose control and surrogate measures of insulin 
sensitivity between intervention and control group. The first study (Avery et al. 1997) 
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had two supervised sessions lasting 20 minutes, and outcome measures were limited to 
fasting glucose, HbA1c and use of insulin therapy. The second study (Guelfi et al. 
2016) started at 20minutes and increased in duration, the outcome measures used where 
OGTT, HOMA-IR, OGIS and HbA1c.  
Three of these studies recruited a population already diagnosed with GDM, two of 
which reported improvements in outcome measurements (Davenport et al. 2008, Halse 
et al. 2014), whereas Avery et al (1997) did not detect any changes in outcome 
measures. The differences between these studies was the type of exercise, Halse et al., 
(2014) used cycling as a modality, and Davenport (2008) walking, whereas Avery et al 
(1997) used arm ergometer. Frequency and duration of exercise was also less; twice 
per week for 20 minutes (Avery et al. 1997), as opposed to three times per week for 40 
minutes (Davenport et al. 2008, Halse et al. 2014). 
Five of the studies engaged a population at risk of gestational diabetes (Ong et al. 2009, 
Oostdam et al. 2012, Ruchat et al. 2012, Guelfi et al. 2016, Wang et al. 2017). The 
duration of these interventions ranged from 10 to 20 weeks in comparison to the 4-6 
week duration of intervention in those studies who engaged a population diagnosed 
with GDM (Avery et al. 1997, Davenport et al. 2008, Halse et al. 2014). Improvements 
were found in capillary blood glucose (Ruchat et al. 2012), blood glucose response to 
OGTT (Ong et al. 2009, Wang et al. 2017), insulin resistance (Wang et al. 2017), 
gestational weight gain and incidence of GDM was reportedly improved in one study 
(Wang et al. 2017). One study in particular (Guelfi et al. 2016) reported no difference 
in all outcome measures, despite similar frequency, intensity, type and duration of 
exercise intervention. This study differed from the above studies in the population 
recruited, where women with previous GDM where recruited as opposed to obesity. 
These women had a lower BMI than those women engaged in the other studies, with 
44% in the exercise group and 55% in the control group within a healthy BMI. It is also 
worth noting this had sample size powered to gestational weight gain and not measure 




Table 3.3 Abridged summary table for aerobic exercise interventions, their main 




Main findings  (control 
vs. Intervention group) 
Halse et al., 
2014 
Cycling 5 x per week. 
3 x a week: supervised 
45 minutes moderate 
intensity and short 
bouts of higher 
intensity, 2 x a week 
30 min moderate 
cycling unsupervised. 
Mean capillary 
blood glucose pre 





Increased in both groups, 
with no difference between 
groups 
OGTT1 ↔No difference 







program 3-4 x per 
week: 40 minutes in 
total with 30 minutes 
at target HR of  30 or 
70% HRR2 according 
to group allocation 
Capillary blood 
glucose pre & post 
exercise 
↓ Improved in all groups 
and durations. Longer 
durations of exercise 
(40min). Improvements in 
capillary glucose 
attenuated with longer 
durations of exercise. 
Davenport 
et al., 2008 3-4 walking sessions a 






insulin ↓ Improved 
Amount of insulin ↓ Improved 
Ong et al., 
2009 
3 x per week 45 min 




↓ Improved OGTT at  1 
hour 
Insulin sensitivity 





exercise plan, to reach 
recommendation of 
7.5-12.5 MET-h/week6 







↔ No difference 
Fasting glucose ↓ Improved 
Fasting insulin ↓ Improved 
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Avery et al., 
1997 
 
2 supervised session per 
week 30min 5min warm 
up, 20min 70%HRmax, 
5 min cool down on 
cycle ergometer. In 
addition, 1-2 
unsupervised sessions at 






Use of insulin therapy 
↔ No difference 
 
↔ No difference 
 
↔ No difference 
 
 
Guelfi et al., 
2016 
 
3 x per week at home 
supervised on cycle 
ergometer. Warm up for 
5 min at 55-65%HRmax, 
intervals alternating 
between 65-75%HRmax 
and 75-85% HRmax. 
Sessions progressed by 
increasing in duration by 
5min every 2-3 weeks so 
that they started at 
20minutes up to a 












↔ No difference 
 
 
↔ No difference 
 
↔ No difference 
 
↔ No difference 
 
Wang et al., 
2017 
 
3 x per week supervised 
exercise sessions on 
cycle ergometer.  
5min warm up (55-
65%HRmax)  
30s sprint at 75-
85%HRmax every 2 min 
for 3-5 intervals, 
followed by 5min at 60-





5min cool down at 55-
65%HRmax. Exercise 
period start at 45min and 
increased to 60min 
progressively. 













1 hour post ingestion 






Insulin levels ↓ Improved 
Insulin resistance ↔ 








*OGIS Oral Glucose Insulin Sensitivity index; HOMA-IR Homeostatic Model Assessment-Insulin Resistance; HbA1c Glycated 
haemoglobin; GDM Gestational Diabetes Mellitus; OGTT Oral glucose tolerance test; HRmax Heart rate maximum 
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3.4.3.3 Combined aerobic and strength exercise 
Two studies included both an aerobic and resistance training modalities of exercise 
(Garnaes et al. 2016, Sklempe Kokic et al. 2017). Summary in Table 3.4 below and 
more in-depth details in Table S2b. Both studies had supervised and non-supervised 
elements. Garnaes et al. (2016) reported an incidence of GDM was less in exercise 
group vs. control group (6.1% vs. 27.3%, p=0.04); however no difference was observed 
in OGTT, insulin, HbA1c, and HOMA2-IR. Sklempe and colleagues (2017) found an 
improvement in post-intervention average of three post-prandial measures (4.66± 0.46 
vs. 5.30 ± 0.47, p < 0.001), but no difference in fasting glucose between the two groups. 
The two interventions varied in duration and population characteristics, with Garnaes 
et al. (2016) intervening for 18-24 weeks in pregnant women at risk of GDM (BMI ≥ 




Table 3.4 Abridged summary table for combined aerobic and strength exercise 




Main findings  
(Intervention group 
vs. control) 
Garnaes et al., 
2016 
3 x per week 
supervised. 35min 
aerobic exercise 




lifts, oblique, and 
abdominal crunches. 3 
x30s plank at the end. 
Pelvic floor exercise 
10 sets of 6-8s hold. 
50 min home program 
1x per week (same 
structure as 
supervised session. 



















↔ No difference 
 
↔ No difference 
 
↔ No difference 
 





Sklempe et al., 
2017 
2 x per week 
supervised session. 
(50-55min) 20min 
treadmill walking at 
65-75%HRmax. 
Resistance exercise 
using body weight, 
elastic bands and 0.5-
kg hand held weight. 
6 exercises x 3sets of 
10-15reps. 3 different 
routines were used 
and interchanged. 
Exercise group was 
also asked to perform 
30min brisk walk per 
day. 
 Post intervention 
average of 3 
postprandial 
measures 
 Fasting glucose 


















1OGTT: Oral Glucose Tolerance Test. The specific test used is outlined in each study. 2HRR: Heart 
Rate Reserve. Target heart rate was determined using the HRR equation by Karvonen et al. (1957) 
3HRmax: Heart rate maximum established from predicted formula or sub-maximal exercise testing 
4OGIS: Oral Glucose Insulin Sensitivity index which determines insulin sensitivity from the OGTT 
(Mari et al. 2001) 5HOMA-IR Homeostatic Model Assessment-Insulin Resistance: method to quantify 




Twelve intervention studies met the inclusion criteria for this systematic review and 
were included in this review (Avery et al. 1997, Brankston et al. 2004, Davenport et 
al. 2008, Ong et al. 2009, de Barros et al. 2010, Ruchat et al. 2012, Halse et al. 2014, 
Garnaes et al. 2016, Guelfi et al. 2016, Sklempe Kokic et al. 2017, Wang et al. 2017). 
Modalities of these interventions were resistance exercise (Brankston et al. 2004, de 
Barros et al. 2010) and aerobic exercise (Avery et al. 1997, Davenport et al. 2008, Ong 
et al. 2009, Callaway et al. 2010, Ruchat et al. 2012, Halse et al. 2014, Guelfi et al. 
2016, Wang et al. 2017). Some interventions showed that requirement of insulin 
therapy (Davenport et al. 2008, de Barros et al. 2010), dosage (Brankston et al. 2004, 
Davenport et al. 2008) and latency to administration  (Brankston et al. 2004) improved 
in the exercise groups. Capillary blood-glucose measurements also improved 
(Davenport et al. 2008, Ruchat et al. 2012, Halse et al. 2014), as well as post-meal 
glucose  (Brankston et al. 2004), and blood glucose response (Ong et al. 2009). Other 
outcomes measured showed no difference in insulin sensitivity (Ong et al. 2009, Halse 
et al. 2014, Guelfi et al. 2016), insulin resistance (Callaway et al. 2010, Wang et al. 
2017), requirement of insulin  (Brankston et al. 2004), amount of insulin required (de 
Barros et al. 2010), as well as latency of administration (de Barros et al. 2010). Of note 
is that no studies reported any negative outcomes of exercise on blood glucose control. 
Discrepancies in the timing of intervention, GDM diagnostic criteria and the variety in 
outcome measures used to assess glucose metabolism, make it difficult to draw clear 
recommendations but have useful considerations for the design of future exercise 
interventions in this patient population. 
The details of the exercise (modality, time, intensity) are of high importance during 
GDM, as diagnosis occurs around weeks 24-28 of gestation, allowing for 8-10 weeks 
opportunity for intervention before parturition.  In the studies included in this review, 
the time-frame exposed to the exercise intervention, and degree of hyperglycaemia of 
the participants varied as a product of different GDM diagnostic criteria used by the 
study to define a starting point (Hoffman et al. 1998, Meltzer et al. 1998, CDA 2003, 
Metzger et al. 2007). These criterion are less stringent than the current guidelines by 
the World Health Organisation (WHO 2013) derived from the International 
Association of the Diabetes and Pregnancy Study Groups (IADPSG) group as a result 
of findings from the Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO) 
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study. This could potentially have an effect of the outcomes of the exercise 
interventions, as it still needs to be established at which specific point prior or during 
GDM can an exercise intervention be most effective. 
Interventions delivered in ‘at risk’ population (Ong et al. 2009, Callaway et al. 2010, 
Ruchat et al. 2012, Garnaes et al. 2016, Guelfi et al. 2016, Wang et al. 2017) 
commenced earlier in gestation and lasted 10-24 weeks. Ong et al. (2009) recruited 
pregnant women with obesity; otherwise not at risk of GDM and the length of time of 
intervention was over six weeks. Commencing exercise intervention earlier gave 
positive results to glycaemic control in all cases, bar in a population who had previous 
GDM. This is in line with exercise interventions in type II diabetic patients, where 
positive outcomes were attributed to the benefits of metabolic control and adaptation 
over 15 weeks or more (Boulé et al. 2001), with even one week of aerobic training 
known to improve whole body insulin sensitivity in obese individuals with type II 
diabetes (Winnick et al. 2008). In light of this, it is worth considering at which point to 
intervene with an exercise intervention, even though it is recognized that exercise prior 
to pregnancy is effective at reducing the risk of GDM (Han et al. 2012), the most 
effective strategies to maximise results have not been identified.  
The modality of exercise also needs to be considered in terms of the longer term aspects 
of the effects it may have. Most of the studies included in this literature review did not 
follow up the women or infants postpartum, with the exception of Halse et al. (2014) 
who reported follow-up data separately (Halse et al. 2015). This is very valuable, as 
they reported a reduced incidence of macrosomia in the offspring and less maternal 
weight gain over the intervention period in the group who engaged in the exercise 
intervention. No other improvements in obstetric or neonatal outcomes were observed, 
despite this, it is also positive that no adverse effects where reported consequent to the 
exercise intervention.  These data are relevant in understanding what benefits aerobic 
activity confer in the longer term. Specifically this population group is at higher risk of 
developing type II diabetes following gestation (Kim et al. 2002), and the benefits of 
various exercise modalities can extend beyond the acute (Golbidi and Laher 2013, 
Ruchat et al. 2016).  
The tests used to assess glycaemic control in the interventions are typically 75g-Oral 
glucose tolerance test (OGTT) results at diagnosis and later in pregnancy, postprandial 
blood glucose, random blood glucose and insulin measures, HbA1c, indirect measures 
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of insulin sensitivity (OGIS) based from OGTT  (Mari et al. 2001), HOMA-IR, as well 
as need for insulin treatment and others as indicators of progression of hyperglycaemia, 
however additionally, treatment criteria depends on which criteria the health centre 
practices. Sensitivity of these measures needs to be considered, and can explain the 
variation in results, sometimes seeing a positive outcome in one outcome with no 
change in another, all within the same study. Postprandial plasma glucose excursions 
have been found to be as important (Sorkin et al. 2005) in achieving HbA1c goals in 
type II diabetic patients, and due to the limited timeframe of pregnancy this may be a 
more relevant marker than HbA1c, as blood renews itself after 8-12 weeks therefore 
missing out the period of the acute interventions delivers. The lack of homogeneity in 
measurements across studies makes them difficult to compare.  
Adherence was measured in each of the trials, with the use of attendance logs  
(Brankston et al. 2004, Ong et al. 2009, Ruchat et al. 2012, Halse et al. 2014), 
pedometer readings (Davenport et al. 2008), self- monitored exercise diaries (Halse et 
al. 2014) and combination of attendance and log-book  (Brankston et al. 2004, Ruchat 
et al. 2012). All included trials reported high attendances with over 90% exercise 
sessions attended by intervention groups. Trials involving supervised components of at 
least three times per week with at least 40min of exercise had better outcomes in 
glycaemic management, than those who engaged in less. 
Measuring adherence is an important component of exercise interventions in pregnancy 
as women typically experience more perceived barriers to exercise during pregnancy 
resulting in decreased participation to exercise (Evenson et al. 2008, Gaston and Cramp 
2011). These barriers are compounded in women at risk of GDM (Leppänen et al. 
2014), including obesity (Seneviratne et al. 2015), as well as those with GDM in a 
previous pregnancy (Infanti et al. 2014). These women experience more barriers 
specific to their condition, and pre-pregnancy weight.   
In a pregnant cohort who had GDM in a previous pregnancy, Infanti et al. (2014) found 
that requiring insulin treatment was a barrier to participation in exercise, whilst women 
over the age of 34 were more likely to participate. Within a GDM cohort, Downs and 
Ulbrecht (2006) found that the strongest perceived advantage of exercise during 
pregnancy was controlling blood glucose levels, whilst postpartum was for weight 
control. The most common barrier to exercise during pregnancy was fatigue and 
postpartum was a lack of time. Women exercised more during the postpartum period 
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than before or during pregnancy and number of exercise advantages reported was 
positively associated with the amount of exercise engaged in whilst pregnant and 
postpartum (Downs and Ulbrecht 2006).   
In a Finnish cohort of women at risk of GDM, barriers to exercise included not meeting 
physical activity recommendations prior to pregnancy, education level and working 
full-time (Leppänen et al. 2014). They found strong predictors of meeting physical 
activity recommendations was education level, working part-time and having a 
physically active spouse. The latter being the strongest predictor and consistent with 
findings in another GDM cohort (Downs and Ulbrecht 2006).  Children, other family 
members, weather and pre-pregnancy activity levels were also factors that motivated 
these women to meet physical activity recommendations. Tiredness, nausea, perceived 
health, work and lack of time restricted their physical activity level the most, with the 
latter three reported as the most common barriers (Leppänen et al. 2014). 
In addition to these specific populations, women tend to engage in less physical activity 
as a whole during pregnancy (Seneviratne et al. 2015). A number of pregnancy-related 
physiological changes make exercise increasingly challenging and less acceptable 
during pregnancy. These include an increased sense of breathlessness, change in centre 
of gravity (with alteration of posture and balance), and increased laxity of ligaments 
(Cherni et al. 2019). Furthermore, weight gain in pregnancy due to expansion of 
maternal blood volume leads to an increase in the cardiorespiratory effort required to 
perform a given amount of physical activity. Perceived barriers to exercise such as 
tiredness, low motivation, lack of enjoyment and concerns regarding pregnancy 
complications and foetal harm have also been reported widely in this population 
(Seneviratne et al. 2015). Additionally, a number of external factors that are important 
to pregnant women, such as lack of childcare, lack of time, overly protective family 
members, lack of outdoor spaces to be active, and the cost of exercise facilities. 
Additional barriers specifically in pregnant women with obesity have been reported by 
Seneviratne et al. (2015). These pertain to negative self-image, lack of adequate 
antenatal support on safe exercise, perception that the healthcare provider’s knowledge 
on appropriate exercise in pregnancy was limited, conflicting advice, and lack of access 
to correct information. In a recent review, Bauer et al. (2018) postulated that pregnant 
women should be given tailored advice/motivation according to pre-pregnancy body 
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mass index, as they found motivational factors and barriers to be specific amongst 
different BMI groups and mostly of a modifiable nature. 
Lessons learned from these studies should be considered in future in the design of 
interventions to ensure a targeted intervention design to be more likely for pregnant 
women at risk or diagnosed with GDM to participate. Gaston and Cramp (2011) 
outlined demographic and theory-based correlates that should be taken into 
consideration when developing interventions to increase physical activity among 
pregnant women. This body of research should be considered in order to maximize 
engagement in this population. In this systematic review, studies with supervised 
exercise had better adherence. Future work into the potential barriers supervision helps 
overcome in this population would be useful in guiding further exercise intervention 
studies. 
When lifestyle changes do not normalise blood glucose levels, pharmacological 
treatment can be utilized, progressing to insulin treatment as a final course of action. 
Delaying and minimising treatment with insulin is of clinical importance not only as 
an indicator of progression of hyperglycaemia, but also due to its association with 
vascular damage (Meigs et al. 2000). Both resistance interventions took measures of 
insulin administration (Brankston et al. 2004, de Barros et al. 2010), and though these 
specific interventions were not statistically powered for this outcome measure, they 
showed improvements in response to the intervention. Future studies should 
incorporate these measures within their trials. 
The mechanisms behind impaired insulin sensitivity during GDM are not completely 
understood, and therefore remains a very fertile ground for research. Exercise may be 
an effective strategy to optimize glucose homeostasis as it can lower blood glucose 
levels, thereby improving insulin sensitivity during pregnancy reducing the burden on 
the compensating β-cells (Buchanan and Xiang 2005). Exercise lowers blood glucose 
concentration via two distinct mechanisms: the contraction-mediated pathway, and the 
insulin-stimulated pathway (Hawley and Lessard 2008). The physiological 
mechanisms involved in increasing insulin sensitivity include increased number of 
insulin-sensitive glucose transporters (GLUT-4), enhanced response of GLUT-4 to 
insulin and increased glycogen synthase activity, all within skeletal muscle. These 
work in combination to lower capillary glucose concentrations. The underlying 
mechanisms surrounding this are described in-depth elsewhere (Golbidi and Laher 
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2013). As skeletal muscle is the major source for insulin-stimulated glucose uptake, 
any treatment targeted to improve glucose uptake in this tissue will improve whole-
body insulin sensitivity. The metabolic benefits of exercise, specifically during GDM 
pregnancy, are thought to be due to changes affecting pathways which influence insulin 
sensitivity, adipokines and reduction-oxidation reactions (Golbidi and Laher 2013). 
Aerobic and resistance exercise trigger various metabolic pathways to elicit metabolic 
benefits when performed prior to pregnancy (Bain et al. 2015) and as part of medical 
therapy for glycaemic management in type II diabetic patients (Thomas et al. 2006). 
Some research has shown that the metabolic benefits and protective effects are dose-
dependent (Warburton et al. 2006) leading some studies to turn their focus to energy 
expenditure (Callaway et al. 2010, Kumareswaran et al. 2013). However, studies 
investigating the effects of differing modality of exercise on several metabolic markers 
and compartmental changes in body composition show that the metabolic benefits are 
specific and diverse according to modality (Ibanez et al. 2005, Dreyer et al. 2006, 
Rattarasarn 2006, Dreyer et al. 2010, Ku et al. 2010).  
Aerobic exercise may work best for increased uptake of glucose into the muscle and 
reducing fat mass (reduced adipokine and leptin production). However, resistance 
exercise may be more effective at increasing lean muscle, and thus basal metabolic rate, 
and therefore may have its place in the management of GDM pregnancies, in terms of 
long-term maternal outcomes and their risk of developing type II diabetes mellitus 
(Kim et al. 2002). Previous studies have suggested that the maternal environment, in 
particular reduction in maternal insulin sensitivity, contributes significantly to foetal 
growth (Scholl et al. 2001). Regular aerobic exercise, through an effect on maternal 
insulin sensitivity, may influence offspring size by regulating nutrient supply to the 
foetus. 
The discrepancies in the results of the resistance exercise interventions (Brankston et 
al. 2004, de Barros et al. 2010) included in this review may be due to the higher 
numbers recruited in De Barros et al., (2010). Also of note is the difference in delivery 
of interventions. Brankston et al., (2004) supervised three sessions per week, including 
a weekly phone call to ensure adherence. This was in contrast to De Barros et al., 
(2010), where one session per week was supervised and phone contact was made with 
participants to encourage adherence for the two other sessions that took place at 
participants home unsupervised.  In both trials, resistance was adjusted via the length 
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of the elastic band to increase tension, and even though it is speculated this modality is 
self-limiting unlike free weights, a short-term study in women has found elastic bands 
to produce the same benefits in body composition changes as free weights (Colado and 
Triplett 2008). The aerobic interventions had varying results, as the delivery of their 
intervention and outcome measures were different in each study. Therefore as 
previously alluded to, it is suggested that future study designs are homogenised in order 
to make comparisons between effectiveness of exercise modality on glycaemic 
parameters. 
Studies have previously shown that greater exercise intensity exercise yields greater 
glucose uptake by skeletal muscle cells acutely, and over time through the contraction 
mediated and insulin stimulated pathways, to increase insulin sensitivity (Keshel and 
Coker 2015). Exercise prior to pregnancy is known to reduce the risk of developing 
GDM (Winnick et al. 2008, Ruchat and Mottola 2013). In an overweight/obese non-
diabetic population, it has been shown that aerobic exercise was more effective at 
reducing fat mass, and resistance training was more effective at increasing lean mass. 
However performing both, and hence doubling the time committed to exercise by 
participants, did not double the benefits (Willis et al. 2012). This, as well as the limited 
time-frame between diagnosis of GDM and parturition (~8weeks), further highlights 
the importance of establishing the most effective modality of exercise as a treatment 
for hyperglycaemia in GDM patients during pregnancy, in order to maximise strategies 
for minimising hyperglycaemia in the antenatal period. 
 
3.6 Conclusion for practice 
This systematic review recommends that patients with GDM and pregnant women with 
obesity can improve glycaemic management and incidence of GDM during pregnancy 
through exercise. Evidence collated in this review suggests that women diagnosed with 
GDM benefit from exercise performed a minimum of three times per week, resistance 
exercise consisting of eight exercises of 15-20 repetitions each using major muscle 
groups, or aerobic exercise using major muscle groups such as cycling, and walking, 
performed at 12-14 RPE (65-75% age predicted HRmax) for 40-60 minutes. For 
adherence purposes, supervising sessions and making these sessions interesting using 
brief intervals of increased intensity such as RPE 13-15 (75-85% age predicted 
HRmax) using resistance or speed can be undertaken safely with suitable monitoring 
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and realistic increments of time and intensity according to the patients previous ability 
and progress. Combinations of aerobic and resistance exercise also confer such benefits 
to glycaemic control, in line with the 7.5-12.5 MET-h/week (~900kcal) of moderate to 
vigorous exercise guideline set out for this population group. Women at risk of GDM 
due to high BMI (>28 kg/m2) would benefit from similar intervention; however those 
at high risk of GDM due to previous exposure to GDM without obesity do not seem to 
improve glycaemic control with such interventions.  
Despite no studies reporting any negative outcomes of exercise on blood glucose 
control, the lack of heterogeneity amongst the studies make it difficult to draw clear 
recommendations, however have useful considerations for the design of future exercise 
interventions in this patient population. Heterogeneity amongst studies arose due to 
discrepancies in the timing of intervention, criteria used for GDM diagnosis and the 
variety in outcome measures used to assess glucose metabolism. In light of this, it is 
recommended that further research on the effectiveness of exercise interventions needs 
to take place, in a standardized manner, in order to compare results and answer what is 
the most effective exercise intervention in this population. This includes timing and 
duration of intervention, as well as methods of measuring glucose control and indices 
of insulin sensitivity. It is recommended that dietary intake and physical activity are to 
be measured as confounding factors, in order to isolate and observe the effects of 
specific exercise interventions. Future studies should also focus on measurements of 
hyperglycaemia, as confirmed by the large HAPO study, that small degrees of 
hyperglycaemia have a significant effect on pregnancy and neonatal outcomes. The 
clinical significance of the outcome measures used should be considered. Interventions 
should aim to follow-up participants postpartum to understand longer-term benefits of 
antenatal exercise intervention.  
Well-controlled exercise interventions, which are homogenous in the measures used, 
specific gestational period when intervention is implemented, and clinical population 
(i.e. all diagnosed at the same diagnostic threshold) are required to understand which 





There is a paucity of literature on exercise interventions during pregnancy on women 
with GDM, specifically including measures of glycaemic control. The studies included 
in this review showed an improvement in blood glucose measures in two modalities of 
exercise: aerobic and resistance exercise. Future studies looking at exercise strategies 
to maximise non-insulin stimulated uptake of glucose through are needed to counteract 
the increase in insulin resistance observed during pregnancy, and especially of GDM.  
This systematic review was an important prelude to the work that follows in subsequent 
chapters. As we have learnt from this study that the longer the duration of intervention 
resulted in better outcomes in insulin sensitivity and glycaemic control, there was a 
decision to shift focus to early detection of GDM. Early prediction of GDM is a very 
pertinent topic at this time as prevalence of GDM is on the rise in Ireland and globally, 
and has related economic implications (Gillespie et al. 2011, Poon et al. 2018).  
In order to do this, we initially explored the relationship between maternal parameters 
and degree of hyperglycaemia to neonatal outcomes within a cohort of mothers with 
GDM. The next chapter sets out to address this (Chapter 4). A focus on maternal obesity 
is taken as exercise affects both maternal fat stores as well as insulin sensitivity, both 
of which have been implicated in the pathophysiology of GDM (Kirwan et al. 2002, 
Jayabalan et al. 2017). This shift in the thesis was undertaken as it is recognised that 
early detection of GDM could improve the benefits of medical nutrition therapy and 
exercise interventions as well as shed light on who might respond better to various 
types of lifestyle and pharmacological preventative interventions (Thangaratinam et al. 
2012, Koivusalo et al. 2016, Syngelaki et al. 2016).  
Despite this shift, the evidence presented in this chapter is carried forward later on in 
the thesis, were physical activity levels are captured in a prospective study as a potential 
confounding factor to predictors of GDM (Chapter 6). 
Studies examining specific exercise interventions in this particular population are of 
importance on several levels. They help to understand the mechanisms behind the 
exercise being performed by discerning which modality and duration is most effective. 
This can be used to make recommendations by informing public health policy to 
promote derived recommendation to this specific population. Also, economically, as 
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effective interventions may reduce the medical burden this condition constitutes to both 
mother and infant. 
There needs to be a shift in paradigm, similar to the nutrition adage of “eating for two” 
has been dispelled in recent years through education. It is important to emphasize to 
pregnant women that moderate intensity exercise during pregnancy is safe, healthy and 
indeed beneficial to both mother and child, when done in line with guidelines (ACOG, 
2015). In recent years, nutrition has taken the role as the ‘cornerstone of therapy’; also 
referred to as ‘medical nutritional therapy’, however, exercise has not quite caught up 
to this reputation, despite the effects it has on multiple metabolic mechanisms in the 
body (Keshel and Coker 2015). In the months during pregnancy, mothers are known to 
be very receptive to behaviour change and have many ‘teachable moments’. This is 
certainly supported by the studies included with high adherence rates in these studies, 
and should be considered a good opportunity for behavioural change to be maximised 




3.8 Supplemental information  
Table S1a Cochrane assessment of risk of bias for randomized control trials 




















































































































































































































Brankston et al., 2004 + + - - - + ? 
de Barros et al., 2010 + + + - - + + 
Halse et al., 2014 + + - - - + + 
Ruchat et al., 2012  ? ? - - - + + 
Ong et al., 2009 ? ? - - + + + 
Callaway et al., 2010 + + ? - ? + + 
Oostdam et al., 2012 + - - + ? - - 
Avery et al., 1997 + ? - ? - ? ? 
Guelfi et al., 2016 + - - ? ? + + 
Wang et al., 2017 + + - + ? + + 
Garnaes et al., 2016 + ? - + + + + 





Table S1b Quality assessment for case-controlled trial 
  
Davenport et al., 2008 (Case -controlled) 
   
  Yes No Other 
(CD, NR, 
NA) 
1. Was the research question or objective in this 
paper clearly stated and appropriate? 
X   
  
2. Was the study population clearly specified and 
defined? 
X   
  
3. Did the authors include a sample size 
justification? 
    
NR 
4. Were controls selected or recruited from the 
same or similar population that gave rise to the 
cases (including the same timeframe)? 
X   
  
5. Were the definitions, inclusion and exclusion 
criteria, algorithms or processes used to identify or 
select cases and controls valid, reliable, and 
implemented consistently across all study 
participants? 
X   
  
6. Were the cases clearly defined and differentiated 
from controls? 
X   
  
7. If less than 100 percent of eligible cases and/or 
controls were selected for the study, were the cases 
and/or controls randomly selected from those 
eligible? 
    
NR 
8. Was there use of concurrent controls?   X   
9. Were the investigators able to confirm that the 
exposure/risk occurred prior to the development of 
the condition or event that defined a participant as 
a case? 
    
NA 
10. Were the measures of exposure/risk clearly 
defined, valid, reliable, and implemented 
consistently (including the same time period) 
across all study participants? 
x   
  
11. Were the assessors of exposure/risk blinded to 
the case or control status of participants? 
    
NR 
12. Were key potential confounding variables 
measured and adjusted statistically in the analyses? 
If matching was used, did the investigators account 
for matching during study analysis? X   
  
*CD, cannot determine; NA, not applicable; NR, 
not reported 





Table S2a Details of exercise intervention, the outcome measures taken and main findings for the interventions using a resistance 
exercise intervention 
Article Details of exercise intervention Outcome measures taken Main findings 
Brankston 
et al., 2004 
Supervised 3 introductory 
sessions, followed by circuit type 
exercise 3 x per week consisting of 
8 exercises with short rests (less 
than 1 min).  
The exercises were 1.plies 
2.military press 3. Bench press 4. 
Lateral pull down 5. Seated row 6. 
Triceps press with the use of 
rubber tubing instead of weights.  
Progression of exercise program 
started with 2 sets x 12 reps in 
week 1, 2 sets x 12 reps in week 2, 
3 sets x 15 reps in week 3, and in 
week 4 up to delivery 3 sets x 20 
reps were performed. 
• Requirement of insulin (Insulin 
therapy was initiated if any of the 
following three values were 
exceeded consistently at any time 
during diet therapy: mean fasting, 
≥5.3 mmol/L (95 mg/dL); mean 1-
hour post-prandial:  ≥7.8 mmol/L 
(140 mg/dL); or 2-hour post 
prandial, ≥6.7 mmol/L (120 
mg/dL).) 
• Amount of insulin required 
(units/kg)  
• Latency to insulin requirement 
(weeks) 
• Gestational age at delivery  
• Rate of caesarean deliveries  
• Birth weight  
• Daily fasted blood glucose 
measurement 
• 1- or 2h postprandial 
measurements 
EX2 intervention required less insulin during 
gestation (43.8%) in comparison to diet 
alone (CON) (56.3%) however this was not 
significant (p=0.48).  
Amount of insulin required (units/kg) were 
less in EX group 0.22±0.2 vs. 0.48±0.3 
(p<0.05), and women required insulin later 
in pregnancy 3.71±3.1 vs. 1.11±0.8 weeks 
after diagnosis (p<0.05).  
No detectable difference in blood glucose 
levels, except in pooled post-meal (2h) 
glucose, which was lower in EX group 
6.0±0.29 vs. 6.4±0.81 in CON3(p<0.05).  
                                                 
All measures are mean± standard deviation (SD). Abbreviations:  2 EX refers to the specific exercise intervention applied in the study.  
3 CON refers to the control group of the specific intervention 
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de Barros et 
al., 2010 
Circuit style exercise with 
resistance band. 8 exercises were 
incorporated in 1 circuit with 15 
reps. 30-60s rest was taken 
between exercises. RPE scale was 
used for exertion, participants 
were asked to maintain an 
intensity close 5 to 6, which 
corresponds to 'somewhat heavy'. 
Circuits were performed on 3 non-
consecutive days per week 2 
circuits in the first and second 
week, 3 from there on. 
• Requirement of insulin (Insulin 
was introduced when more than 
30% of the glucose measurements 
were above the recommended value 
or when 20-30% of the 
measurements indicated 
hyperglycaemia and foetal weight 
was above 75th percentile.) 
• Amount of insulin required  
(U/kg)  
• Latency to insulin requirement 
(weeks),  
• Percentage of weeks spent within 
the target glucose range 
• Capillary glucose levels 
Less patients in the exercise group 21.9% vs. 
56.3% required insulin during gestation 
(p=0.005). Moreover, EX patient who used 
insulin continued to present adequate 
glycaemic control according to the target 
established for a longer percent period of 
weeks than control patients who used insulin 
(EX= 0.63 ± 0.30 vs CON = 0.41± 0.30 p = 
.006).  
No difference was detected between groups 
in mean glucose levels, amount of insulin 
required and latency to insulin requirement 
in those patients requiring insulin.  
Mean glucose levels was observed between 
patients of the 2 groups who used insulin 





Table S2b Details of exercise intervention, the outcome measures taken and main findings for the interventions using an aerobic 
exercise intervention. 







Home-based cycling program 5x per week. 
3 supervised sessions:  Warm up: 5min of low-intensity pedalling 
(55%–65% age-predicted HRmax1; RPE2, 9–11). This was followed 
by a conditioning period that was broken up into several phases.  
3 phases included periods of: a) continuous moderate intensity 
cycling at an intensity of 65%–75% age-predicted HRmax 
(calculated using the formula 220 - age) and a target RPE of 12–14 
and;  b) intervals of varying intensities consisting of 15–60 s of 
higher-intensity bouts (75%–85% age-predicted HRmax; RPE, 15–
16) performed every 2 min, interspersed with lower- intensity 
(55%–65% age-predicted HRmax; RPE, 9–11) recovery pedalling 
between. The cycling resistance was adjusted accordingly. 
Warn up: 25-30 min sessions at the lower end of the calculated HR 
ranges during week 1 to familiarize participants with the structured 
exercise. Intensity and duration of exercise progressively increased 
according to individual ability, with the aim of achieving a 45-min 
session performed at the upper end of the calculated HR ranges by 
week 4.  
c) The session finished with 5–10 min of low-intensity pedalling 
(55%–65% age-predicted HRmax; RPE, 9–11) and gentle static 
stretching of all major muscle groups.  















• Latency to 
insulin 
administration 
Supervised home-based program:  
Mean (of 321 sessions) capillary [glucose] 
6.3 ± 0.8 mmol/L; pre-exercise to 4.9 ± 
0.7 mmol/L;  
post-exercise (p <0.001).  
 
Requirement for insulin therapy:  
The mean dose required and latency from 
baseline to insulin treatment was 13 ± 1 
units, commenced at 2.3 weeks for 
CON4(n =2), and 7 ± 1 units, commenced 
at 2.9 weeks for EX5 (n = 2).   
Percentage HbA1c was higher at the post- 
intervention assessment in both CON 
(5.4% ± 0.3%, p = 0.029) and EX (5.3% ± 
0.4%, p= 0.012) compared with pre-
intervention values, with no difference 
between groups (p > 0.05). 
Overall mean postprandial capillary 
glucose concentration was significantly 
lower in EX compared with that in CON 




al., 2012  
Participants underwent a peak test previously 
validated in pregnant women (Mottola et al. 2006), 
to determine HR zones. 
The participants then started the supervised walking 
program at their calculated target HR zone of 30% 
HRR6 or 70% HRR 3-4 times per week according to 
their allocated group. 
At each exercise session, participants wore an HR 
monitor (Polar PacerW, USA) to ensure they were 
exercising within the predetermined target HR zone.  
The first week consisted of 25 min of walking per 
session (5 min warm-up, 15 min at target intensity 
and 5 min cool-down). The warm-up started at 4.8 
km/h with no incline and was ramped up over the 5-
min warm-up to the speed and incline corresponding 
to 30% HRR or 70% HRR.  
The 5-min cool-down was done at 4.8 km/h with no 
incline. Each subsequent week thereafter, the time at 
the prescribed intensity increased by 2 min, until a 
maximum of 30 min was reached, plus 5 min warm-
up and 5 min cool-down. This duration was then 
maintained until the end of the program. 
• Capillary blood 
glucose pre and 
post exercise 
Capillary glucose responses to exercise 
were strongly influenced by an interaction 
between GDM risk, exercise duration and 
exercise intensity (p=0.006).  
 
Decreases in glucose concentrations were 
observed after 25 (4±13%), 35 (21±12%) 
and 40 min (15±18%) of walking in high 
risk-30%I women, with the most 
noticeable decline after 35 and 40 min. In 
the high risk-70%I, glucose concentrations 
decreased significantly only after 25 
(22±14%) and 35 min (7±23%) and 
increasing the exercise time attenuated 
glucose concentrations decline. In low risk 
women, regardless of exercise intensity 
and duration, decreases in glucose 







Prior to beginning the walking program, each 
participant in the intervention group wore a 
pedometer (Accusplit Eagle 120 Activity) for 3 
days to define her baseline activity level.  
The walking program consisted of 3–4 exercise 
sessions/week at 30% heart rate reserve (HRR).  
3-4 times per week supervised walking at 30% 
HRR beginning at 25min/session and building to 
40 min.  
• Capillary blood 
glucose 
• Insulin requirement  
• Pregnancy outcomes 
In addition to lower capillary blood 
glucose values, the exercise group 
required significantly fewer units of 
insulin per kg of body weight than did the 
control group at the end of the study 
(CON, 0.50 ± 0.37 U.kg–1; EX, 0.16 ± 
0.13 U.kg–1; p < 0.05).  
 
Although the women in both groups 
initiated insulin around the same week of 
gestation, the exercise group required 
insulin less frequently. The control group 
required significantly more slow-acting 
insulin at bedtime (CON, 0.21 ± 0.16 
U.kg–1; EX, 0.11 ± 0.09 U.kg–1) and fast-
acting insulin during the day than did the 
exercise intervention group (CON, 0.29 ± 
0.21 U.kg–1; EX, 0.05 ± 0.04 U.kg–1) at 







The exercise group undertook 
10 weeks of home-based 
supervised exercise (3 x per 
week). Exercise training was 
performed on an upright 
stationary cycle ergometer that 
each participant kept in their 
home for the duration of the 
intervention. Each session 
involved a 10 min warm-up 
followed by one or two 15 min 
bouts of cycling (with rest 
periods if necessary) at an 
intensity of 50–60%HRmax.As 
the weeks progressed, the 
exercise intensity was increased 
to 60–70% HRmax, while the 
duration was increased to 40–45 
min. Sessions ended with a 10 










The blood glucose response to OGTT in the exercise group remained similar to 
pre-intervention levels. In contrast, the glucose tolerance in control group 
worsened, as indicated by a trend towards higher blood glucose levels at 1 h 
post glucose ingestion compared with pre intervention levels (p=0.072). 
Furthermore, at 2 h of the post intervention OGTT, there was a tendency for 
blood glucose to remain elevated from baseline in the control group (p=0.077), 
whereas glucose levels returned to baseline in the exercise group (p=0.480). 
Control group blood glucose response to 75g-OGTT (mean ± SD): 
• Pre-intervention 4.7 ± 0.3 (0 min); 6.4 ± 1.7 (60 min); 5.9 ± 0.9 (120 min)  
• Post-intervention 4.7 ± 0.4 (0 min); 8.5 ± 2.5 (60 min); 7.1 ± 2.5 (120 min) 
Exercise group Blood glucose response to 75 g OGTT (mean ± SD): 
• Pre-intervention 4.8 ± 0.5 (0 min); 6.9 ± 1.3 (60 min); 5.6 ± 1.1 (120 min) 
• Post-intervention 5.0 ± 0.5 (0 min); 7.8 ± 0.7 (60 min); 5.4 ± 1.1 (120 min) 
Although insulin levels were higher post intervention in both groups, the 
difference was not significant. Despite these observations, there were no 
significant differences between groups in glucose or insulin after the 
intervention.  
Likewise, there was no significant interaction of time and group 
on insulin sensitivity based on the OGIS model (p=0.638), despite a noticeably 
greater decline over the intervention period in CON (pre intervention: 354±29 
mL.min−1m−2; post intervention: 324±44mLmin−1m−2) compared with the EX 








An individualized exercise plan was provided to each 
participant in the exercise intervention. The 
individualised exercise plan was designed to meet the 
exercise-specific energy expenditure requirements and 
suit each woman’s lifestyle 
This was based on a PPAQ8 (Pregnancy Physical 
Activity Questionnaire) walking, jogging, prenatal 
classes, swimming and dancing are assessed (Chasan-
Taber et al. 2004).  
To calculate weekly energy expenditure using the PPAQ, 
the duration of time spent in these exercise activities was 
multiplied by specific intensities (i.e MET values) and 
scores are expressed as MET-hours per week. The 
recommendation for energy expenditure was 7.5-12.5 
MET-h/wk to meet exercise guidelines for weekly 
moderate to vigorous intensity activity (Haskell et al. 
2007). 
• Energy expenditure 
expressed as MET9 
hours and kilocalories 
per week. Energy 
expenditure was 
derived from PPAQ 
collected at 12, 20, 28, 
and 26 weeks 
gestation.  
• Fasting plasma 
glucose and insulin.   
• Insulin resistance 
from HOMA-IR10 
There was no difference in 
HOMA-IR between the 
intervention and control groups 
at 12, 20, 28 and 36 weeks. 
 
At week 28 fasting glucose was 
higher in CON vs.EX 4.67 
(±0.54) vs. 4.38 (±0.48) mmol/L, 
p=0.03.  Fasting insulin was less 
in EX vs. CON groups 14.59 
(±8.51) vs. 20.28 (±10.8) mlU/L, 






Exercise group undertook aerobic exercise 3-4 times per 
week till parturition. Sub-maximal cycle ergometer test 
was performed as a measure of cardiorespiratory fitness. 
Two sessions per week were supervised with maternal 
(use of heart rate monitor) and foetal monitoring (foetal 
heart rate and uterine contractions). This consisted of 
30min split into 5min warm up, 20min cycle ergometer 
or walking (70%HRmax), 5min cool down. In addition, 
this group where instructed to undertake 1-2 more 
session per week unsupervised. The control group 
continued dietary therapy and physical activity as usual, 
and where asked not to change their usual physical 
activity levels. Weekly telephone calls took place to 
monitor participants. 
 3 times per week  
fasting blood 
glucose levels, and 
2  hour 
postprandial blood 
glucose levels  
 HbA1C at baseline 
& 4 weeks 
intervals 
 
 Use of insulin 
therapy 
 Incidence of 
neonatal 
hypoglycaemia 
(<45mg/dL at 1, 3, 
5h after birth) 
 Infant birth weight 
 APGAR score at 
birth 





No change in mean HbA1C at 4 
weeks between exercise group 
and controls (5.22% vs 5.24) 
 













3 sessions per week home-based program, supervised by 
an exercise physiologist to monitor duration and 
intensity of exercise. The session consisted of 5min 
warm up at 55-65% HRmax (RPE 9–11). The 
subsequent conditioning period was divided into 5-
minute periods of continuous moderate-intensity cycling 
(65– 75% HRmax; RPE12–13) alternating with 5-minute 
periods of interval cycling. Two types of intervals were 
used; (1) increase in pedalling rate for 15s and (2) 
increase in cycling resistance for 30s to reach a target 
intensity 75–85% HRmax; RPE 14–16) repeated every 2 
min. A 5min cool down (55-65% HRmax; RPE 9–11), 
followed by light stretching. The duration of each 
session progressively increased by 5-minute increments 
every 2–3 weeks, as tolerated, from 20 to 30 minutes to a 
maximum session duration of 60 minutes. Sessions were 
tailored to progress according to baseline fitness level of 
the woman and her ongoing pregnancy symptoms. 
 






 Incidence of 
recurrence of 
GDM 
No difference reported in OGTT 
between groups 
 
Insulin resistance, and sensitivity 
did not differ between groups 
 
Glycated haemoglobin did not 
change between groups 
 
No difference in incidence of re-
occurrence of GDM: 40.5% in 
exercise group and 40% control; 






Patients allocated to the exercise group were randomized 
to exercise 3 days per week in a supervised environment. 
Each session started with 5 min warm up (55-65% 
HRmax, RPE 9-11), followed by 30s rapid pedalling 
(sprints, higher intensity efforts) at 75-85% HRmax 
(RPE 15-16) every 2 minutes for 3-5 intervals. This 
sprinting was followed by 5 minutes of continuous 
cycling at low-to-moderate intensity (60-70% HRmax; 
RPE 10-12) before beginning another period of interval 
cycling. During this interval phase, continuous 
moderate-intensity cycling at 65-75%HRmax (RPE 12-
14) was interspersed with 1-minute periods of pedalling 
against increased resistance (hill climb) at 75-85% 
HRmax (RPE 13-15); these periods alternated every 2 
minutes for 3 repeats. 5min cool down (55-65% HRmax, 
RPE 9-11). 
Additionally, the exercise duration progressively 
increased to 45-60 minutes by adding 5 minutes to the 
intervals or the continuous moderate intensity cycling 
phases according to individual ability. Cervical length 
was assessed before each of the 4 examinations during 
pregnancy, if it was less than 25mm these women were 
excluded from the study (due to known risk of preterm 
birth). 
 
Both exercise and control group received standard 
prenatal care. 



























Exercise group had lower 
incidence of GDM (22.0% vs. 
40.6%; p<0.001) 
Exercise group had less 
gestational weight gain by 25 
gestational weeks  (4.08 ±3.02 vs 
5.92 ±2.58 kg; p< .001) and at 
the end of pregnancy (8.38 ±3.65 
vs 10.47 ±3.33 kg; p < .001) 
 
Insulin levels were reduced in 
exercise group (2.92± 1.27 vs. 
3.38± 2.00; p =0.033) at 25 
gestational weeks, however 
insulin resistance levels at 36 
gestational weeks were not 
different between groups. 
 
The exercise group had lower 
blood glucose levels at all 3 
time-points of OGTT post 
intervention when compared to 
the control group (P=0.001, 
P=0.009, P=0.009) 
 
Infants born to women following 






Obstetric, infant and 
pregnancy outcomes. 
significantly lower birthweight 
compared with those born to 
women allocated to the control 
group (3345± 397 vs 3457± 446 
g; P =0.049). No differences in 
all other obstetric and neonatal 
outcomes. 
All measures are mean± standard deviation (SD). Abbreviations: 1HRmax: Heart rate maximum established from predicted formula 
or sub-maximal exercise testing 2RPE Rate of Perceived Exertion: A scale used to monitor intensity of exercise (Borg 1982) 3 OGTT: 
Oral Glucose Tolerance Test. The specific test used is outlined in each study. 4CON refers to control and 5EX to exercise intervention 
applied specific to the study intervention. 6HRR: Heart Rate Reserve. Target heart rate was determined using the HRR equation by 
Karvonen et al. (1957). 7OGIS: Oral Glucose Insulin Sensitivity index which determines insulin sensitivity from the OGTT. This tool 
has been previously validated in an antenatal population. 8PPAQ Pregnancy Physical Activity Questionnaire 9METs Metabolic 
Equivalents 10HOMA-IR Homeostatic Model Assessment-Insulin Resistance: method to quantify insulin resistance.11HOMA2-IR 





Table S2c Details of exercise intervention, the outcome measures taken and main findings for the interventions using a 
combination of aerobic and resistance exercise intervention. 






The exercise group received standard maternity care, in 
conjunction with exercise sessions 3 times weekly. The exercise 
sessions were supervised by a physical therapist. Each session was 
60min of treadmill walking/jogging for 35min (aerobic exercise) at 
~80%HRmax (RPE 12-15) followed by resistance training (body 
weight) for large muscle groups and the pelvic floor muscles for 
25min. These exercises consisted of squats, push-ups, diagonal 
lifts on all fours, and oblique abdominal crunches, with 3 sets of 10 
repetitions of each exercise separated by a 1-min rest between sets. 
Participants also did three sets of the “plank exercise” for 30s. 
Resistance was tailored to ability. The pelvic floor exercises 
consisted of three sets of 10 repetitions of pulling the pelvic floor 
up and holding the contraction for 6–8s.  
In addition, the women were asked to follow a 50min home 
exercise program at least once weekly (35min of aerobic exercise 
and 15 min of strength exercises) and to do daily pelvic floor 
muscle exercises.  
Participants received a weight gain curve showing recommended 
weight gain throughout pregnancy in accordance to 2009 IOM 
guidelines, and were encouraged to compare their own weight gain 
with this curve. The women were invited to attend one 
motivational interview session, either individually or in a group, 
during the intervention period. 


















 HOMA2-IR11  
No difference in weight gain 
was reported, also with the 
proportion of women 
exceeding recommended 
gestational weight gain being 
similar in both groups. 
 
Less women developed GDM 
in the exercise group vs. 
control (6.1% vs. 27.3%, 
p=0.04). 
 
No difference in OGTT 
results between the groups 
post- intervention 
 
No difference in insulin, 









Women in the EX group received individualised, supervised, 
structured exercise programme 2 times per week, along with their 
standard prenatal care. This group were also asked to perform 
30min of brisk walking per day. The minimum total duration of the 
exercise programme was set at 6 weeks. Each exercise session 
lasted for 50–55min and consisted of aerobic exercise (20min), 
resistance exercises (20–25min), pelvic floor and stretching 
exercises, and a period of relaxation to end the session (10min). 
The aerobic part of the session was performed on treadmill (Axos 
Runner, Heinz Kettler GmbH, Ense-Parsit, Germany) and aimed to 
achieve a heart rate within the aerobic zone (65–75% HRmax, 13-
14 RPE). Resistance exercises incorporated all major muscle 
groups, and were performed at each session with the same target 
values as the aerobic component (65–75% HRmax, 13-14 RPE). 
Six different exercises were performed in 3 sets of 10–15 
repetitions in each set. Three standardized resistance exercise 
protocols were developed and interchanged. These included 
exercises for the trunk, and upper and lower limb muscles. They 
were carried out using body weight, elastic bands (TheraBand, The 
Hygenic Corporation, Akron, OH, USA) and hand held weights of 
0.5 and 1kg (Aerobic Dumbbels, Heinz Kettler GmbH, Ense-
Parsit, Germany). Stretching and pelvic floor exercises were 
performed at the end of every session, followed by a short period 
of relaxation to allow a thorough cool-down.  
All participants commenced on usual medical nutrition therapy 
recommended for women with GDM. This consisted of 1800 kcal 
per day: 20% proteins (90 g), 30% fat (60 g) and 50% 
carbohydrates (225 g), distributed over three main meals and three 
snacks. Women in the CG received standard prenatal care for 






























Post intervention measures of 
average of 3 postprandial glucose 
was lower in EX vs. control (4.66± 
0.46 vs. 5.30 ± 0.47, p < 0.001).  
 
 
There was no difference in fasted 
glucose measures between groups. 
 
Pre-pregnancy regular physical 
activity negatively correlated with 
fasting glucose level (rpbi  = -0.429, 
p = 0.007). There was a strong 
negative correlation between 
activity levels in the 30th and 36th 
weeks of pregnancy, (r =  -0.527, p 
= 0.001; r = -0.537, p = 0.001 
respectively) and a positive 
correlation between inactivity 
levels and postprandial glucose 
levels (r = 0.369, p = 0.023). 
No participants required 
pharmacological therapy 
 
No differences were observed 
between groups. They report that 
percentage of exercise intensity 
negatively correlated with neonatal 
body mass (r = - 0.481, p = 0.043) 
and body mass index (r = -0.469, p 
= 0.05), however this is invalid due 
to not accounting for gestational 





Chapter 4: Maternal obesity and degree of 
glucose intolerance on neonatal hypoglycaemia 
and birth weight: A retrospective observational 
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Introduction: Gestational diabetes mellitus (GDM) is an increasing problem 
worldwide. Post-natal hypoglycaemia and excess foetal growth are known important 
metabolic complications of neonates born to women with diabetes. This retrospective-
cohort-study aims to determine the influence of obesity and glucose-intolerance on 
neonatal-hypoglycaemia and birth-weight over the 90th percentile (LGA). 
Method: Data were abstracted from 303 patient medical records from singleton 
pregnancies diagnosed with GDM. Data were recorded during routine hospital visits. 
Demographic data were acquired by facilitated questionnaires and anthropometrics 
measured at the first antenatal appointment. Blood-biochemical-indices were recorded. 
Plasma-glucose-area-under-the-curve (PG-AUC) was calculated from OGTT results as 
an index of glucose intolerance.  
Results: OGTT results of 303 pregnant women aged between 33.6y (29.8-37.7), 
diagnosed with GDM were described. Neonates of     mothers   with   a   BMI of   over            
30kg/m2 were more likely to experience neonatal-hypoglycaemia (24(9.2%) vs. 
23(8.8%), p=0.016) with odds-ratio for neonatal-hypoglycaemia significantly higher at 
2.105, 95% CI (1.108, 4.00), p=0.023. ROC analysis showed poor strength of 
association (0.587(95% CI, .487 to .687). Neonatal LGA was neither associated with 
nor predicted PG-AUC or obesity; however, multiparous women were 2.8 (95% CI 
(1.14, 6.78), p=0.024) times more likely to have a baby born LGA. 
Conclusion: Maternal obesity but not degree of glucose intolerance increased 
occurrence of neonatal hypoglycaemia. Multiparous women had greater risk of 
neonates born LGA. 
Key words: gestational diabetes, neonatal hypoglycaemia, glucose intolerance, 





Worldwide rates of obesity are increasing (Gallus et al. 2015) and this trend exists 
amongst the pregnant population too (Griffin et al. 2000). The prevalence of 
pregnancies complicated with gestational diabetes mellitus (GDM) is increasing 
concurrently with a reported prevalence of 17.8% globally (Sacks et al. 2012a), and 
13.2% in Ireland (Ali et al. 2013). It is of concern as obesity and GDM are 
independently associated with an increased risk of complications in both mother and 
foetus (Metzger et al. 2008, Catalano 2010, Catalano et al. 2012).  
Maternal obesity has been linked to increased morbidity and mortality in pregnancy 
putting both the mother and infant at risk in the short and long term (Cedergren 2004, 
Dodd et al. 2011). Large population studies examining pregnancy outcomes, based on 
the World Health Organisation BMI sub-classifications (WHO, 2013) of obesity, found 
a relationship with increasing risk of adverse outcomes, including gestational diabetes 
mellitus, hypertensive disorders, caesarean section, macrosomia, admission to neonatal 
intensive care unit and neonatal hypoglycaemia (Dodd et al. 2011, Catalano et al. 2012, 
Scott-Pillai et al. 2013). In addition, women in the highest obesity group are at risk of 
additional adverse outcomes, including stillbirth, a longer postnatal hospital stay, and 
wound problems following Caesarean section (Wloch et al. 2012). Maternal obesity 
has also been linked with negative perinatal outcomes in glucose tolerant, as well as 
glucose intolerant pregnancies establishing it as an independent risk factor (Catalano 
et al. 2012, Wahabi et al. 2014).  
Obesity and gestational diabetes mellitus (GDM) have both been shown to increase 
insulin resistance (Catalano 2010). The glucose intolerance that develops in pregnancy 
resulting in GDM is a combination of metabolic defects via a decreased tissue insulin 
sensitivity, together with an inadequate insulin response (Buchanan and Xiang 2005). 
The Pederson hypothesis (Pedersen 1952) suggests that this insulin resistance produces 
high maternal blood glucose, subsequently crosses the placenta, stimulating excess 
foetal insulin production resulting in excess foetal growth. 
Hypoglycaemia at birth is one of the most common metabolic disorders of the neonate 
born to mothers with GDM. It occurs due to foetal hyperinsulinaemia in response to 
the maternal hyperglycaemia in utero (Kamana et al. 2015). In a healthy pregnancy, 
the placenta ensures a steady supply of glucose to the foetus primarily by the trans 




substrate delivery and a major change in metabolism. Neonatal hypoglycaemia in 
pregnancies with glucose intolerance is driven by excess insulin. The effects of these 
can be transient or persistent. It can lead to more serious complications such as 
disturbances of the CNS and cardiopulmonary system (Kamana et al. 2015). The 
transition from foetal to neonatal life is a crucial physiological adaptation in the human 
lifecycle (Platt and Deshpande 2005, Hillman et al. 2012). It is understood that as the 
placental supply of glucose ceases, the plasma glucose values hit a nadir in the first 
couple of hours postpartum after cord clamping and thus a removal of the maternal 
glucose supply, triggering the initiation of normal glucose homeostatic control via 
decreased insulin and increased glucagon. The large catecholamine release and 
increase in cortisol are probably the major acute regulators of plasma glucose and free 
fatty acid levels in the immediate new-born period (Kamana et al. 2015), triggering 
gluconeogenesis within the first six to 24 hours after birth (Sharma et al. 2017). It is 
thought that in pregnancies with hyperglycaemia that the resulting pathogenesis of 
hypoglycaemia is due to two processes being affected. Continuing foetal 
hyperinsulinism results in an exaggerated, or more prolonged, postnatal fall in blood 
glucose concentration, as well as defective hormonal counter-regulation post-partum. 
Plasma glucagon concentrations two hours after birth in insulin dependent diabetes 
mellitus were found to be less than half those of term infants born to mothers without 
diabetes, indicating a blunted glucagon response (Bloom and Johnston 1972). Chronic 
hyperglycaemic stress in utero due to poorly controlled maternal diabetes is thought to 
result in foetal sympathoadrenal exhaustion, increasing the risk of hypoglycaemia in 
insulin dependent type I diabetes (Platt and Deshpande 2005).  
Previous studies in the area include Collins et al. (2018) who examined 471 singleton 
pregnancies affected by GDM finding that women with obesity (BMI ≥30kg/m2) 
experienced higher rates of neonatal hypoglycaemia, as well as a higher likelihood of 
having multiple hypoglycaemic episodes. Makgoba et al. (2012) observed over twelve 
thousand pregnancies and found neonates born to women with GDM during pregnancy 
were heavier, and this was observed across all racial groups. In addition, mothers from 
non-white origin with higher BMI and GDM had the highest neonatal birthweight. 
While both obesity and glucose intolerance are risk factors on occurrence of neonatal 
hypoglycaemia and increased birthweight, the combined effect of both risk factors has 




is to determine the influence of obesity and degree of glucose intolerance and their 
combined effect on occurrence of neonatal hypoglycaemia and birth weight over the 
90th percentile classifying the new-born as large for gestational age (LGA). 
 
4.3 Materials and methods: 
4.3.1 Procedure 
Data were collected as a retrospective observational cohort of singleton pregnancies 
diagnosed with gestational diabetes mellitus (GDM) born during 2016 at the University 
Maternity Hospital, Limerick, Ireland. Ethics committee approval was sought and 
granted from the HSE Research Ethics Committee (REC ref 029/17). Patient medical 
records of women diagnosed with GDM were identified through the hospital database. 
Retrospective data were anonymised, and abstracted from medical records onto an 
Excel™ spreadsheet. Inclusion criteria were singleton pregnancies, diagnoses of GDM 
according to the diagnostic thresholds set out by the IADPSG guidelines (WHO, 2013) 
and born at the University Maternity Hospital, Limerick (UMHL), Ireland. Exclusion 
criteria included twin pregnancies, and neonates not born at UMHL. 
Data were recorded during routine hospital visits by medics and allied health 
professionals at approximately 12 weeks gestation. Demographic data were acquired 
by facilitated questionnaires, anthropometrics measured at the first antenatal 
appointment, and blood biochemistry through laboratory diagnostic tests. Percentile 
birth weight at specific gestational age was calculated using the Perinatal Ireland centile 
calculator (Unterscheider et al. 2013). All data were retrieved and abstracted from 
medical notes. Glucose intolerance was calculated from plasma glucose area under the 
curve (PG-AUC) using trapezoidal technique (Sakamoto et al. 2013) derived from 75g-
Oral glucose tolerance test (collection of samples in fasted state, one and two hours 





4.3.2 Definitions of pregnancy risk and neonatal complications 
Parameters to define pregnancy risk were maternal age (≥35y), delivery methods of 
caesarean section (elective and emergency), and vaginal, maternal BMI ≥ 30 kg/m2, 
multiparous (≥3), presence of family history for diabetes mellitus in first degree 
relative, pre-existing insulin resistant condition (PCOS, hypothyroidism, endometriosis 
and previous GDM). Neonatal complications were defined as birthweight over the 90th 
centile for gestational age (LGA), admission to Neonatal Intensive Care Unit (NICU), 
neonatal hypoglycaemia (<2.2mmol/L in the first 72h of life) (Marles and Casiro 1998), 
neonatal jaundice (serum bilirubin level plotted on or above treatments line of 
phototherapy chart), preterm delivery (born ≤ 37weeks gestational age), respiratory 
distress requiring medical intervention, and low APGAR score of <7 at 1 or 5 minutes. 
4.3.3 Statistical analysis 
Group differences between non-obese (BMI<30) and mothers with obesity (BMI≥30) 
were analysed via independent T-tests, or non-parametric alternatives if conditions for 
normality were violated. Significance was set at a p-value of <0.05. Equality of 
variances was assessed by Levene’s test for equality of variances. Where χ2 test 
assumptions were violated, Fisher’s Exact test was used. Odd’s ratios were calculated 
using crosstab functions. Bivariate regression models were used to assess predictive 
nature of independent variables; these are presented with and without potential 
confounders (co-variates). Where associations were made, ROC analysis was used to 
assess strength of association (Hosmer et al. 2013). All statistical analyses were 
performed using the SPSS program, version 25 (SPSS Inc., Chicago, IL). 





4.4.1 Demographic characteristics 
The demographic composition of the studied population of 303 singleton pregnancies 
with GDM diagnosis and their infants are described in Table 4.1a and 4.1b 
respectively.  All scalar data was skewly distributed so medians and IQR are given in 
the table. 
Table 4.1a: Maternal characteristics (n=303):  
Maternal characteristic Median (IQR) n 
Age (y) 33.6 (29.8-37.7) 303 
Weight (kg) 74.0 (64.0-88.9) 297 
Height (cm) 1.64 (1.60-1.69) 294 
BMI (kg/m2)  
<18.5 kg/m2 











Timing of GDM diagnosis  (weeks gestation) 28.3 (27.4-32.2) 303 
FPG (mmol/L) 4.8 (4.3-5.2) 303 
1h post 75g OGTT (mmol/L) 10.2 (9.1-10.8) 303 
2h post 75g OGTT (mmol/L) 6.8 (6.0-8.4) 303 
PG-AUC 25.0 (23.0-26.0) 303 





















Gravida 2 (2-4) 303 
Parity 1 (0-2) 303 
*IQR Interquartile range; GDM gestational diabetes mellitus; FPG Fasting plasma glucose; PG-AUC plasma glucose-area under 





Table 4.1b: Neonatal characteristics of infants born to mothers with gestational 
diabetes (n=303) 









Birth weight (g)  3395 (3160-3718)   303 
Birth Weight Percentile (5) 51.1 (30.2-73.4)   300 
Head circumference (cm) 35.0 (34.0-35.5)   255 
Length (cm) 51.0 (48.0-52.0)   134 
Gestational age (days)  273 (267-277)   303 
*IQR Interquartile range 
4.4.2 Frequencies and percentages of obstetric risks indicating OGTT 
Of the 303 pregnancies analysed, 37 (12.2%) had a maternal age of 35y or more. Sixty 
(19.8%) women were primigravid, whilst 243 (80.5%) had a gravida of two or more. 
Out of the women who had a gravida of more than two, 68 (28%) had previously had 
GDM and 174 (71.6%) had GDM for the first time. 126 (42%) of these women reported 
a family history of diabetes mellitus, and 103 (34%) had a pre-existing insulin resistant 
condition (IRC). The conditions included: PCOS 16 (5.3%), fibroids 6 (2%), 
hyperprolactinaemia 1(0.3%), endometriosis 3 (1%), hypothyroidism 20 (6.6%), 
Sarcoidosis 1(0.3%) and one patient presented with Addison’s and Graves’ disease 
(0.3%). 128 (42.3%) were delivered via Caesarean section, of these 39 (12.9%) were 
emergencies. 188 (62%) women had a BMI ≥30 kg/m2. Table 4.2 below summarises 
these figures. 
Table 4.2 Table showing pregnancy risk factors indicating OGTT  
 
n (303) % 
Maternal age ≥35 years 37 12.2 
BMI ≥30 kg.m-2 188 62.0 
GDM in previous pregnancy 68 22.4 
Multiparous (parity ≥3) 38 12.5 
Family history diabetes 126 42.0 
Pre-existing insulin resistant condition                              103 34.0 





4.4.3 Frequencies and percentages of neonatal complications 
Neonatal complications included 40 (13.3%) neonates who were born LGA, of which 
37 (12.2%) were macrosomic. 60 (19.8%) were admitted to the neonatal intensive care 
unit, 47 (17.5%) out of 269 recorded neonatal blood glucose experienced 
hypoglycaemia, 51 (17%) neonates had neonatal jaundice- of which 38 (12.7%) 
required treatment with phototherapy. 27 (8.9%) were born pre-term, and 13 (4.3%) 
had a low APGAR score at birth.   
4.4.4 Obstetric pregnancy risk and neonatal complications stratified 
according to maternal BMI category 
Pregnant women with GDM who had a BMI of over 30 kg/m2were more likely to have 
GDM in a previous pregnancy (34 (11.6%) vs 32 (10.9%), p=0.003). They also had a 
higher fasting plasma glucose (5.1 (4.5-5.3) vs. 4.6 (4.3-5.2) mmol/L, p<0.001). They 
were more likely to be treated with insulin (19 (6.4%) vs. 16 (5.4%), p=0.018). 
Neonates of mothers with a BMI of over 30 kg/m2 were also more likely to experience 
neonatal hypoglycaemia (24 (9.2%) vs. 23 (8.8%), p=0.016). All other characteristics 
were found to be not significantly different. See Table 4.3 for full set of results. 
Table 4.3: Maternal and neonatal characteristics stratified according to maternal 
BMI at 12 weeks gestation. 
 BMI<30 kg/m2 BMI ≥30 kg/m2 p-value 
n 188 107 -- 
Maternal age (y) 33.1 (29.6-36.8) 34.8 (26.1-38.3) 0.141 
Previous GDM 32 (10.9%) 34 (11.6%) 0.003** 
Fasting plasma glucose 
(mmol/L) 
4.6 (4.3-5.2) 5.1 (4.5-5.3) <0.001*** 
1h post 75g glucose challenge 
(mmol/L) 
10.2 (9.1-10.7) 10.2 (8.9-10.9) 0.885 
2h post 75g glucose challenge 
(mmol/L) 
7.0 (6.2-8.4) 6.6 (5.9-8.3) 0.315 
PGAUC 25 (23.0-26.0) 24 (22.0-27.0) 0.745 
Required insulin treatment 16 (5.4%) 19 (6.4%) 0.018* 
Macrosomia 18 (6.1%) 17(5.8%) 0.107 
LGA 23 (7.9%) 16 (5.5%) 0.542 
NNU admission 33 (11.2%) 27 (9.2%) 0.116 
Age adjusted birth centile  53.9 (31.1-77.1) 39.9 (16.4-79.6) 0.052 
Neonatal hypoglycaemia 23 (8.8%) 24 (9.2%) 0.016* 
Data presented as median (IQR; interquartile range) or where frequency Count (%) 
*denotes significant difference (p<0.05),  




4.4.5 Effect of maternal BMI and PGAUC on neonatal hypoglycaemia 
Maternal BMI was not normally distributed, as assessed by Shapiro-Wilk’s test 
(p<0.05). The non-parametric Mann-Whitney U test was run to determine if there were 
differences in maternal BMI between mother of neonates who experienced neonatal 
hypoglycaemia at birth, and those who did not. Distributions of the groups were not 
similar, as assessed by visual inspection. Median maternal BMI for neonates who 
experienced hypoglycaemia at birth was 29.1, IQR (23.1, 36.2), and those with no 
hypoglycaemia: median 26.8 IQR (23.1, 31.5). These distributions were not 
statistically significantly different, U=4140, z=-1.855, p=0.064, using an exact 
sampling distribution for U (Dineen and Blakesley 1973).  
A Chi-square test for association was conducted between obesity (maternal BMI 
kg/m2) and neonatal hypoglycaemia. All expected cell frequencies were greater than 
five. There was a statistically significant association between obesity and neonatal 
hypoglycaemia χ2 (1) =5.511, p=0.019. There was a moderately strong association 
between obesity and neonatal hypoglycaemia, as assessed by Cramer’s Vφ=0.146.  
PG-AUC was found to be not normally distributed, as assessed by Shapiro-Wilk’s test 
(p<0.05). The non-parametric Mann-Whitney U test was run to determine if there were 
differences in maternal PG-AUC in mother of neonates who experienced neonatal 
hypoglycaemia and those who did not. The differences were not statistically 
significantly different, U=5182, z=-0.023, p=0.982. In addition, a Kendall's tau-b 
correlation was run to determine the relationship between degree of glucose intolerance 
and neonatal hypoglycaemia. There was no association between degree of glucose 
intolerance and neonatal hypoglycaemia, τb =-0.001, p = .982. 
A binomial logistic regression was performed to ascertain the effects of BMI and 
PGAUC on the likelihood that neonatal hypoglycaemia occurs at birth. Linearity of the 
continuous variables with respect to the logit of the dependent variable was assessed 
via the Box-Tidwell (1962) procedure. A Bonferroni correction was applied using all 
eight terms in the model resulting in statistical significance being accepted when p < 
.05 (Tabachnick & Fidell, 2014). Based on this assessment, all continuous independent 
variables were found to be linearly related to the logit of the dependent variable. The 
logistic regression model was statistically significant p < .05. The model explained 




classified 82.1% of cases. Of the two predictor-variables only BMI was statistically 
significant (Table 4.4). When covariates where added to the model, these were not 
significant (Table 4.4). The area under the ROC curve was .560 (95% CI, .500 to .621), 
which is a poor level of discrimination according to Hosmer et al. (2013). When 
maternal BMI was analysed dichotomously using maternal a cut-off of ≥30 kg/m2 in 
the model, odds ratio was higher at 2.105, 95% CI (1.108, 4.00) and significant, 
p=0.023. 
 
Table 4.4 Logistic regression predicting likelihood of neonatal hypoglycaemia 
based on BMI and PGAUC, without co-variates (model 1) followed by inclusion 
of potential confounders (co-variates) (model 2).  
 B SE Wald df p Odds 
Ratio 
95% CI for 
Odds Ratio 
 Lower       
Upper 
      
Model 1: Without 
co-variates 
        
Maternal BMI .061 .024 6.157 1 .013 1.062 1.013 1.114 
PGAUC -.017 .038 .189 1 .664 .983 .912 1.060 
Constant -2.873 1.150 6.239 1 .012 .057 - - 
Model 2: With co-
variates 
      
  
Maternal BMI .065 .025 6.665 1 .010 1.067 1.016 1.121 
PGAUC -.003 .043 .004 1 .952 .997 .916 1.086 
Maternal age -.039 .030 1.667 1 .197 .961 .906 1.021 
High parity .432 .497 .755 1 .385 1.541 .581 4.084 
Family Hx diabetes -.473 .335 2.000 1 .157 .623 .323 1.200 
Overall IRC -364 .375 .943 1 .331 1.440 .790 3.003 
Requiring insulin -.665 .626 1.128 1 .288 .514 .151 1.755 
Constant -2.022 1.519 1.771 1 .183 .132 - - 
*BMI body mass index; PGAUC Plasma glucose area under the curve; SE standard error; CI Confidence interval; df degrees of 





4.4.6 Effect of maternal BMI and PGAUC on LGA 
Scatter plots showed no relationship between maternal BMI and percentile birth weight 
(R2 =0.002), as well as unadjusted birth weight (R2 =0.012). Therefore, we cannot reject 
the null hypothesis and cannot accept the alternative hypothesis. 
A binomial logistic regression was performed to ascertain the effects of BMI and 
PGAUC on the likelihood that the neonate is born LGA. Both independent variables 
and confounders were not linearly related to the logit of the dependent variable. High 
parity was the only significant independent predictor of LGA, OR 2.78, 95%CI (1.14, 
6.81), p=0.025. These results are tabulated in Table 4.5. 
Table 4.5 Logistic regression predicting likelihood of LGA based on maternal 
BMI and PGAUC, including co-variates  
 B SE Wald df p Odds 
Ratio 
95% CI for 
Odds Ratio 
Lower       
Upper 
      
Model 1: With co-
variates 
      
  
Maternal BMI .037 .027 1.875 1 .171 1.037 .984 1.093 
PGAUC .037 .044 .713 1 .399 1.038 .952 1.131 
Maternal age .007 .034 .040 1 .841 1.007 .943 1.075 
High parity 1.023 .457 5.017 1 .025 2.782 1.136 6.810 
Family Hx diabetes .022 .363 .004 1 .952 1.022 .502 2.083 
Overall IRC .515 .412 1.564 1 .211 1.674 .747 3.753 
Requiring insulin .015 .572 .001 1 .979 1.016 .331 3.117 
Constant -4.665 1.655 7.947 1 .005 .009   
*BMI body mass index; PGAUC Plasma glucose area under the curve; SE standard error; CI Confidence interval; df degrees of 







This study sought to elucidate the contribution of maternal obesity and degree of 
glucose intolerance on the occurrence of neonatal hypoglycaemia and LGA. Our study 
confirms a high prevalence of maternal obesity and occurrence of neonatal 
hypoglycaemia among a cohort of singleton pregnancies diagnosed with GDM. 
Significant findings from this study are that maternal obesity increased the risk of 
occurrence of neonatal hypoglycaemia within 72 hours of birth, independent of the 
degree of glucose intolerance experienced by the pregnant women at the time of GDM 
diagnosis. Maternal obesity and degree of glucose intolerance did not predict LGA in 
neonates; however, multiparous women were 2.8 times more likely to have a baby born 
LGA. 
Neonatal hypoglycaemia has been confirmed to cause long-term neurological 
dysfunction at 4.5 years associated with a dose-dependent increased risk of poor 
executive function and visual motor function, and may thus influence later learning 
(McKinlay et al. 2017). A recent study by Cai et al. (2016) investigated specifically a 
GDM cohort and concluded that maternal blood glucose levels are associated with 
offspring neuronal activity during an attention task at both six and eighteen months. 
Postulating that such electrophysiological differences are likely functionally important, 
having been previously linked to attention difficulties later in life. There have been 
large observational studies, which confirmed that increased maternal BMI during 
pregnancy was associated with higher risk of GDM during the index pregnancy, as well 
as occurrence of macrosomia in neonates, in addition to other detrimental perinatal 
outcomes (Dodd et al. 2011, Garcia-Patterson et al. 2012). Maternal obesity increased 
risk of macrosomia in a glucose-tolerant pregnancy cohort (Jensen et al. 2003), thus 
confirming the independent relationship of maternal glucose tolerance and obesity in 
the role of developing macrosomia. In addition, two large observational studies (Ricart 
et al. 2005, Ijäs et al. 2019) also found maternal BMI to have a greater impact of 
pregnancy outcome than gestational hyperglycaemia on occurrence of macrosomia and 
this was dose-dependent, however neonatal hypoglycaemia was not reported, and 
degree of hyperglycaemia was not accounted for. A limited number of studies have 
investigated the occurrence of neonatal hypoglycaemia (Simmons et al. 2000, Collins 
et al. 2018) and LGA (Schneider et al. 2011) in a GDM cohort of pregnancies. Forty-




to 25% reported by Collins et al. (2018) and average of 30.3kg/m2 reported in 
O'Sullivan et al. (2012). However, results reporting higher rates of neonatal 
hypoglycaemia in women within an obese category are consistent with this study.  
As screening for OGTT is indicated by the presence of one or more risk factors in this 
hospital, the sample population may not be representative of a typical GDM cohort. 
However, an Irish study which described a GDM cohort using universal screening 
(O'Sullivan et al. 2012), reported similar occurrence of occurrence of neonatal 
hypoglycaemia (17.5%), and lower occurrence of LGA (22.6% vs.13.3%).  This 
discrepancy in occurrence of LGA could be due to definition of LGA not accounting 
for ethnicity in the calculation of percentile at gestational age, a criticism made in the 
study and a factor accounted for in this study with the use of the Perinatal Ireland 
percentile calculator developed by Unterscheider et al. (2013). 
The study limitations and confounders should inform future study designs in the area. 
An important limitation of this study is that testing for GDM does not occur universally, 
and is indicated for older women, with higher BMI, or with a pre-existing condition or 
history of GDM or family history of diabetes. This lack of universal testing of GDM 
with an OGTT is a limitation common to studies in this field of research (Schneider et 
al. 2011), and explains the high rate of obesity found in this cohort. This presents a 
source of selection bias, as the cohort is not representative of all women who develop 
GDM, therefore the research questions posed in this chapter would be answered more 
accurately in a prospective cohort of women universally screened for GDM via OGTT 
at 28 week’s gestation. This would ensure a cohort representative of the population of 
all patients with GDM, a requirement for avoiding selection bias (Sedgwick 2012). 
However, an advantage for both retrospective and prospective study designs is that 
exposure to risk factors is recorded before the occurrence of the outcome. This is 
important because it allows the temporal sequence of risk factors and outcomes to be 
assessed (Sedgwick 2014).  
 
Due to the substantial length of follow-up between measurement of BMI and diagnosis 
of GDM, and it is difficult to ensure outcomes are measured consistently. Furthermore, 
as time elapsed between the measurement of obstetric risk factors and OGTT, the 




with time. As is typical of observational studies, only association and not causation can 
be inferred from the results of the above cohort study (Sedgwick 2014). In addition, a 
consequence of retrospective cohort studies using health records that have already been 
collected is that not all pertinent risk factors are likely to have been identified and 
subsequently recorded. A further disadvantage of retrospective cohort studies is that 
many different healthcare professionals will have been involved in patient care, so the 
measurement of risk factors and outcome(s) throughout the database would probably 
be less accurate and consistent than that achieved with a prospective cohort study 
design. In this study, the measurement of BMI by clinicians may present an issue of 
accuracy. 
In particular, it was not possible to measure and then control for, through statistical 
analysis, all factors that may have affected the outcome of neonatal hypoglycaemia or 
LGA, despite recording confounders—despite recording exposure to a wide range of 
risk factors. In contrast, experimental studies such as clinical trials use random 
allocation of participants to treatment groups, to control for confounding at baseline, 
thus overcoming the limitations and biases of retrospective studies. These methods are 
therefore recommended as a more robust study design for such research questions 
(Sedgwick 2013). 
In addition, the use of BMI as a classification of obesity does not provide insight to the 
composition or distribution of tissue compartments in the body. This may be a more 
important factor when looking at perinatal outcomes in GDM population due to 
hormonal regulators (Fattah et al. 2011, Brisson et al. 2013). Using measures of body 
composition which distinguish between tissue compartments and distribution could 
potentially further explain why women with a higher parity are more likely to have 
neonates born LGA, as was the case in this study. Women with a higher BMI are also 
less likely to breastfeed, consistent throughout the literature (Baker et al. 2007, Scott-
Pillai et al. 2013). This is of note, as breastfeeding has been linked with reduced 
postpartum weight retention (Hoffmann et al. 2019, Pereira et al. 2019) and subsequent 
prevention of childhood obesity (Dietz 2001). A strength of this study was the 
identification of LGA using percentile calculations adjusting for gestational age, 
neonate gender and maternal ethnicity based on algorithms defined by Unterscheider 
et al. (2013). These are constantly developing to reflect the specific various ethnicities 




was measured using PG-AUC from 75g- OGTT results (Sakamoto et al. 2013). Future 
studies should endeavour to use measures of insulin sensitivity, which capture 
metabolic clearance rate during OGTT with the use of plasma insulin measures, such 
as the Matsuda index or HOMA-IR, which are validated in pregnancy against the 
euglycaemic-clamp (Antuna-Puente et al. 2011, Zhang et al. 2013). Future studies 
should also note the actual neonatal hypoglycaemia rather than binary values due to 
controversy around classification of neonatal hypoglycaemia (Stanescu and Stoicescu 
2014).  
4.6 Conclusions  
In conclusion, maternal BMI during the first trimester of pregnancy exhibits a strong 
influence on neonatal hypoglycaemia but not neonatal birthweight in a cohort of 
pregnancies affected by GDM. Women with a high parity are more likely to have an 
infant born LGA. Future studies should examine the relationship between maternal 
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Background: Excess abdominal adiposity cause metabolic disturbances, particularly 
in pregnancy. Methods of accurate measurement are limited in pregnancy due to risks 
associated with these procedures. This study outlines a non-invasive methodology for 
the measurement of adipose tissue in pregnancy and determines the intra- and inter-
observer reliability of ultrasound (US) measurements of the two components of adipose 
tissue (subcutaneous (SAT) and visceral adipose tissue (VAT)) within a pregnant 
population.  
Methods: Thirty pregnant women were recruited at the end of their first trimester, from 
routine antenatal clinic at the University Maternity Hospital Limerick, Ireland. 
Measurements of adipose tissue thickness were obtained using a GE Voluson E8 
employing a 1-5MHz curvilinear array transducer. Two observers, employing 
methodological rigour in US technique, measured thickness of adipose tissue three 
times, and segmented the US image systematically in order to define measurements of 
SAT and VAT using specifically pre-defined anatomical landmarks.  
Results: Intra-observer and interobserver precision was assessed using Coefficient of 
Variation (CV). Measurements of SAT and total adipose for both observers were <5% 
CV and <10% CV for VAT in measures by both observers. Inter-observer reliability 
was assessed by Limits of Agreement (LoA). LoA were determined to be -0.45 to 
0.46cm for SAT and -0.34 to 0.53cm for VAT values. Systematic bias of SAT 
measurement was 0.01cm and 0.10cm for VAT. Inter-observer precision was also 
assessed by co-efficient of variation (CV: SAT, 3.1%; VAT, 7.2; Total adipose, 3.0%). 
Conclusion: Intra-observer precision was found to be acceptable for measures of SAT, 
VAT and total adipose according to anthropometric criterion, with higher precision 
reported in SAT values than in VAT. Inter-observer reliability assessed by Limits-Of-
Agreement (LoA) confirm anthropometrically reliable to 0.5cm. Systematic bias was 
minimal for both measures, falling within 95% confidence intervals. These results 
suggest that US can produce reliable, repeatable and accurate measures of SAT and 







Ultrasound (US) has been used effectively to assess body fat for decades (Armellini et 
al. 1990). Limitations to its use are due to lack of standardization of technique, and 
data on repeatability amongst different operators (Wagner 2013, Bazzocchi et al. 
2016). The current gold standard for the quantitative assessment of intra-abdominal 
adipose tissue uses computed tomography (CT) scanning (Seidell et al. 1990). Validity 
and reproducibility of ultrasound techniques against CT scanning has been previously 
assessed (Armellini et al. 1993, Stolk et al. 2001, Berker et al. 2010, Bazzocchi et al. 
2011) in non-pregnant populations, and reportedly the inter-observer correlation co-
efficient of the mean ultrasound distance was 0.94 (P<0.001), and coefficient of 
variation 5.4% within a non-pregnant population (Stolk et al. 2001). Other methods for 
quantifying risk using abdominal measures and ratios of these, are; DXA scanning, 
waist: hip circumference ratio, and anthropometric skinfold measurements. However, 
during pregnancy these three techniques have distinct disadvantages, which render 
them inadequate within a clinical setting and in a pregnant population (Robič et al. 
2014, Most et al. 2018). Limitations include exposure to ionising radiation, expense, 
lack of validation of technique, time-consuming techniques and requirement of a 
trained skilful measurer (Robič et al. 2014, Most et al. 2018). 
Despite methods of capturing body composition being limited within a pregnant 
population, the use of ultrasound to measure abdominal adipose tissue has been 
recently reviewed and found to be a useful tool for measuring body composition non-
invasively (Wagner 2013, Bazzocchi et al. 2016). While US requires skill and training 
with a cost implication, pregnant women undergo US by a skilled ultra-sonographer at 
the end of the first trimester, as part of routine care, making this a contact point with 
healthcare professionals with potential opportunity for measurements to be carried out. 
Measuring components of abdominal adipose tissue- VAT and SAT, are of particular 
current relevance and importance as these depots of adiposity have been implicated in 
the pathogenesis of metabolic and cardiovascular health in non-pregnant populations 
(Despres and Lemieux 2006, Hamagawa et al. 2010, Bazzocchi et al. 2016), as well as 
in a pregnant population (Bartha et al. 2007).  
Maternal obesity has been linked to increased morbidity and mortality in pregnancy 
putting both the mother and infant at risk in the short and long term (Cedergren 2004, 




the World Health Organisation (WHO) body mass index (BMI) sub-classifications of 
obesity found a relationship to increasing risk of adverse outcomes, including 
gestational diabetes, hypertensive disorders, caesarean section, macrosomia, admission 
to neonatal unit and neonatal hypoglycaemia (Dodd et al. 2011, Catalano et al. 2012, 
Scott-Pillai et al. 2013). However, BMI does not provide insight into components of 
body composition, such as lean tissue, subcutaneous or visceral adipose tissue, which 
are known to exert different physiological effects in the pregnancy state (Wahabi et al. 
2014). Crude measures of adipose thickness such as that possible via ultrasound 
provide a non-invasive technique for insight into subcutaneous and visceral adipose 
compartments of body composition. It is understood that visceral fat, specifically pre-
peritoneal fat thickness, has been identified in the production of excess adipokines, 
which play a role in increased insulin resistance by disrupting post-insulin signalling 
mechanisms, thus contributing to the pathogenesis of gestational diabetes mellitus 
(Kirwan et al. 2002, Jayabalan et al. 2017). It has also been associated with an increase 
in other cardio-metabolic risk factors within various studies (Yamamoto et al. 1997, 
Tayama et al. 1999, Tadokoro et al. 2000, Hamagawa et al. 2010). The role of 
subcutaneous fat in the development of obesity related disorders remains controversial 
according to a recent review by Bazzocchi et al. (2016). The review attributes 
contradictory findings from investigations of subcutaneous fat (Porter et al. 2009, Patel 
and Abate 2013), to the variation in location of the measurement and lack of 
consistency in the methods used to capture this specific depot of adipose (Bazzocchi et 
al. 2013).  
To be clinically useful within a pregnant population, reliability and reproducibility of 
abdominal fat quantification needed to be assessed within this specific population. 
Therefore, this study sought to standardise and outline a technically rigorous 
methodology used to quantify abdominal adipose tissue  in pregnant women, and to 
segment this into its constituents, visceral (VAT) measured as the pre-peritoneal fat 
thickness, and subcutaneous adipose tissue (SAT) as the minimum abdominal 
subcutaneous fat thickness. Subsequently, both inter- and intra-observer variability 





5.3.1 Study population 
Thirty subjects were recruited prospectively. These subjects were attending the 
University Maternity Hospital Limerick (Ireland) for their first routine antenatal visit 
at 12-weeks’ gestation, at which an ultrasound scan is routinely performed. Informed 
consent was sought and granted (REC 082/17) in accordance with the ethical 
recommendations of Health Service Executive (HSE) University Hospital Limerick 
committee on human research. 
 
5.3.2 Ultrasonography 
Measurements of adipose tissue were taken via abdominal ultrasonography (US) using 
a GE Voluson E8 employing a 1-5MHz curvilinear array transducer. This transducer 
was a practical choice as it required no changeover from the preceding obstetric scan, 
and the frequency was sufficiently high to provide adequate resolution at the shallow 
depth of measurement. 
With the patient in a supine position and the transducer perpendicular to the skin, the 
required image was obtained in sagittal plane at the xiphisternum, producing a 
longitudinal view of the left lobe of liver and the aorta (see Figures 5.2 a-b). Minimal 
pressure was exerted on the skin, in order to avoid compression of the adipose tissue. 
The transducer was rocked left to right, in order to identify the narrowest projection of 
the linea alba. The scan depth was reduced, excluding the aorta from the image. The 
sector width was reduced to 40 degrees; increasing line density. Thus, an image of both 
layers of adipose tissue was obtained with the inferior part of the left lobe of liver seen 
posteriorly (see Figures 5.1 and 5.2 a-b). At this point, the time gain compensation 
(TGC) and overall gain were adjusted carefully to allow clear visualisation of 
subcutaneous adipose tissue and homogenous echogenicity within the left lobe of liver. 
The image was then frozen. 
Calipers were placed to measure in millimetres. Subcutaneous fatty tissue was 
measured from the lower border of the cutaneous layer to the upper border of the linea 
alba and visceral fatty tissue was measured from the lower border of linea alba to the 




The US measurements were performed at the time of routine first trimester ultrasound 
examination. Both observers took three measurements each of both VAT and SAT on 
30 subjects. A new image was acquired between each set of measurements. The second 
observer entered the examination room once the first observer’s measurements were 
completed and removed from the screen. All six images were saved using 
ViewPoint™, GE’s ultrasound image management and reporting solution software and 
were identified with each observers’ initials prior to transfer. Measurements recorded 
by observer one where undertaken by an obstetrician, and measurements by observer 
two where undertaken by a trained radiographer. Both observers were regularly 
involved in antenatal scanning at this clinical site. 
 
 
Figure 5.1 Example ultrasound screenshot image at correct position for 










Figure 5.2a Anatomical schematic representation of xiphisternum in relation to 
positioning of ultrasound probe. 
 
Figure 5.2b Anatomical schematic of ultrasound image to illustrate anatomical 
landmarks and positioning. SAT Subcutaneous Adipose Tissue, VAT Visceral 






5.3.3 Statistical methods 
The aim of this study is to determine the level of an intra and inter-rater agreement of 
abdominal SAT and VAT in pregnant women at 12 weeks gestation by two clinicians.  
When each clinician is allowed three chances of rating, a minimum sample size of 23 
pregnant women would be required to be assessed by the two clinicians to achieve the 
statistical significance for an alpha-value set at 0.04 and with the minimum power of 
at least 90.0%. An additional 30% (7) of subjects were recruited to account for attrition. 
These figures were derived from the tables and recommendations in Bujang and 
Baharum (2017). 
Intra-observer precision was assessed using Coefficient-of-Variation (Table 5.1). Inter-
observer reliability was assessed using Coefficient-of-variation, and precision 
expressed as repeatability standard deviations (SD) and their respective co-efficients, 
as well as Limits-of-Agreement. Graphical comparisons of the measurements obtained 
by the two observers were made using Bland-Altman plots showing unlinked replicates 
(Bland and Altman 2003). These were generated using the method comparison studies 
R package MethComp (Carstensen et al. 2015) which determines the LoA by fitting a 
variance component model that assumes unlinked replicates (Carstensen 2010). 
Comparison plots were constructed (see Figures 5.3a-b and 5.4a-b). Estimates of the 
LoA were obtained from the corresponding variance component model.  
 
5.4 Results 
SAT and VAT on 30 subjects were obtained by two observers, (coded here as K and 
C). Each measurement was replicated three times, (with the exception of one occasion 
where observer K made just two replicate measurements of subcutaneous fat on a 
particular subject).  
Intra-observer precision was assessed by co-efficient of variation. The data are 
presented in Table 5.1. Intra-observer precision was to an acceptable degree according 
to anthropometric criterion. Measurements of SAT and total adipose for both observers 





Table 5.1 Coefficient of variation (CV) for observer 1 and observer 2 based on 
triplicate measures of SAT, VAT and total adipose (SAT + VAT) on replicates 
(n=30) 
  Observer 1 Observer 2 
Thickness (cm) Mean (±SD) %CV Mean (SD) %CV 
SAT 1.5 ±0.1 2.6 1.5 ±0.1 3.5 
VAT 1.0 ±0.1 5.8 0.9 ±0.1 8.5 
Total adipose (SAT + VAT) 2.5 ±0.1 2.6 2.4 ±0.1 3.3 
*SAT subcutaneous adipose tissue; VAT Visceral adipose tissue; CV Coefficient of variation; SD Standard deviation 
Inter-observer precision and repeatability was also assessed by co-efficient of variation, 
with %CV of 3.05, 7.15 and 2.95% for SAT, VAT and total adipose respectively. Inter-
observer repeatability standard deviations and coefficients are presented in Table 5.2.  
 
Table 5.2 Inter-observer repeatability SDs and repeatability coefficients (CV). 
SD: standard deviation of the difference between two measurements by the same 
method on the item under identical circumstances; the repeatability coefficient 
the numerical extent of the prediction interval for this difference, i.e. 2*SQRT (2) 
*SD. 
 
 SAT VAT Total adipose 
 SD CV SD CV SD CV 
Observer 1 0.079 0.157 0.087    0.174 0.122       0.245 
Observer 2 0.107 0.215 0.128 0.256 0.155       0.310 
*SAT subcutaneous adipose tissue; VAT Visceral adipose tissue; CV Coefficient of variation; SD Standard deviation; SQRT 
Square root 
 
Inter-observer reliability was assessed by LoA. Determinations by each of the two 
observers was made in triplicate. LoA were determined to be -0.45 to 0.46cm for SAT 
and -0.34 to 0.53cm for VAT values. Systematic bias of SAT measurement was 0.01cm 





Figure 5.3 a-b Graphical comparisons of the measurements obtained for SAT by 
the two observers were made using Bland-Altman plots showing unlinked 
replicates (a). On the right; Plot of difference between measures of observer 1 
and observer 2 against the mean of the two measurements of SAT (b). Solid line 
represents the mean; upper line shows the mean +1.96 SD and lower line the 
mean -1.96 SD.  
 
Figure 5.4 a-b Graphical comparisons of the measurements obtained for VAT by 
the two observers were made using Bland-Altman plots showing unlinked 
replicates (a). On the right; Plot of difference between measures of observer 1 
and observer 2 against the mean of the two measurements of VAT (b). Solid line 
represents the mean; upper line shows the mean +1.96 SD and lower line the 







The results of this reliability study show that intra-abdominal ultrasound, using a strict 
protocol, is a reliable method to assess the amount of subcutaneous and visceral adipose 
tissue. Within the same operator, intra-observer precision is acceptable for measures of 
SAT, VAT and total adipose, with higher precision in SAT values than VAT. Between 
different operators, inter-observer reliability assessed by LoA confirm 
anthropometrically reliable to 0.5cm. Systematic bias was minimal for both measures 
falling within 95% confidence intervals. 
The link between metabolic health and adiposity in pregnancy is currently a fertile 
ground of Adipose tissue has been previously measured via various specific 
methodologies, to produce different indices including intra-abdominal fat, abdominal 
wall fat index, pre-peritoneal fat, mesenteric fat and several others. These have been 
defined and characterised based on the specific anatomical sites utilized to measure 
them, as well as specific conditions such as fasting and breathe exhalation. As well as 
characterizing these methodologies, Bazzocchi et al. (2016) compiles the work around 
the validation of these measures via ultrasound technique against the gold standard CT 
scanning and their reproducibility (intra observer and inter- observer reliability). Pre-
peritoneal fat thickness, (defined as the measurement taken on xiphoumbilical line just 
below the xiphoid process, as the major distance between the anterior surface of the 
peritoneum covering the liver lobe, to the posterior surface of the linea alba) is the 
specific abdominal adipose index measured in this study, and has been validated with 
success against  CT imaging in recent times (Bazzocchi et al. 2011) demonstrated 
strong correlation between the CT imaging and US techniques (Lin’s correlation 
coefficient of 0.85-0.87). Minimum Subcutaneous fat thickness (determined as the 
distance between the anterior surface of the linea alba and the peritoneum covering the 
liver lobe, in the same anatomical place of maximum preperitoneal fat thickness) also 
had excellent correlation with CT imaging (Lin’s correlation coefficient of 0.94-0.96).  
Inter and intra-observer reliability has also been found to be acceptable in obese and 
non-obese patients, with co-efficients of variation reported between 4.3 and 6.4% 
(Hamagawa et al. 2010, Bazzocchi et al. 2011). Reliability of these measures has never 
been tested in a pregnant population, and this is important as hydration of tissue 
changes during pregnancy affecting compressibility of tissues and therefore potentially 




1988). Thus, this study contributes to this area of research in a population where the 
obesity epidemic is pertinent and timely. 
The link between metabolic health and adiposity in pregnancy is currently a fertile 
ground of research (Tumurbaatar et al. 2017, Bi et al. 2018, Selovic and Belci 2018, 
Svensson et al. 2018). Excessive accumulation of adipose tissue into the viscera has 
been implicated in increased risk of cardio-metabolic risk (Ribeiro-Filho et al. 2001, 
Bartha et al. 2007, Vlachos et al. 2007) and diabetes mellitus (Bartha et al. 2007, 
Vlachos et al. 2007, Bray et al. 2008, Neeland et al. 2012). Further to this, some studies 
have investigated measures of abdominal adipose tissue in early pregnancy, and 
established its ability to predict glucose intolerance and gestational diabetes in later 
pregnancy (Martin et al. 2009, De Souza et al. 2014, Gur et al. 2014, Yang et al. 2017, 
Bourdages et al. 2018, D'Ambrosi et al. 2018). These research investigations give 
insight into how measures in early pregnancy can play an important role in earlier 
diagnosis and/or intervention, at a time when there is established contact with 
healthcare professional (Poon et al. 2018). Further to this, early detection of risk or 
diagnosis of GDM, has been found to be critical in improving outcomes of various 
types of interventions. Dietary (Thangaratinam et al. 2012); exercise (Cremona et al. 
2018); pharmacological (Syngelaki et al. 2016) intervention, as well a combination of 
these (Koivusalo et al. 2016), showed improved outcomes when applied for a longer 
time-span. 
The end of the first trimester (12 weeks gestation) is a clinically significant clinical 
time-point, at which women attend routine antenatal appointments to the maternity 
hospital to undertake an ultrasound scan to determine gestation, foetal number and to 
out-rule major foetal abnormalities. Following the scan, the patient is booked in the 
Antenatal Clinic; medical and pregnancy history and any comorbidities are recorded 
and antenatal bloods are drawn. This 'booking visit' therefore presents a special 
opportunity of contact with healthcare staff. This should be utilized effectively and 
efficiently to identify women at higher risk, in order to improve management of disease. 
At this time point, maternal BMI and other obstetric risk factors are noted. Despite BMI 
being criticised due to its inability to provide information on components of body 
composition, it is used as a risk-stratification tool in pregnancy to identify women at 
risk of developing GDM (Farah et al. 2011, Farah et al. 2012, Most et al. 2018). 




to contribute to the development of GDM through various pathways (Buchanan and 
Xiang 2005). Subcutaneous and visceral adipose and its distribution around the body 
may play a role in the level of risk constituted. Quantifying these parameters may 
provide a more accurate risk factor than the currently used BMI, and therefore 
potentially be an early identification tool of GDM early in pregnancy. Fattah et al. 
(2010) showed that maternal BMI and total body water do not change within the first 
14 weeks of gestation. Therefore, this time point was selected with the scope that it 
could be tested as an early predictor of GDM together with other parameters of body 
composition via skinfold measurements in a prospective study presented in chapter 6 
within this thesis. 
This specific population is difficult to research with respect to obtaining ethical 
approval and consent due to concerns of invasive procedures during such vulnerable 
period. The proposed US method to measure abdominal adipose is safe, non-invasive, 
economical, and does not involve any extra intervention for the patient- such as, 
specific procedural preparation. In addition, it is time-efficient, as it took the 
researchers less than three minutes to record three repeated measures on one person. 
We would recommend that future studies incorporate recording time taken to take the 
measurements. In practice, routine scans at antenatal visit are allocated 15 minutes 
each, despite variations according to clinical requirement.  
Future studies should endeavour to determine reliability of ultrasound measurement in 
each BMI category separately within a pregnant population. This will help determine 
specific reliability of measurement in each BMI category and to determine if this differs 
between categories. It is possible that the measurement have narrower LoA in 
underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 
kg/m2), class I obese (30.0-34.9 kg/m2), class II obese (35.0-39.9 kg/m2) and class III 
obese (40-45 kg/m2) categories (WHO, 2013). This could have implications on the 
interpretation and therefore clinical meaning of the measurement (Armijo-Olivo 2018). 
This would determine reliability of SAT and VAT parameters within these cohorts and 
address the clinical meaning of the LoA as higher BMIs are linked with negative 
metabolic health. This is confirmed by large population studies examining pregnancy 
outcomes, having previously demonstrated a relationship with increasing risk of 
adverse outcomes, including GDM, hypertensive disorders, caesarean section, 




(Catalano and Hauguel-De Mouzon 2011, Dodd et al. 2011, Catalano et al. 2012, Scott-
Pillai et al. 2013). 
Future studies examining relationships between abdominal adiposity and pregnancy 
outcomes may prove to be clinically useful in terms of risk- stratification, therefore 
using US as a research tool will translate easily to an applicable tool in practice. 
Currently, body mass index is used as a risk-stratification tool during pregnancy; 
however, this does not capture body composition parameters such as abdominal 
adiposity, which are specifically implicated in metabolic health (Kirwan et al. 2002, 
Despres and Lemieux 2006, Hamagawa et al. 2010, Jayabalan et al. 2017).  
 
5.7 Conclusions 
Ultrasound is a non-invasive, safe, quick and available tool for quantifying adiposity 
in both clinical practice as a research tool. Standardized techniques for abdominal 
adiposity, specifically visceral fat thickness at the xiphoid region (pre-peritoneal fat) 
has not been previously investigated in a pregnant population, thus addressing a gap 
within the literature previously identified (Wagner 2013, Bazzocchi et al. 2016). 
Therefore, this study offers a technique which when replicated, is a highly reliable and 
practical tool, which does not require demanding operator training. Therefore, it can be 
implemented by researchers and clinicians during routine antenatal ultrasonography. 
Measurement of intra-abdominal adipose by ultrasound is suitable for use in 





Chapter 6: Association of early pregnancy body 
composition and physical activity to glucose 





6.1 Abstract  
Background: Accurate early risk prediction for gestational diabetes mellitus (GDM) 
would target intervention and prevention in women at the highest risk. We evaluated 
maternal risk factors and parameters of body composition to develop a prediction 
model for GDM in early gestation.  
Methods:  A prospective observational study was undertaken. Pregnant women aged 
between 18-50y of age with gestational age between 10-16 weeks were included in the 
study. Women aged ≤18y, twin-pregnancies, known foetal anomaly or pre-existing 
condition affecting oedema status were excluded. 8-point skinfold thickness, MUAC, 
waist, hip, weight and ultrasound measurements of subcutaneous (SAT) and visceral 
abdominal adipose (VAT) were measured. Oral glucose tolerance test (OGTT) for 
GDM diagnosis was undertaken at 30w gestation. Binomial logistic regression models 
were used to predict GDM. ROC analysis determined discrimination and concordance 
of model and individual variables.  
Results: 188 women underwent OGTT at 28(27.1-28.6) weeks gestation. Eighteen 
(9.6%) women developed GDM. BMI (24.7kg/m2 (±6.1), 29.9 kg/m2  (±7.8), p=.022), 
abdominal SAT (1.32cm (CI 1.31-1.53), 1.99cm (CI 1.64-2.31), p=.027), abdominal 
VAT (.78cm (CI .8-.96), 1.41cm (CI 1.11-1.65), p=.002),  truncal SFT  (84.8mm (CI 
88.2-101.6), 130.4mm (CI 105.1-140.1), p=.010), waist (79.8cm (CI 80.3-84.1), 
90.3cm (CI 85.9-96.2), p=.006) and gluteal hip (94.3cm (93.9-98.0), 108.6cm (99.9-
111.6), p=.023) were higher in GDM vs. non-GDM.  After screening variables for 
inclusion into the multivariate model, family history of diabetes, previous perinatal 
death, and overall insulin resistant condition, abdominal SAT and VAT, 8-point SFT, 
MUAC and weight were included. The combined multivariate prediction model 
achieved an excellent level of discrimination, with an AUC of 0.860 (CI 0.774–0.945) 
for early GDM.  
Conclusions: An early gestation risk prediction model, which incorporates known risk 
factors, and parameters of body composition accurately identify pregnant women in 
their first trimester who developed GDM later on in gestation. This methodology could 
be used clinically to identify at risk pregnancies, and target specific treatment through 






Gestational diabetes has become more prevalent since the introduction of more 
stringent criteria used for diagnosis (WHO, 2013). Currently, in Ireland, risk 
stratification takes place in early pregnancy to identify women at higher risk of 
developing GDM. These women are indicated an 75g-Oral Glucose Tolerance Test 
(OGTT) at 28-32 weeks gestation, in order to confirm GDM status (Tietz 2006). In the 
case where diagnostic thresholds are superseded, subsequent referral management 
using medical nutrition therapy and pharmacological therapy takes place in order to 
improve the perinatal outcomes of the index pregnancy (HSE, 2010). This screening 
method has shown poor detection rate of 60% for GDM. The nature of the test in 
picking up excursions of blood glucose response to 75g glucose ingestion taking place 
so late in pregnancy significantly delays the diagnosis and treatment of GDM. This 
allows for a limited timeframe of about 8-10 weeks for treatment during pregnancy, 
whilst many lifestyle interventions in patients with diabetes have shown success in 
interventions lasting longer (Cremona et al. 2018). Early detection of GDM could 
improve the benefits of medical nutrition therapy and exercise interventions as well as 
shed light on who might respond better to various types of lifestyle and 
pharmacological preventative interventions (Thangaratinam et al. 2012, Koivusalo et 
al. 2016, Syngelaki et al. 2016). Early prediction of GDM is a very pertinent topic at 
this time as prevalence of GDM is on the rise and has related economic implications 
(Gillespie et al. 2011, Poon et al. 2018). 
Obesity and the accumulation of adipose tissue associated with pregnancy is thought 
to contribute to the development of GDM through various pathways (Buchanan and 
Xiang 2005). During pregnancy, both adipose and muscle mass play an antagonistic 
role in insulin sensitivity (Wolfe 2006, Srikanthan and Karlamangla 2011, Xiang et al. 
2015). Despite BMI being criticised due to its inability to provide information on 
components of body composition, it is used as a risk-stratification tool in pregnancy to 
identify women at risk of developing GDM (Farah et al. 2011, Farah et al. 2012, Most 
et al. 2018). Subcutaneous and visceral adipose and its distribution around the body 
may play a role in the level of risk constituted. Quantifying these parameters may 
provide a more accurate risk factor than the currently used BMI, and therefore 




Previous studies indicate a link between maternal obesity and developing GDM 
visceral fat thickness to developing GDM, insulin resistance and metabolic syndrome 
(Gur et al. 2014, De Souza et al. 2016a, Tumurbaatar et al. 2017). Most recently, a 
study by Bourdages et al. (2018) examined the predictive effect of subcutaneous and 
visceral adiposity on development of GDM, and found that it was more suited for 
predicting GDM which went on to requiring pharmacological management with 
insulin. These studies looked at measures of abdominal obesity forgoing adiposity 
distribution around the whole body. Despite these studies, the role of early 
measurement of adiposity in clinical practice is yet be defined. 
We therefore hypothesize, that quantification of body composition may provide a more 
accurate warning sign than BMI to indicate higher risk stratification of development of 
diabetes during pregnancy. 
The aims of this study are (1) to investigate the relationship between parameters of 
body composition to glucose tolerance, and birth weight in a pregnant population; (2) 
to develop a prediction model for GDM based on multivariate analysis of maternal risk 
factors combined with body composition parameters in early pregnancy; (3) to estimate 






The study was approved by the HSE Research Ethics Committee (REC Ref 082/17). 
Details available in Appendix G. 
6.3.1 Participant selection and recruitment 
Participants who attended routine outpatient appointment at the outpatients unit in the 
University of Limerick Maternity Hospital were selected for the study. An invitation 
note (see Appendix A) and study information sheet (see Appendix B) were attached to 
patient medical notes who were attending their first antenatal appointment. Potential 
participants attended routine antenatal ultrasound scan. Before the study, foetal growth, 
amniotic fluid volume, and foetal anatomy were assessed and nuchal translucency 
measured. Women with twin pregnancies or maternal conditions (i.e., uterine 
leiomyoma, ovarian cysts) that could affect uterine length at this early stage were 
excluded. Otherwise, the participant was asked if they would like to participate in the 
study, at which point written consent was sought (see Appendix C). 
6.3.2 Inclusion and exclusion criteria 
Pregnant women aged 18 to 50 years of age, with gestational age between 10-16 weeks 
were included in the study. Exclusion criteria included women aged less than 18 years, 
twin pregnancies, known foetal anomaly or known pre-existing condition affecting 






Following informed consent, measurements of abdominal adipose via ultrasound were 
first recorded. Following this, physical activity level was measured via Pregnancy 
Physical Activity Questionnaire (PPAQ), and anthropometrics were recorded. 
Participants attended routine Oral Glucose Tolerance Test (OGTT) at about 28-30 
weeks gestation. Pregnancy outcomes were then abstracted from medical notes. Figure 
6.1 shows the time-points of data collection. Each measured outcome is detailed next. 
  
Figure 6.1 Timeline of data-collection time-points 
*OGTT Oral glucose tolerance test; PPAQ Pregnancy Physical Activity Questionnaire; SAT Subcutaneous adipose tissue; VAT 





6.3.4 Ultrasound measurements 
Measurements of adipose tissue were taken via abdominal ultrasonography (US) using 
a GE Voluson E8 employing a 1-5MHz curvilinear array transducer. This procedure is 
outlined in detail in Chapter 5. In summary, with the patient in a supine position and 
the transducer perpendicular to the skin, the required image was obtained in sagittal 
plane in at the xiphisternum, producing a longitudinal view of the left lobe of liver and 
the aorta. Minimal pressure was exerted on the skin, in order to avoid compression of 
the adipose tissue. The transducer was rocked left to right, in order to identify the 
narrowest projection of the linea alba. The scan depth was reduced, excluding the aorta 
from the image. The sector width was reduced to 40 degrees; increasing line density. 
Thus, an image of both layers of adipose tissue was obtained with the inferior part of 
the left lobe of liver seen posteriorly (see Figures 5.1 and 5.2a-b). At this point, the 
time gain compensation (TGC) and overall gain were adjusted carefully to allow clear 
visualisation of subcutaneous adipose tissue and homogenous echogenicity within the 
left lobe of liver. The image was then frozen. Calipers were placed to measure in 
millimetres. Subcutaneous fatty tissue was measured from the lower border of the 
cutaneous layer to the upper border of the linea alba and visceral fatty tissue was 
measured from the lower border of linea alba to the upper border of the liver capsule. 
6.3.5 Physical Activity measurements 
Physical activity was captured via facilitated questionnaire. The questionnaire used was 
a validate questionnaire in a pregnant population (Chasan-Taber et al. 2004). The 36-
item questionnaire can be found in Appendix D and the instructions followed to 
interpret the questionnaire can be found in Appendix E. Metabolic Equivalent of Task 
(MET) values were used to categorise energy cost of activities (Ainsworth et al. 2011). 
6.3.6 Anthropometric and kinanthropometry measurements 
 Height and weight 
Height was measured to the nearest 0.1cm using a portable stadiometer (Seca 213, 
Hamburg, Germany). Body mass was recorded to the nearest 0.1kg using electronic 





 Skinfold thickness 
Skinfold thickness measures at eight anatomical sites (bicep, tricep, subscapular, 
supraspinale, iliac crest, abdominal, front thigh, medial calf) were recorded to the 
closest mm using Class I skinfold calipers (HarpendenCE, HSB-BI, Warwickshire, UK). 
Skinfold calipers require a constant closing compression of 10 g.mm–2 throughout the 
range of measurements. The calipers were calibrated within 40 mm in 0.2 mm 
divisions’ requirements (Schmidt and Carter 1990, Gore et al. 1995, Gore et al. 2000). 
A segmometer (Cescorf, CC01, Rosscraft, Canada) was used to determine skinfold 
sites between identified anatomical landmarks. Skinfold sites were located according 
to specifically identified anatomical landmarks defined by the International Society for 
the Advancement in Kinanthropometry (ISAK). These are illustrated in Figure 6.2 and 
detailed in Table 6.1 (Stewart and Marfell-Jones 2011). The researcher who carried out 
the measurements is a level II ISAK trained anthropomotrist (inter-tester and intra-
tester technical error of measurement (TEM) is ≤5% for SFT, and <1% for girth 
measurements). All measurement were repeated twice initially. Were the value was 
below these TEM thresholds, then the mean of two measures was used, if it was greater 
than these values, then an additional measure was taken and median used for analysis 
as per set ISAK criterion and standards (Olds et al. 2011).  
 Girths 
Girth measurements of waist, gluteal hip and mid upper arm were also recorded using 
a flexible steel measuring tape (Lufkin W606PM, Warwickshire, UK). MUAC was 
measured at the mid-point between the olecranon and acromion process, to the nearest 






6.3.7 Derived measurements 
 MAMC 
MAMC (cm) = MUAC (cm) – 0.314 x tricep SFT (mm) 
 % body fat 
 
Percentage body fat was derived from the equation developed by (Kannieappan et al. 
2013). FM and FFM mass were subsequently calculated from this equation. 
 
BF% = 12.7+0.457 x tricep SFT(mm) +0.352 x subscapular SFT (mm) + 0.103 x bicep 
SFT(mm) -0.057 x ht(cm) +0.265 x MUAC(cm) 
 
 Appendicular SFT 
Appendicular skinfold thickness was calculated as the sum of four skinfolds measures: 
𝐴𝑆𝐹𝑇 =  ∑(biceps SFT +  tricep SFT +  thigh SFT +  medial calf SFT)  
 
 Truncal SFT 
Truncal skinfold thickness was calculated as the sum of four skinfolds measures: 
ΣSFT = ∑(supraspinale SFT +  subscapular SFT +  abdominal SFT 
+  iliac crest SFT) 
 
 Total SFT 
Total skinfold thickness was derived as sum of all eight skinfold measures: 
Total SFT =  ∑(supraspinale SFT +  subscapular SFT +  abdominal SFT 
+  iliac crest SFT biceps SFT +  tricep SFT +  thigh SFT 





Figure 6.2 Location of skinfold sites: anterior view (left) and posterior view 








Table 6.1 Measurements recorded with anatomical description of site of measurement, subject positioning and technique used to 
obtain measurement. 
 
Measurement Anatomical site Subject position Technique 
Body mass Whole body measurement Minimal clothing, standing with weight 
distributed equally. 
Ensure scale is reading at 0, then the subject 
stands on the centre of the scales without 
support and with the weight distributed evenly 
on both feet. 
Stretch 
stature 
Full body height. The stretch stature method requires the 
subject to stand with the feet together and 
the heels, buttocks and upper part of the 
back touching the scale. The head when 
placed in the Frankfort plane need not be 
touching the scale. The Frankfort plane is 
achieved when the Orbitale (lower edge of 
the eye socket) is in the same horizontal 
plane as the Tragion (the notch superior to 
the tragus of the ear). When aligned, the 
Vertex is the highest point on the skull.  
The measurer places the hands far enough along 
the line of the jaw of the subject to ensure that 
upward pressure is transferred through the 
mastoid processes. The subject is instructed to 
take and hold a deep breath and while keeping 
the head in the Frankfort plane the measurer 
applies gentle upward lift through the mastoid 
processes. The recorder places the head board 
firmly down on the vertex, pushing the hair as 
much as possible. Measurement is taken at the 








Anatomical site Subject position Technique 
Tricep The most posterior part of the 
triceps when viewed from the 
side at the marked mid-
acromiale- radiale level. 
Equidistant point from 
acromiale (The point on the 
superior part of the acromion 
border in line with the most 
lateral aspect) to the radiale 
(The point at the proximal and 
lateral border of the head of 
the radius). 
The subject assumes a relaxed standing 
position with the left arm hanging by the 
side. The right arm should be relaxed with 
the shoulder joint slightly externally 
rotated and elbow extended by the side of 
the body. 
The fold is parallel to the long axis of the arm.  
The mid-point is located using a segmometer to 
identify the centre point between the acromiale 
and radiale. 
Subscapular The site 2 cm along a line 
running laterally and obliquely 
downward from the 
subscapulare landmark at a 45° 
angle. The subscapulare is the 
undermost tip of the inferior 
angle of the scapula.  
The subject assumes a relaxed standing 
position with the arms hanging by the sides. 
The line of the skinfold is determined by the 
natural fold lines of the skin. The site is located 
via palpating at the inferior angle of the scapula 
with the left thumb 
Bicep The most anterior part of the 
biceps Equidistant point from 
acromiale to radiale (mid-
acromiale). 
The subject assumes a relaxed standing 
position with the left arm hanging by the 
side. The right arm should be relaxed with 
the shoulder joint slightly externally 
rotated and elbow extended by the side of 
the body. 





Iliac crest The site at the centre of the 
skinfold raised immediately 
above the iliocristale The 
iliocristale is the point on the 
most lateral aspect of the iliac 
tubercle, which is on the iliac 
crest.  
The subject assumes a relaxed standing 
position with the left arm hanging by the 
side. The right arm should be either 
abducted or placed across the trunk. 
The line of the skinfold generally runs slightly 
downward posterior-anterior, as determined by 
the natural fold lines of the skin.  
From behind the subject, locate the most lateral 
edge of the iliac crest on the ilium using the right 
hand. The left hand is used to stabilise the body 
by providing resistance on the left side of the 
pelvis. The landmark is the most lateral point 
made at the identified edge of the ilium 
Supraspinale The most inferior or undermost 
part of the tip of the anterior 
superior iliac spine. The site is 
located  at the intersection of 
two lines: (1) the line from the 
marked iliospinale (The most 
inferior or undermost part of 
the tip of the anterior superior 
iliac spine) to the anterior 
axillary border, and (2) the 
horizontal line at the level of 
the marked iliocristale (the site 
at the centre of the skinfold 
raised immediately above the 
iliocristale). 
The subject assumes a relaxed standing 
position with the arms hanging by the sides. 
The fold runs medially downward at about a 45° 
angle as determined by the natural fold of the 
skin. 
Abdominal The site 5 cm to the right hand 
side of the omphalion 
(midpoint of the navel). This is 
a vertical fold raised 5 cm from 
The subject assumes a relaxed standing 
position with the arms hanging by the sides. 
This is a vertical fold. It is particularly important 
at this site that the measurer is sure the initial 
grasp is firm and broad since often the 




the right hand side of the 
omphalion. 
may result in an underestimation of the 
thickness of the subcutaneous layer of tissue.  
Front thigh The site at the mid-point of the 
distance between the inguinal 
fold and the anterior surface of 
the patella (Anterior patalla) on 
the midline of the thigh. 
The subject assumes a seated position at 
the front edge of the box with the torso 
erect and the arms hanging by the sides. 
The knee of the right leg is usually bent at a 
right angle. In some subjects, this skinfold 
may be easier to take with the knee 
extended. 
The measurer stands facing the right side of the 
subject on the lateral side of the thigh. The 
skinfold is raised at the marked site. The skinfold 
measurement is taken while the knee is bent. 
This is the standard and preferred method. If the 
fold is difficult to raise the subject is asked to 
assist by lifting with both hands the underside of 
the thigh to relieve the tension of the skin. 
Medial calf The site on the most medial 
aspect of the calf at the level of 
the maximal girth.  
The subject assumes a relaxed standing 
position with the arms hanging by the sides 
and the right foot placed on the box. The 
right knee is bent at about 90°. 
The subject’s right foot is placed on a box with 
the calf relaxed. The level of the maximum girth 
is determined and marked with a small 
horizontal line on the medial aspect of the calf. 
The maximal girth is found by using the middle 
fingers to manipulate the position of the tape in 
a series of up or down measurements to 
determine the maximum girth. View the marked 
site from the front to locate the most medial 
point and mark this with an intersecting vertical 
line. The fold is parallel to the long axis of the leg. 
Girth 
measurements 





The girth of the arm is 
measured at the marked level 
of the Mid-acromiale- radiale. 
The subject assumes a relaxed standing 
position with the arms hanging by the sides. 
The subject’s right arm is abducted slightly 
The girth of the arm is measured at the marked 
level of the mid-acromiale- radiale. The tape 
should be positioned perpendicular to the long 




to allow the tape to be passed around the 
arm. 
 
Waist This girth is taken at the level of 
the narrowest point between 
the lower costal (10th rib) 
border and the iliac crest.  
The subject assumes a relaxed standing 
position with the arms folded across the 
thorax. 
The anthropometrist stands in front of the 
subject who abducts the arms slightly allowing 
the tape to be passed around the abdomen. The 
stub of the tape and the housing are then both 
held in the right hand while the anthropometrist 
uses the left hand to adjust the level of the tape 
at the back to the adjudged level of the 
narrowest point. The anthropometrist resumes 
control of the stub with the left hand and using 
the cross-hand technique positions the tape in 
front at the target level. The subject is instructed 
to lower their arms to the relaxed position. The 
tape is then readjusted as necessary to ensure it 
has not slipped and does not excessively indent 
the skin. The subject should breathe normally 
and the measurement is taken at the end of a 





Gluteal (hip) The girth is taken at the level of 
the greatest posterior 
protuberance of the buttocks 
which usually corresponds 
anteriorly to about the level of 
the symphysis pubis. 
The subject assumes a relaxed standing 
position with the arms folded across the 
thorax. The subject’s feet should be 
together and the gluteal muscles relaxed. 
The anthropometrist passes the tape around the 
hips from the side. The stub of the tape and the 
housing are then both held in the right hand 
while the anthropometrist uses the left hand to 
adjust the level of the tape at the back to the 
adjudged level of the greatest posterior 
protuberance of the buttocks. The 
anthropometrist resumes control of the stub 
with the left hand, and using the cross-hand 
technique, positions the tape in front and the 
sides so that the tape is held in a horizontal plane 
at the target level. The tape is then readjusted as 
necessary to ensure it has not slipped and does 




6.3.8 Outcome measures  
6.3.8.1 Primary outcome measure: Oral Glucose Tolerance Test  
Patients underwent oral glucose tolerance testing (OGTT) at 28 weeks gestation. 
Patients presented for their morning appointment following a period of fasting (food 
and fluid) of 12 hours. The test was carried out by an experienced clinician in a 
dedicated clinical setting in the hospital. On arrival for the test, patients were advised 
not to move around or smoke for the duration of the test. A baseline (fasted) venous 
blood sample was drawn. Patients were provided with a 75g oral glucose solution 
(Rapilose) to drink within a five minute timeframe. A second venous blood sample was 
drawn one hour post ingestion of glucose load, followed by another sample two hour 
post glucose load.  
The samples of blood glucose serum were analysed on an Abbott ARCHITECT c1600 
clinical chemistry analyzer™. The test principal is based on an ultraviolet (UV) test 
with the enzymatic reference method with hexokinase. Hexokinase catalyses the 
phosphorylation of glucose to glucose-6-phosphate by ATP. Glucose-6-phosphate 
dehydrogenase oxidizes glucose-6-phosphate in the presence of NADP to gluconate-6-
phosphate. No other carbohydrate is oxidized. The rate of NADPH formation during 
the reaction is directly proportional to the glucose concentration and is measured 
photometrically against reference values (Kunst et al. 1984, Tietz 2006). The co-
efficient of variation (CV) values at the lab report 1.84% at 2.8mmol/L, 2.07% at 
7.6mmol/L and 1.5% at 16.4mmol/L. Results were reported on the hospital laboratory 
IT system, and retrieved by the researcher post-partum. 
Glucose intolerance was calculated from plasma glucose area under the curve (PG-
AUC) using trapezoidal technique (Sakamoto et al. 2013). Binary classification of 
GDM was made using diagnoses based on the IADPSG revised diagnostic thresholds 
(WHO, 2013). These thresholds were a fasting plasma glucose of 5.1-6.9 mmol/L, a 1-
h post 75g oral glucose load ≥10.0 mmol/L or a 2-h post glucose load of ≥8.5–11.0 
mmol/L. An OGTT result meeting the threshold at one or more time points indicated a 




6.3.8.2 Secondary outcome measure: Birth weight 
Weight of neonate measured at the time of birth was recorded via clinicians. This was 
abstracted from medical notes. Birth weight was expressed as percentile birth weight 
after adjustment for maternal ethnicity, sex and gestational age. This was done using 
Perinatal Ireland centile calculator (Unterscheider et al. 2013). Binary classification of 
birthweight was set at >90th centile defining large for gestational age (LGA). 
6.3.8.3 Co-variates: Obstetric risk factors and pregnancy outcomes 
Risk factors for GDM were captured via data abstraction. These included age, smoking, 
family history of diabetes, occurrence of GDM in a previous pregnancy, previous 
perinatal death (previous miscarriage or still birth), glycosuria at antenatal visit (2+ or 
1+ detected by reagent strip test at routine antenatal visit, previous polyhydramnios or 
macrosomia, high risk ethnicity, parity, and PCOS. Other pre-existing conditions 
implicated to have insulin resistance were also considered as potential confounders 
(Garrison and Breeding 2003, Tuzcu et al. 2003, Diamanti-Kandarakis and Christakou 
2009, Fan et al. 2009, Giordano et al. 2009, Kapadia et al. 2012, Polic et al. 2018, Kaya 
et al. 2019, Yıldız Gülhan et al. 2020). These were pooled together for analysis and 






6.3.9 Statistical approaches 
6.3.9.1 Sample size determination 
By applying the formula in Hsieh et al. (1998):  
𝑛 = (𝑍_ {1 −
𝛼
2
} +  Ζ_{𝑝𝑜𝑤𝑒𝑟})∧2[𝑝_1(1 − 𝑝1)[log (𝑂𝑅)]∧2] 
Where n is the required total sample size, OR is the odds ratio to be tested, p_1 is the 
event rate at the mean of the predictor X, and Z_u is the u-th percentile of the standard 
normal distribution. 
For α = 5%, power = 80%, OR = 1.5 and p1 = 50%: n = 191.  
Detecting an OR of 1.5 or 1.6 or 1.7 required between 110 and 190 subjects. The 
minimum required is 110, striving for 150 or 200. 
In order to proceed with the sample size calculation, three inputs were specified a 
priori. These were:   
Alpha (𝜶): the probability of a type I error 
Power: the probability of detecting the effect size of interest 
ES: the effect size of interest 
 An alpha = 5% and power = 80% were selected.   
For the ES to be determined, OR (the magnitude of the odds ratio to be tested) and p1 
(the event rate of the mean of the predictor X) needed to be specified.  
 
An OR = 1.5 would indicate that a subject 1.5 time more likely to develop the outcome 
than not. The simplest scenario is to examine deviation from p1 = 50%, that is a 
predictor with no discriminant power.  
The following formula was then applied (Hsieh et al. 1998) as follows:  





Where n is the required total sample size, OR is the odds ratio to be tested, p_1 is the 
event rate at the mean of the predictor X, and Z_u is the u-th percentile of the standard 
normal distribution. 
N= 191 when alpha = 5%, power = 80%, OR = 1.5 and p1 = 50%  
N= 143 when alpha = 5%, power = 80%, OR = 1.6 and p1 = 50%  
N= 112 when alpha = 5%, power = 80%, OR = 1.7 and p1 = 50% N= 91 when alpha = 
5%, power = 80%, OR = 1.8 and p1 = 50%  
N= 77 when alpha = 5%, power = 80%, OR = 1.9 and p1 = 50%  
N = 66 when alpha = 5%, power = 80%, OR = 2.0 and p1 = 50%  
Therefore, detecting an OR of 1.5 or 1.6 or 1.7 would require between 110 and 190 
subjects. As the study is exploratory in nature, it was recommended to aim for a 
minimum of 110, but strive for 150 or 200.  
 
6.3.9.2 Inter-tester and intra-tester reliability of measures 
Precision reliability was calculated via intra-tester technical error of measurement 
(TEM). This is a measure of the variability between two separate series of 
measurements taken from one subject by one tester. 
Accuracy validity was calculated via inter-tester TEM. This is the variability between 
two testers taking a series of measurements from the one subject 
To calculate the following formula is applied, where d is the difference between two 
measures, and n the sample size: 




Fore relative TEM, the calculated TEM was expressed as a percentage, where ?̅? is the 
average of the measurements recorded: 
%TEM =  
TEM
?̅?





6.3.9.3 Statistical analysis 
All collected data was compiled into a single Excel™ spreadsheet database. Data was 
coded and inputted into SPSS© V.25 for analysis. Normality tests where undertaken to 
determine if data was to be treated as parametric or non-parametric (see Appendix H 
for normality tests on all variables, and split for both GDM and LGA). Bivariate logistic 
regression analysis was performed for bivariate correlation coefficients using non-
parametric Spearman’s rho was conducted to assess the relationship between the 
continuous independent variables. Non-parametric independent sample tests were 
conducted on to test differences between screen-positive OGTT, and occurrence of 
LGA. Co-variates were also analysed dichotomously using cross tabulation and non-
parametric independent sample testing. A significance probability (p value) of ≤ .200 
was used to screen co-variates for inclusion in multi-variate regression model.  
A binomial regression (multivariate regression) was constructed to consider the effect 
of all variables on the outcome of GDM. Receiver operating characteristics (ROC) were 
used to evaluate sensitivity and specificity of single and binary classifiers and to 
determine discrimination thresholds. ROC curves were generated to identify a cut-off 







6.4 Results overview 
The results section is presented in five parts. The first part describes the overall sample 
demographic and characteristics (section 6.4.1). The second part describes the body 
composition parameters (test variables), physical activity variables (potential 
confounding variable), and outcome measures: OGTT results (primary outcome) and 
birth weight (secondary) (section 6.4.2). The third part examines any potential 
relationship between the test variables and the outcome measures through correlation 
analysis (section 6.4.3). The fourth part assesses for group differences in the test 
variable which are classified into binary outcomes: GDM vs non-GDM (primary) and 
LGA vs. non-LGA (secondary). Variables that were found to be statistically different 
between groups (p<0.05) are illustrated in this section. (Section 6.4.4).  The fifth and 
final part of the results has a regression model built with test variables from part four 
of the results which were found to be significantly different between groups (p<0.200) 
to predict the occurrence of GDM. A receiver operator characteristic (ROC) curve was 
then generated to evaluate sensitivity and specificity of the regression model and of all 
predictive variables individually. This section presents the concordance statistic (AUC) 
and ROC curves for the predictive model and all predictive variables individually 





6.4.1 Description of the overall sample 
Two-hundred thirty-eight pregnant women were recruited to participate in the study 
from 34 antenatal clinics. These clinics took place from October 2017 to June 2018, at 
the University Maternity Hospital Limerick (UMHL), Ireland. Figure 6.3 below 
presents a flow chart of participants according to STROBE (strengthening the reporting 
of observational studies in epidemiology) guidelines (Vandenbroucke et al. 2007). 
 
Figure 6.3 Flow chart showing participant recruitment according to STROBE 
(Strengthening the Reporting of Observational studies in Epidemiology) guidelines 








6.4.1.1 Demographic characteristics 
Two hundred thirty-eight pregnant women aged 32.6 (IQR 29.3, 36.0) years 
participated in the study. Eighty-eight participants were primiparous. The rest of the 
participants had a parity ranging from one to five. Majority of participants were Irish 
(80.6%), followed by 8.9% participants of Eastern & Central European ethnicity 
(Russia, Poland, Lithuania, and Romania). 
 
Table 6.2 Demographic characteristics of recruited participants 
 
 Median (IQR) 
Age (y) 32.6 (29.3, 36.0) 
Gravida 2 (1,3) 
Parity 1 (0,2) 







South Asian  2 (0.8%) 
Americas  4 (1.7%) 
Sub Saharan Africa  4 (1.7%) 










6.4.1.2 Obstetric risk factors for gestational diabetes 
Risk factors for GDM include a BMI ≥ 30kg/m2; age ≥ 40y; a family history of diabetes 
in a 1st degree relative; ethnicity (specifically South Asian (specifically India, Pakistan 
or Bangladesh), black Caribbean or Middle Eastern (specifically Saudi Arabia, United 
Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, Lebanon or Egypt)); previous 
baby born ≥ 4.5kg, GDM in a previous pregnancy; polycystic ovarian syndrome 
(PCOS); previous perinatal death; and positive detection of glycosuria at the antenatal 
visit. Figure 6.4 illustrates the risk profile for all participants. The most prevalent risk 
factors identified were previous perinatal death (76 (32%)), followed by having a 
family history of diabetes in a first-degree relative (69 (29%)), and a high BMI (51 
(21%)). 
Figure 6.4 Bar chart showing frequency of risk factors for GDM in recruited 
participants.
 
*GDM Gestational diabetes mellitus; PCOS Polycystic ovary syndrome; BMI Body mass index; Hx history 
  














6.4.1.3 BMI classification and distribution according to GDM positive 
screen 
Weight and height were used to calculate BMI. These were categorised according to 
the WHO categories of underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), 
overweight (25.0-29.9 kg/m2), class I obese (30.0-34.9 kg/m2), class II obese (35.0-
39.9 kg/m2) and class III obese (40-45 kg/m2). Figure 6.5 shows the frequency of 
participants according their BMI classification. The largest proportion of participants 
were of a normal weight 97 (41%), with 62 (26.2%) in the overweight category and 45 
(19%) of the overall cohort were obese (≥30 kg/m2). A small proportion of the overall 
cohort (nine (4%) had a BMI in the underweight category. 
 






Eighteen (9.6%) out of 188 participants who underwent OGTT were diagnosed with 
GDM according the IADPSG (2011) diagnostic criteria. Figure 6.6 illustrates the 
distribution of GDM occurrence amongst the BMI categories: one participant was in 
the underweight category, three in the normal weight, five in the overweight, 45 in class 
I obese, four in class II obese and none in the BMI >40 category. The greatest 
proportion of diagnosed GDM cases were in the obese class I category (26.3% of this 
category were diagnosed with GDM) and 23.5% of the obese class II category. Whilst 
the other categories ranged from 4.1-12.5% of participants diagnosed with GDM in 
their respective categories. These relative proportions are illustrated in Figure 6.6.  
 
  
Figure 6.6 Distribution of BMI indices for cohort, showing proportion of GDM 
diagnosis in each group 
 







Figure 6.7 Relative proportion of GDM diagnosis across BMI categories 
 
*BMI Body mass index; GDM Gestational diabetes mellitus 
6.4.1.4 Cigarette smoking status 
One hundred ninety two (81%) of participants do not smoke cigarettes. 35 (15%) smoke 
cigarettes, of which 30 (12.7%) smoked during the index pregnancy. Figure 6.8 
illutrates these findings. 
Figure 6.8 Cigarette smoking status in participants 
 
 
Smoking in index pregnancy Non-smoker




6.4.1.5 Incidence of insulin resistant conditions in overall sample 
Twenty-nine participants presented with potentially insulin resistant conditions. These 
conditions are listed and ranked in Figure 6.9, where the distribution of presentations 
for each condition is illustrated. Five participants presented with two of these 
conditions; two presented with hypothyroidism together with endometriosis, one with 
PCOS with fibromyalgia, one incidence of PCOS with hypothyroidism and one 
incidence of hypothyroidism with Addison’s disease. The most common co-morbidity 
was thyroid dysfunction, followed by polycystic ovarian syndrome (PCOS) and 
endometriosis. 
 
Figure 6.9 Bar chart showing incidence of insulin resistant conditions in 29 
participants 
 
*PCOS Polycystic ovary syndrome 
 
  















6.4.2 Description of body composition measurements, physical activity data 
and glucose tolerance test (GTT) in all participants 
Below are descriptive details of the test variables for the whole cohort of participants 
(Table 6.3). Total skinfold thickness were excluded list wise if there was one or more 
missing values from the 8-point skinfold thickness measurements. The same was 
applied the appendicular and truncal derived SFT. 
 
Table 6.3 Description of body composition measurements 
 n Mean 
(±SD) 
Median (IQR) Range (min-
max) 
Height (m) 213 164.4 ±6.3 164.3 
(160.0,168.9) 
149.0-181.0 








































17.2 (11.4, 27.0) 
25.4 (19.7, 33.4) 
34.1 (26.3, 47.2) 











































1.50 ± 0.73 
0.92 ± 0.50 











MUAC (cm) 213 30.5±6.7 29.9 (29.9-32.9) 18.2-100.8 
MAMC (cm) 213 23.3 ± 5.1 22.7 (21.4, 24.6) 16.3-86.5 
Waist (cm) 212 82.7±11.8 79.9 (74.5-88.4) 58.5-130.3 
Hip (cm) 212 96.5±13.3 94.5 (86.6,103.4) 62.4-142.7 
*SD standard deviation; IQR Interquartile range; SFT Skinfold thickness; MUAC Mid upper arm circumference; MAMC Mid 





Physical activity levels in the cohort measured via PPAQ are described for all 
participants below (Table 6.4). 
Table 6.4 Description of physical activity levels (n=216) 
(MET-h.week-1) Mean (±SD) Median (IQR) Range (min-max) 
Total activity  189.8 ± 91.4 170.0 (127.2,237.8) 17.8-545.9 
Sedentary activity  
(<1.5 METs) 
11.3 ± 11.7 7.4 (4.4,17.4) 0-74.2 
Light activity  
(1.5 to <3.0 METs) 
110.5 ± 46.5 112.7 (78.4, 142.6) 1.5-246.1 
Moderate activity  
(3.0-6.0 METs) 
66.3 ± 66.4 45.9 (17.3,97.4) 0-399.4 
Vigorous (>6.0 METs) 1.7 ± 4.7 0 (0,0.8) 0-39.3 
Total light activity & 
above 
178.5 ± 92.5 158.3 (118.0,227.4) 7.9-542.4 
Household/caregiving 
activity 
87.1 ± 74.2 61.5 (31.5, 122.8) 0-354.7 
Occupational activity 65.1 ± 59.4 66.2 (8.2-93.7) 0-363.3 
Sports/exercise 
activity 
9.2 ± 9.7 6.4 (1.6,13.8) 0-53.8 
Transportation 
activity 
12.6 ± 12.4 10.0 (5.3, 15.3) 0-85.3 
Inactive 15.7 ± 16.2 8.9 (5.9,17.9) 0-112 
* MET-h/week Metabolic Equivalents- hours per week; SD standard deviation; IQR Interquartile range; ; MIN Minimum; MAX 
maximum 
 
One hundred eighty-eight participants underwent an OGTT at 28 weeks gestation 
(27.1-28.6). Eighteen (9.7%) of participants were diagnosed with GDM according to 
the IADPSG (2011) diagnostic thresholds (Table 6.5). Median PG-AUC was 18.6 
(15.6-21.3). Out of the 18 participants diagnosed with GDM, three had two raised blood 
plasma glucose values whilst the remaining 15 were diagnosed on one raised value. 
There were five raised values in the fasted state, 12 one-hour post glucose ingestion 











standard deviation; IQR Interquartile range; ; MIN Minimum; MAX maximum; OGTT Oral glucose tolerance test; FPG Fasting 
plasma glucose; PG-AUC Plasma glucose area under the curve 
 
Figure 6.10 illustrates the distribution of the blood glucose values at each time-point 
of the OGTT.  
 
Figure 6.10 Box plots illustrating distribution of blood glucose parameters at the 












Timing of OGTT   
(weeks gestation) 
 27.7 ±4.7 28 (27.1,28.6) 
 
24.7-37.7 
FPG (mmol/L)  4.3 ± 0.5 4.3 (4.0,4.5) 3.5-9.2 
1h post 75g OGTT (mmol/L)  7.3 ± 1.9 7.4 (5.9,7.4) 3.0-13.3 
2h post 75g OGTT (mmol/L)  5.6 ± 1.3 5.6 (4.7,6.5) 2.2-9.2 




6.4.3 Associations between dependant variables and PG-AUC 
Data was not normally distributed as assessed via Shapiro-Wilk’s (see Appendix H for 
results of normality tests for each variable for whole cohort). A Spearman's rank-order 
correlation was run to assess the relationship between all test variable and OGTT results 
as fasted, one and two hours post 75g oral glucose challenge, as well as PG-AUC, birth 
weight and birth weight percentile. One hundred eighty-eight participants underwent 
an OGTT. Preliminary analysis showed the relationships to be monotonic, as assessed 
by visual inspection of a scatterplot. There were statistically significant (p<0.05), small 
(0.1<rho <.3) and moderate (.3< rho > .5) correlations ranging from .157- .353 across 
most test variables when correlated with all blood parameters. Very few significant, 
but weak (rho ~.1) correlations were found with birth weight and all test variables. No 
correlations were found for all test variables when correlated with birth weight centile. 





Table 6.6 Results from Spearman rho correlation analysis showing relationship 














n 188 188 188 188 176 176 
Weight .329** .185* .097 .174* .186** -.008 
BMI .325** .242** .118 .226** .098 -.008 
Ultrasound 
measures 
      
Abdominal 
(SAT) 
.297** .237** .211** .254** .052 .049 
Abdominal 
(VAT) 
.322** .231** .181* .244** .105 .002 
Abdominal 
(Total) 
.329** .258** .221** .275** .084 .030 
Skinfold 
Thickness (SFT) 
      
Bicep  .257** .204** .157* .208** .140* .022 
Tricep  .280** .229** .201** .247** .022 .044 
Subscapular  .287** .254** .235** .272** .095 .030 
Supra-iliac  .245** .277** .269** .295** .128 .134 
Supraspinale .262** .295** .297** .322** .175* .084 
Abdominal  .236** .321** .311** .353** .118 .054 
Thigh .299** .217** .132 .214** .068 .044 
Calf .256** .150 .130 .158* .103 .072 
Total SFT .301** .289** .278** .314** .116 .066 
Appendicular 
SFT 
.307** .217** .168* .224** .127 .057 
Truncal SFT .281** .308** .319** .342** .120 .081 
% body fat  .305** .258** .234** .277** .135 .043 
Girths       
MUAC .279** .239** .179* .244** .126 .025 
MAMC .248* .176* .166 .174* .154 .013 
Waist .328** .232** .131 .219** .128 -.005 
Hip .327** .211** .130 .203** .171 .028 
Activity       
Total Activity .041 0.029 .005 .024 -.019 .076 
Sedentary  .027 .074 .060 .073 -.029 .106 
Light -.038 .166* .132 .159* .018 .076 
Moderate .111 -.086 -.098 -.092 .000 .053 
Vigorous -.086 -.057 .045 -.021 -.118 -.116 
*= correlation is statistically significant at p<0.05, **= correlation is statistically 
significant at p<0.01  
[SD standard deviation; IQR Interquartile range; SFT Skinfold thickness; MUAC Mid upper arm circumference; MAMC Mid arm 
muscle circumference; MIN Minimum; MAX maximum; SAT Subcutaneous adipose tissue; VAT visceral adipose tissue; OGTT 




6.4.4 Group differences in GDM vs. non-GDM  
Non-parametric independent sample test was used to assess differences between groups 
for risk factors (categorical data). Binary classification of GDM and non-GDM was 
made according to IADPSG diagnostic thresholds. Cross tabulation was used to 
identify count and percentage of variables in each group. The results are presented in 
table 6.7 below. There were significantly more women with an insulin resistant 
condition (IRC) in the women who developed GDM (six (31.6%) vs. 17 (10.6%), p= 
.027). Other variables which met criteria for inclusion in regression model had a p value 
of <.200. These included women with a history of diabetes in a first degree family 
relative, and women who experienced one or more previous perinatal death. There was 




Table 6.7 Risk factors for GDM presented for sample. Count and relative 
probability from cross-tabulation is presented. Parametric independent sample 
test for median group difference was used to test differences between groups.  
 GDM Non-GDM p value 
Parity ≥3 9 (5%) 9 (5.6%) .613 
Family Hx diabetes  10 (52.6%) 48 (30%) .083≠ 
Previous GDM 0 (0%) 1 (0.6%) .200≠ 
Smoking 1 (5.3%) 17 (94.4%) .500 
Overall IRC 6 (31.6%) 17 (10.6%) .027* 
Previous macrosomia 
(≥4.5kg) 
0 (0 %) 3 (1.9%) .735 
Previous baby ≥4.0kg 2 (10.5%) 17 (10.7%) .711 
Glucosuria 0 (0%) 4 (2.4%) .834 
High risk ethnicity 0 (0%) 5 (3.1%) .964 
Age ≥40 0 (0%) 9 (5.4%) .609 
Previous perinatal death 11 (57.9%) 55 (34.4%) .079≠ 
*= statistically significant at p≤0.05, **= statistically significant at p≤0.01, ≠ = screening 
for multivariable model at p≤0.200 






Test variables split for occurrence of GDM were assessed for normality using Shapiro 
Wilk (see Appendix H). Non-parametric independent sample test was used to assess 
differences between groups for all test variables (continuous data). Medians and 95% 
confidence intervals (CI) are presented for both groups in table 6.8 below. All three 
ultrasound measurements of abdominal fat, waist and hip as well as most skinfold 
measures were significantly different (p<0.05) between women who developed GDM 
and those who did not. These are further illustrated in box-plots in Figures 6.10 (a-k).  
In addition, thigh and calf, percentage body fat, MUAC and MAMC met the p<.200 
cut-off used to identify variables to construct a predictive regression model used in 
subsequent analysis. Total physical activity and its constituent parts were not found to 






Table 6.8 Medians (95%CI) for each dependant variable, with non-parametric 
independent sample test of group differences between screen-positive (GDM) and 
screen-negative (non-GDM) OGTT. 
  GDM (n=20) Non-GDM (n=167) p value 
BMI  (kg/m2)  29.85 (7.8) 24.7(6.1) .022* 
Weight (kg)  79.0(72.9-88.6) 67.9 (67.2-72.34) .081≠ 
Height (m)  165.3 (162.2-169.0) 164.4 (163.4-165.6) .803 
     
Ultrasound measures (cm)     
Abdominal (SAT)  1.99(1.64-2.31) 1.32 (1.31-1.53) .027* 
Abdominal (VAT)  1.41(1.11-1.65) 0.78(.80-.96) .002** 
Abdominal (Total)  3.46(2.82-3.88) 2.23(2.12-2.47) .031* 
     
Skinfold Thickness (mm)     
Bicep   23.3(15.8-24.1) 13.8(14.3-16.8) .213 
Tricep   27.3 (22.8-31.0) 21.2 (21.2-23.8) .455 
Subscapular   27.1(22.1-32.2) 16.8 (18.4-21.7) .025* 
Supra-iliac   37.5 (30.3-40.3) 25.4 (26.3-30.3) .025* 
Supraspinale  28.6 (22.0-31.0) 17.3 (18.0-21.5) .025* 
Abdominal   35.4 (29.2-38.1) 25.8 (25.0-28.6) .011* 
Thigh  40.3 (37.9-51.9) 34.1 (35.0-39.8) .068≠ 
Calf  25.9 (21.0-29.6) 19.0 (19.6-22.8) .076≠ 
Total SFT  226.4 (184.1-244.7) 158 (159.4-181.2) .010* 
Appendicular SFT  119.3 (99.3-134.9) 90.0 (90.6-102.7) .203 
Truncal SFT  130.4 (105.1-140.1) 84.8 (88.2-101.6) .010* 
% body fat   45.6 (39.2-49.0) 37.9 (38.6-41.6) .081≠ 
Girths (cm)     
MUAC  32.9 (30.1-36.4) 29.6 (29.3-30.8) .081≠ 
MAMC  24.0 (22.8-26.8) 22.7 (22.6-23.4) .194≠ 
Waist  90.3 (85.9-96.2) 79.8 (80.3-84.1) .006* 
Hip  108.6 (99.9-111.6) 94.3 (93.9-98.0) .023* 
     
Activity (MET-h.week-1)     
Total Activity  176.6 (152.8-265.0) 171.1 (171.2-200.9) .607 
Sedentary  7.3 (6.3-15.6) 7.4 (9.1-13.3) .432 
Light  129.8 (104.1-152.0) 108.0 (98.6-113.9) .570 
Moderate  50.9 (33.6-105.2) 47.2 (55.1-78.0) .607 
Vigorous  .0 (.0-.9) .0 (0-39.3) .929 
*= statistically significant at p≤0.05, **= statistically significant at p≤0.01, ≠ = screening 
for multivariable model at p≤0.2 
[SD standard deviation; IQR Interquartile range; SFT Skinfold thickness; MUAC Mid upper arm circumference; MAMC Mid 
arm muscle circumference; MIN Minimum; MAX maximum; SAT Subcutaneous adipose tissue; VAT visceral adipose tissue; 





Figures 6.11 (a-k): Box-plots showing significantly different (p≤0.05) median and 
spread of data of test variables for screen-positive (GDM) and screen-negative 
OGTT (non-GDM).  
 
a) Pre-peritoneal abdominal SAT  
    






c) Total pre-peritoneal abdominal adipose  
 






e) Supra-iliac SFT 
 






g) Abdominal SFT 
 


















Twenty-five (10.5%) of infants from the overall cohort (n=224) where born above the 
90th centile for adjusted-birthweight (percentile). Test variables were split for neonates 
born large for gestational age (LGA). Binary classification of LGA was made using a 
criterion of percentile birth weight over 90th. Data were assessed for normality using 
Shapiro Wilk (see Appendix H). Non-parametric independent sample test was used to 
assess differences between groups for all test variables (continuous data). Medians and 
95% confidence intervals (CI) are presented for both groups in table 6.9 below. No test 
variables were found to be statistically different (p<0.05) between the two groups. This 





Table 6.9 Medians (95%CI) for each dependant variable, with non-parametric 
independent sample test of group differences in LGA vs. non-LGA 
 LGA (n=25) Non-LGA 
(n=199) 
p value 
BMI 24.9 (23.3-28.6) 25.9 (25.3-27.1) .979 
Weight 65.7 (63.0-78.7) 69.5 (68.3-73.5) .768 
Height 164.3 (162.6-167.2) 165.1 (163.4-
165.7) 
.936 
    
Ultrasound 
measures 
   
Abdominal (SAT) 1.45 (1.27-1.82) 1.37 (1.35-1.58) .671 
Abdominal (VAT) .78 (.65-1.04) .84 (.85-1.03) 1.0 
Abdominal (Total) 2.37 (1.94-2.83) 2.32 (2.22-2.60) 1.0 
    
Skinfold Thickness    
Bicep  13.6 (12.7-18.8) 14.3 (14.7-17.4) .689 
Tricep  21.4 (20.2-26.2) 21.3 (21.6-24.3) .852 
Subscapular  16.8 (15.2-22.6) 18.3 (19.3-22.9) .669 
Supra-iliac  32.1 (25.7-36.9) 26.2 (26.6-30.6) .350 
Supraspinale 21.4 (16.9-25.8) 17.9 (18.5-22.1) .173 
Abdominal  27.4 (23.0-31.4) 26.2 (25.7-29.4) .363 
Thigh 35.8 (35.7-40.7) 34.2 (31.6-44.4) .893 
Calf 22.2 (17.1-26.2) 19.9 (20.0-23.3) .611 
Total SFT 163.8 (148.4-202.9) 160.7 (163.4-
186.1) 
.392 
Appendicular SFT 95.2 (83.3-114.0) 91.9 (92.5-105.1) .979 
Truncal SFT 93.8 (82.1-115.3) 86.8 (90.6-104.6) .979 
% body fat 38.1 (36.2-42.3) 38.0 (38.3-40.9) 1.00 
Girths    
MUAC 30.0 (28.4-32.3) 30.2 (29.6-31.2) .936 
MAMC 23.0 (21.8-24.4) 22.7 (22.7-23.7) .979 
Waist 80.2 (78.1-88.3) 80.3 (81.1-85.1) .957 
Hip 94.8 (91.9-104.1) 95.0 (94.7-98.8) 1.000 
    
Activity    
Total Activity 198.6 (169.9-260.4) 171.6 (168.7-
198.7) 
1.000 
Sedentary 4.7 (5.1-10.9) 7.4 (9.5-14.0) .573 
Light 121.1 (106.1-146.6) 107.6 (97.7-113.2) .365 
Moderate 59.2 (47.5-110.3) 46.9 (53.2-76.3) .393 
Vigorous .0 (-.1-4.0) .0 (.9-2.7) .964 
*= statistically significant at p≤0.05,  
**= statistically significant at p≤0.01  
[SD standard deviation; CI confidence interval; SFT Skinfold thickness; MUAC Mid upper arm circumference; MAMC Mid 
arm muscle circumference; MIN Minimum; MAX maximum; SAT Subcutaneous adipose tissue; VAT visceral adipose tissue; 




6.4.5 Predictive ability of test variables to classify between GDM & non-
GDM  
6.4.5.1 Multi-variate model to predict occurrence of GDM 
A binomial logistic regression was performed to ascertain the effects of body 
composition parameters on the likelihood that pregnant women develop GDM later in 
pregnancy. Linearity of the continuous variables with respect to the logit of the 
dependent variable was assessed via the Box-Tidwell (1962) procedure. Based on this 
assessment, all continuous independent variables were found to be linearly related to 
the logit of the dependent variable. There was no evidence of collinearity as confirmed 
by VIF values < 10 and tolerance >.1 (Hair et al. 2014). Multicollinearity statistics are 
presented for independent variables used in the regression model in Appendix I. The 
logistic regression model was statistically significant, χ2 (17) = 28.190, p=0.043. The 
model explained 34.0% (Nagelkerke R2) of the variance in GDM and correctly 
classified 89.9% of cases. Sensitivity was 18.8%, specificity was 97.9%, positive 
predictive value was 50% and negative predictive value was 91.4%. Of the 15 predictor 
variables, only abdominal visceral adipose was significant, shown in Table 6.10. 
Women with higher abdominal pre-peritoneal visceral fat thickness (VAT) were 13 
times at  higher odds to develop GDM, and 3.5 times higher odds if they had higher 






Table 6.10 Logistic regression predicting likelihood of GDM diagnosis based on, 
without co-variates (model 1) followed by inclusion of potential confounders (co-
variates) (model 2).  
 B SE Wald df p Odds 
Ratio 
95% CI for 
Odds Ratio 
Lower       
Upper 
     
Model 1: Without co-variates   
Abdominal SAT .929 .857 1.175 1 .278 2.531 .472 13.573 
Abdominal VAT 1.964 .784 6.272 1 .012 7.131 1.533 33.180 
Bicep SFT -.011 .085 .016 1 .899 .989 .838 1.168 
Tricep SFT .007 .091 .005 1 .941 1.007 .842 1.204 
Subscapular SFT .035 .051 .469 1 .494 1.035 .937 1.144 
Supra-iliac SFT -.012 .057 .040 1 .841 .989 .884 1.106 
Supra-spinale SFT -.074 .073 1.026 1 .311 .929 .805 1.072 
Abdominal SFT .023 .052 .197 1 .657 1.023 .924 1.133 
Thigh SFT  -.040 .044 .830 1 .362 .961 .882 1.047 
Calf SFT -.028 .058 .231 1 .630 .972 .867 1.090 
MUAC .036 .175 .042 1 .837 1.037 .735 1.462 
Weight -.035 .069 .260 1 .610 .965 .843 1.105 
Constant -9.936 5.105 3.788 1 .052 .000 - - 
Model 2: With co-variates       
Family Hx diabetes -1.382 .763 3.285 1 .070 .251 .056 1.119 
Overall IRC -.568 .917 .383 1 .536 .567 .094 3.420 
Previous perinatal 
death 
-1.074 .688 2.435 1 .119 .342 .089 1.316 
Abdominal SAT 1.239 .874 2.011 1 .156 3.453 .623 19.147 
Abdominal VAT 2.599 .948 7.511 1 .006 13.448 2.096 86.271 
Bicep SFT -.017 .092 .035 1 .852 .983 .821 1.177 
Tricep SFT .076 .105 .526 1 .468 1.079 .878 1.326 
Subscapular SFT .031 .057 .307 1 .579 1.032 .924 1.153 
Supra-iliac SFT -.015 .061 .059 1 .808 .985 .875 1.110 
Supra-spinale SFT -.056 .078 .522 1 .470 .946 .812 1.101 
Abdominal SFT .025 .056 .198 1 .656 1.025 .918 1.145 
Thigh SFT -.040 .047 716 1 .398 .961 .876 1.054 
Calf SFT -.064 .064 1.004 1 .316 .938 .827 1.063 
MUAC -.060 .191 .100 1 .752 .942 .648 1.368 
Weight -.035 .078 .207 1 .649 .965 .829 1.124 
Constant -7.106 5.785 1.509 1 .219 .001 - - 
[SE standard error; ; CI confidence interval; SFT Skinfold thickness; MUAC Mid upper arm circumference; MAMC Mid arm 
muscle circumference; MIN Minimum; MAX maximum; SAT Subcutaneous adipose tissue; VAT visceral adipose tissue; OGTT 






6.4.5.2 Sensitivity and specificity terms for predictive regression model 
The area under the ROC curve was .860 (95% CI, .774 to .945), which is an excellent 
level of discrimination according to (Hosmer et al. 2013). 
 
Figure 6.12 ROC curve for GDM using developed predictive regression model 






6.4.5.3 Sensitivity and specificity terms for individual predictive variables  
Concordance statistic and receiver operator analysis (ROC) curves was generated for 
each test variable. The results are shown in Table 6.11 below, in descending order 
starting with highest concordance value. Pre-peritoneal VAT had the highest 
concordance. The top ten variables in the table had acceptable discrimination (AUC > 
0.7), whereas the rest of the variables had poor discrimination (AUC < 0.7) according 
to Hosmer (2013).  
 
Table 6.11 Concordance statistic (AUC) for all variables computed with receiver-
operator curves (ROC) analyses for GDM, in order of descending AUC value 
(n=16) 
Predictive variable AUC 95%CI p-value 
VAT 0.743 .628-.858 <0.0005** 
Σ SAT & VAT 0.739 .618-.860 <0.0005** 
Truncal SFT 0.730 .613-.846 0.002** 
Subscapular SFT 0.728 .607-.848 0.002** 
Supraspinale SFT 0.726 .612-.839 0.002** 
Abdominal SFT 0.722 .605-.839 0.003** 
SAT 0.713 .58-.839 0.002** 
Σ 8-points SFT 0.710 .589-.839 0.005** 
Waist 0.705 .570-.841 0.004** 
Hip 0.701 .564-.838 0.005** 
Supra-iliac SFT 0.699 .585-.814 0.007** 
Thigh SFT 0.681 .564-.799 0.014* 
Weight 0.676 .537-.815 0.015* 
Appendicular SFT 0.673 .552-.794 0.019* 
BMI 0.670 .535-.806 0.018* 
Bicep SFT 0.667 .523-.811 0.024* 
Tricep SFT 0.646 .514-.778 0.049* 
MUAC 0.639 .496-.781 0.055 
Calf SFT 0.637 .501-.773 0.064 
*= statistically significant at p≤0.05, 
**= statistically significant at p≤0.01 
[AUC area under the curve; CI confidence interval; VAT visceral adipose tissue; SAT subcutaneous  






ROC curves were generated with paired variables in order to illustrate the relative 
differences in discrimination. Figure 6.13 illustrates the excellent discrimination for 
the abdominal measures via ultrasound. Figure 6.14 illustrates the various 
discrimination of the 8-point skinfold measures. These are the depicted as appendicular 
and truncal and the sum of 8-point skinfold measures in figure 6.14, where it can be 




Figure 6.13 ROC curve for ultrasound variables SAT, VAT and total abdominal 







Figure 6.14 ROC curve for 8-point skinfold thickness (SFT) and the sum of these 












Figure 6.15 ROC curve for appendicular skinfold thickness (Σ bicep, tricep, 
thigh and calf SFT), truncal skinfold thickness (Σ subscapular, abdominal, 









Maternal body composition parameters in conjunction with known risk factors for 
GDM measured at the end of first trimester were highly predictive of subsequent 
development of GDM at 28 (27.1-28.6) weeks gestation. Women in the cohort who 
developed GDM later on in pregnancy had a higher BMI (24.7 kg/m2 (±6.1), 29.9 kg/m2 
(±7.8), p=.022), abdominal SAT (1.32cm (CI 1.31-1.53), 1.99cm (CI 1.64-2.31), 
p=.027), abdominal VAT (.78cm (CI .8-.96), 1.41cm (CI 1.11-1.65), p=.002),  truncal 
SFT  (84.8mm (CI 88.2-101.6), 130.4mm (CI 105.1-140.1), p=.010), waist (79.8cm 
(CI 80.3-84.1), 90.3cm (CI 85.9-96.2), p=.006) and gluteal hip (94.3cm (93.9-98.0), 
108.6cm (99.9-111.6), p=.023). After screening variables for inclusion into the 
multivariate model, family history of diabetes, previous perinatal death, and overall 
insulin resistant condition, abdominal SAT and VAT, 8-point SFT, MUAC and weight 
were included. The combined multivariate prediction model had an excellent level of 
discrimination for early detection of GDM, with an AUC of 0.860 (CI 0.774–0.945). 
In isolation, the most predictive variables was abdominal visceral adiposity, followed 
by total abdominal adiposity and truncal SFT measurements. This study found that total 
SFT was more predictive than BMI, therefore this study adds to the current literature 
by giving further insight into the role of parameters of body composition in early 
gestation, in predicting GDM. In addition, body composition parameters did not predict 
LGA in the new-born; this is most likely due to those participants diagnosed with GDM 
received lifestyle treatment to manage blood glucose levels for the remaining duration 
of the index pregnancy. 
These findings were in line with the physiological underpinning of the hypothesis. As 
visceral adipose tissue in particular is not as sensitive to the antilipolytic effect of 
insulin and releases more free fatty acids, these free fatty acids are thought to cause 
increased hepatic insulin resistance by increasing gluconeogenesis in response to 
arrival of these free fatty acids via portal vein to the liver directly. It has been suggested 
that other molecules (adiponectins) produced in visceral compartment also have an 
effect on this process. It also has been shown that increased free fatty acids and 
cytokines produced by visceral fat lead to increased insulin resistance in muscle tissue 
(Bergman et al. 2006). 
Our study agrees with other studies, which have reported an association of high 




Gur et al. (2014) reported higher abdominal visceral adiposity in women and without 
GDM. However, the predictive ability of the compartments was similar to BMI (AUC= 
.64) for both VAT) (AUC = .66) and waist circumference (AUC = .64) for waist 
circumference. Other studies have also looked at measures of body composition in 
relation to GDM, and metabolic syndrome specifically in a pregnant population. A 
recent study published by Bourdages et al. (2018) measured abdominal adipose, but 
showed poor discrimination for abdominal subcutaneous adipose (AUC .66), 
abdominal visceral adipose (AUC .65) and total abdominal adipose (AUC .68) in 
determining subsequent GDM screening with a 50g-OGTT. Martin et al. (2009) also 
used a 50g-OGTT. They found no predictive ability of subcutaneous abdominal fat, 
however reported, however upper quartile values of abdominal visceral adipose were 
associated with a positive screen later in pregnancy (OR16.9, 95%CI 1.5-194.6).  
Another large study by De Souza et al. (2016b) found that the co-presence of hepatic 
fat and upper quartile of VAT ((aOR) 6.5, 95% CI: 2.3–18.5) or hepatic fat and Q4 of 
TAT (aOR 7.8 95% CI 2.8–21.7) predicted impaired glucose homeostasis.  
This study augments the current body of literature as it shows that using several 
parameters of body composition and known risk factors early in pregnancy can predict 
GDM diagnosis at 28 weeks gestation. Improving identification of women early in 
pregnancy could have implications on the medical management of these women in 
order to most effectively reduce the development of GDM. It has already been shown 
that lifestyle interventions in women at risk of GDM are effective at preventing GDM 
later in pregnancy, as shown by a large Cochrane study which synthesized the evidence 
from all studies using combined nutrition and exercise intervention and reported an 
average risk ration of 0.85 (Shepherd et al. 2017). Early diagnosis or improved risk-
stratification could help identify women who would most benefit from these 
interventions, and interrupt what is an intergenerational cycle of insulin resistance 
(Battista et al. 2011, Poston 2011, Gillman 2016)  
Skinfold measurements have given a new insight into the role of body composition to 
detect GDM. Multivariate models including multiple blood-borne biomarkers in first 
trimester achieved excellent discrimination in other studies (Nanda et al. 2011, 
Corcoran et al. 2018, Correa et al. 2019). Future studies should look to combine known 
risk factors for GDM, measures of body composition and blood biomarkers. 




plasminogen activator (t-PA) and homeostatic model assessment (HOMA) which 
showed a combined strong discrimination (AUC .870), as well as adiponectin (OR 3.3) 
and 1,5 anhydroglucitol (OR 1.2) (Corcoran et al. 2018, Correa et al. 2019). A study 
by Nanda et al. (2011) showed promising results for blood biomarkers sex hormone 
binding globulin (SHBG) and adiponectin. Adding these two biomarkers to a 
multivariate model built with maternal characteristics, there was a 12% increase in 
detection of GDM (Nanda et al. 2011).  
Future studies should capture a measure of insulin resistance to understand the degree 
of glucose intolerance within the index pregnancy. Bergman et al. (2006) postulated 
that insulin resistance is a related characteristic that may be an essential link between 
central fat and disease risk. In addition, he also stated that it is possible that the 
hyperinsulinemia that accompanies insulin resistance in non-diabetic but at-risk 
individuals may magnify, or even mediate, some of the detrimental effects of visceral 
adiposity (Rizza et al. 1985, Fisher and Kahn 2003) 
Potential limitations of this study includes the OGTT variability due to pre-analytical 
handling of glucose sampling and lack of standardized patient preparation prior to 
OGTT. As patients were not being supervised for the fasting procedure, there may have 
been diversions from the standardized technique required to achieve high reliability. 
This has been criticised in the literature to account for up to 62% of variability (Bruns 
and Knowler 2009, Daly et al. 2016, Chai et al. 2017).  
A further potential limitation is the risk-stratified selective screening for GDM, which 
is part of routine practice at the site of recruitment. A previous study in Ireland has 
shown the true prevalence to be 12.4% with the use of universal screening (O'Sullivan 
et al. 2012). The discrepancy between true prevalence and detection means that some 
women have undiagnosed GDM, which results in lack of management and negative 
perinatal outcomes. This is of particular relevance to this study, as it is possible that 
women who are below a BMI of 30 kg/m2 and are primigravid, therefore they have no 
previous GDM or other risk factors which may indicate OGTT. In chapter 4, we 
reported that out of a GDM cohort of 303 participants, 19.5% were primigravid 
therefore limiting the ability of them to be picked up 
A further potential limitation is the technique employed to measure adiposity in this 




composition as discussed and described in detail in chapter 1. Specifically in terms of 
this study, the lack of ability to quantify muscle tissue mass accurately in this study. It 
is known that higher muscle mass (relative to body size) has been found to be associated 
with better insulin sensitivity and lower risk of pre-diabetes (Srikanthan and 
Karlamangla 2011). This is thought to be due to its role as a primary tissue contributing 
to whole-body insulin-mediated glucose disposal (Wolfe 2006, Srikanthan and 
Karlamangla 2011). On the other hand, sarcopenic obesity may go undiagnosed in a 
pregnant population. This may further increase the risk of women to develop GDM 
independently of biomarkers and parameters of body composition known to predict its 
occurrence. It is possible that women with high muscle mass have a protective effect 
to developing GDM. Studies should investigate this aspect in future. 
The strengths of this study are the rigorous methodological techniques employed to 
measure anthropometric measurements and ultrasound measures reliably (see chapter 
5). Another strength was the sample size. The study was powered prior to commencing 
collecting data, and the required n was achieved. In addition, blinding between the 
measurers for US measurements, skinfold measurements and the main outcome 
measure (OGTT) took place. Additionally, the laboratory analytical CVs for the OGTT 
measurements were minimal, ranging from 1.151-2.07%.  
A further strength of this study was capturing physical activity levels as a potential 
confounder, as it is known that physical activity plays a role in uptake of glucose by 
the working muscles and increased insulin sensitivity of insulin sensitive muscle and 
liver tissue (Hawley and Lessard 2008, Golbidi and Laher 2013). These mechanisms 
have been discussed in detailed in chapter 3. The tool used to capture physical activity 
is a validated tool within pregnancy against ActigGraph method of capturing physical 
activity (Chasan-Taber et al. 2004). It has been shown to be reliable (total activity, ICC 
=.78; sedentary, ICC=.79, light ICC=.78, moderate ICC=.82, vigorous ICC=.81). See 
Appendix E for further data on validity and reliability data. Despite the validity and 
reliability of this questionnaire, it has not been validated within an Irish pregnant 
population and this may be a potential confounder. Our results show that measure of 
physical activity captured via PPAQ did not correlate with continuous measures of 
blood glucose parameters, and neither were group differences detected therefore they 




A limitation of this study is that there were a limited number of events per predictor 
variable (EPV).  When the number of predictors is much larger than the number of 
outcome events, there is a risk of overestimating/overfitting the predictive performance 
of the model. Overfitting is considered a serious concern in statistics/model building 
and should be avoided at all costs (Menard 2010, Osborne 2015). To avoid this, we 
explored the relationship of the variables using various steps, initially with correlation 
tests, followed by testing group differences generating p values for each variable. These 
variables were screened at a cut-off of p <.200 and a minimum of four cases (Song and 
Lu 2015, Lever et al. 2016, Zhang 2016). This strategy avoids overfitting the statistical 
model, thus avoiding developing a model based too closely on the sample data, 
resulting in a model fitting the population well. Further work to externally validate the 
prediction model for patients, other than those in the derivative cohort, is essential to 
support generalizability of the prediction model. External validation can be achieved 
by evaluating the model performance in data other than that used for the model 
development. Therefore, it is performed after developing a prediction model. This 
strategy would test how applicable this predictive model is to a new cohort, weather 
this be based on time (temporal), or ethnicity (Han et al. 2016), in the case of a future 
study were to be undertaken within a validation cohort. In order to externally validate 
a predictor model to be reliable and accurate, it is suggested that a minimum of 100 
events and/or 100 non-events are required (Han et al. 2016).  
6.5.1 Clinical applicability 
In terms of clinical impact, effective predictors and early detection of GDM could lead 
to preventative interventions in high risk pregnancies. These predictive interventions 
could be tested once an effective screening algorithm is defined and validated include 
dietary intervention, oral hypoglycaemic agents (Syngelaki et al. 2016) and probiotic 
(Thangaratinam et al. 2012, Koivusalo et al. 2016). This would follow in the steps of 
recent such successes with pre-eclampsia as postulated by Poon et al. (2018), where 
early identification of pregnancies at high risk of pre-eclampsia was identified 
(Thangaratinam et al. 2011). 
The predictive model presented in this chapter, even though at par with other predictive 
models discussed in section 6.5, is not one that can be utilized easily in practice. It 
would not be practical to measure a full panel of eight skinfold measurements at the 




probably not be very acceptable a procedure for pregnant women attending clinic to 
undergo. However, this chapter offers insights into how body composition and its 
regional distribution has the potential to be utilized in practice as part of an algorithm 
early in pregnancy to detect GDM. On their own, some of the individual predictors 
performed better than BMI, with visceral adipose via ultrasound (VAT) performing the 
best (BMI AUC .743 (.628-.858) p<.0005 vs VAT AUC .670 (.545-.806) p=.018). 
Despite this improvement in accuracy, there is little gain from moving away from using 
BMI in practice to VAT. However, as the model combining anthropometric parameters 
and risk factors, did show improved accuracy, it would be worth exploring more 
clinically applicable methods that could be incorporated into a predictive model for 
GDM. For this to be effectively applicable in practice, the format of capturing body 
composition would need to change to a more one that is more practical. For this to be 
tested, validation of more accessible and clinically viable air-displacement 
plethysmography (ADP) or bio-impedance against magnetic resonance imaging (MRI) 
is suggested in chapter 7 (section 7.3) together with blood borne biomarkers which 
have shown potential in the literature. The economic impact of such gains would have 
to be studies too. It is known that in Ireland, the total aggregated healthcare cost of 
GDM was estimated at €12 433 320 (95% CI €9 298 228–16 778 193). The average 
cost per case detected was €1621 (95% CI €524–2603) and the average total cost per 
case detected and treated was €11 903 (95% CI €7645–16 121) (Gillespie et al. 2011). 
In addition, effective screening algorithms could reduce the costs of later screening. 
These concepts and future directions of research in this field are delved into more detail 
in chapter 7. 
 
6.6 Conclusion 
An early gestation risk prediction model, which incorporates known risk factors, and 
parameters of body composition accurately identify pregnant women in their first 
trimester who developed GDM later on in gestation. This methodology has potential to 
be used clinically to identify pregnancies at risk of GDM, and target specific treatment 





Chapter 7: Thesis Summary, conclusions and 





7.1 Thesis summary  
This thesis confirmed a paucity of literature on exercise interventions during pregnancy 
on women with GDM, specifically including standardised protocols for diagnosis of 
GDM and measures of glycaemic control. The studies included in the systematic 
literature review presented in chapter 3 indicated an improvement in blood glucose 
measures with the use of both aerobic and resistance modalities of exercise. The review 
confirmed that exercising three times per week for 40-60 min at 65-75% age predicted 
HRmax using cycling, walking or circuit training as a modality improved glycaemic 
control in patients diagnosed with GDM, and reduces incidence of GDM in pregnant 
women with obesity. Women at risk of GDM due to high BMI (>28 kg/m2) would 
benefit from similar intervention; however those at high risk of GDM due to previous 
exposure to GDM without obesity do not seem to improve glycaemic control with such 
interventions. Commencing exercise intervention earlier gave positive results to 
glycaemic control in all cases, bar in a population who had previous GDM. This is in 
line with exercise interventions in type II diabetic patients found in the literature. 
Positive outcomes were attributed to the benefits of metabolic control and adaptation 
over 15 weeks or more (Boulé et al. 2001), with even one week of aerobic training 
known to improve whole body insulin sensitivity in obese individuals with type II 
diabetes (Winnick et al. 2008). Though systematic reviews are a strong way of 
assessing the effectiveness of an intervention, the main limitation of this study was that 
the studies that were synthesized in the review presented in chapter 3 did not measure 
glycaemic control with the same markers and therefore, due to heterogeneity it was not 
possible to quantitatively synthesize outcomes for meta-analysis. Despite this 
limitation, a systematic review offers a method for transparently conducting rigorous 
and comprehensive literature reviews (Grant and Booth 2009). Importantly, Corker 
(2018) highlighted that systematic reviews are not just high-quality qualitative reviews, 
due to its inclusion of a thorough method for reviewing research literature that should 
produce reproducible and unbiased findings. Systematic reviews are likewise not solely 
quantitative reviews; they can include meta-analyses but are not required to do so 
(Haddaway and Bilotta 2016). Other biases do exist within systematic reviews; these 
include publication bias and poor quality of evidence in the literature. Corker (2018), 
as well as other studies discuss these pitfalls in detail. This systematic review was an 




diagnosis of GDM as length of intervention was crucial to improving outcomes of 
glycaemic control and reduction of requirement for insulin.  
Complication for both infant and mother in pregnancies complicated by GDM is well 
documented. This thesis further added to this literature. Postnatal hypoglycaemia and 
excess-foetal-growth are known important metabolic complications of neonates born 
to women with diabetes. In the retrospective study presented in chapter 4, we examined 
a cohort of women diagnosed with GDM (n=303), to determine the influence of obesity 
and glucose intolerance on the occurrence of neonatal-hypoglycaemia and birth-weight 
over the 90th percentile (LGA) when adjusted for gestational age, and maternal 
ethnicity. This thesis confirmed that neonates of mothers with a BMI of over 30 kg/m2 
were twice as likely to experience neonatal-hypoglycaemia within 72 hours of birth, 
independent of the degree of glucose intolerance experienced by the pregnant women 
at the time of GDM diagnosis. Maternal obesity and degree of glucose intolerance did 
not predict nor was associated with LGA in neonates; however, multiparous women 
were 2.8 times more likely to have a baby born LGA. The study also confirmed a high 
prevalence of maternal obesity and occurrence of neonatal hypoglycaemia among a 
cohort of singleton pregnancies diagnosed with GDM. 
An important limitation of the retrospective study presented in chapter 4 is that testing 
for GDM does not occur universally, and is indicated for older women, with higher 
BMI, or with a pre-existing condition or history of GDM or family history of diabetes. 
This lack of universal testing of GDM with an OGTT is a limitation common to studies 
in this field of research (Schneider et al. 2011), and explains the high rate of obesity 
found in this cohort. This presents a source of selection bias, as the cohort is not 
representative of all women who develop GDM, therefore the research questions posed 
in this chapter would be answered more accurately in a prospective cohort of women 
universally screened for GDM via OGTT at 28 weeks gestation. This would ensure a 
cohort representative of the population of all patients with GDM, a requirement for 
avoiding selection bias (Sedgwick 2012). However, an advantage for both retrospective 
and prospective study designs is that exposure to risk factors is recorded before the 
occurrence of the outcome. This is important because it allows the temporal sequence 
of risk factors and outcomes to be assessed (Sedgwick 2014).  
Due to the substantial length of follow-up between measurement of BMI and diagnosis 




as time elapsed between the measurement of obstetric risk factors and OGTT, the 
association between the risk factor(s) and the outcome or condition may have changed 
with time. As is typical of observational studies, only association and not causation can 
be inferred from the results of the above cohort study (Sedgwick 2014). In addition, a 
consequence of retrospective cohort studies using health records that have already been 
collected is that not all pertinent risk factors are likely to have been identified and 
subsequently recorded. A further disadvantage of retrospective cohort studies is that 
many different healthcare professionals will have been involved in patient care, so the 
measurement of risk factors and outcome(s) throughout the database would probably 
be less accurate and consistent than that achieved with a prospective cohort study 
design. In this study, the measurement of BMI by clinicians may present an issue of 
accuracy. 
In particular, it was not possible to measure and then control for, through statistical 
analysis, all factors that may have affected the outcome of neonatal hypoglycaemia or 
LGA, despite recording confounders—despite recording exposure to a wide range of 
risk factors. In contrast, experimental studies such as clinical trials use random 
allocation of participants to treatment groups, to control for confounding at baseline, 
thus overcoming the limitations and biases of retrospective studies. These methods are 
therefore recommended as a more robust study design for such research questions 
(Sedgwick 2013). 
 
Prior to this thesis, a standardized technique for abdominal adiposity, specifically 
visceral fat thickness at the xiphoid region (pre-peritoneal fat) had not been determined 
in a pregnant population. To be clinically applicable within a pregnant population, 
reliability and reproducibility of abdominal fat quantification needed to be assessed 
within this specific population. Therefore, the technical study undertaken and presented 
in chapter 5 sought to standardise and outline a technically rigorous novel methodology 
used to quantify abdominal adipose tissue  in pregnant women, and to segment this into 
its constituents, visceral (VAT) measured as the pre-peritoneal fat thickness, and 
subcutaneous adipose tissue (SAT) as the minimum abdominal subcutaneous fat 
thickness. Subsequently, both inter- and intra-observer variability were assessed in 
order to test the reliability of these measures in a pregnant population. The results of 




reliable method to assess the amount of subcutaneous and visceral adipose tissue 
(n=30). Within the same operator, intra-observer precision is acceptable for measures 
of SAT, VAT and total adipose, with higher precision in SAT values than VAT (CV: 
SAT, 3.1%; VAT, 7.2; Total adipose, 3.0%). Between different operators, inter-
observer reliability assessed by LoA confirm anthropometrically reliable to 0.5cm. 
Systematic bias was minimal for both SAT and VAT measures (0.01cm and 0.10cm 
respectively) falling within 95% confidence intervals. 
This ultrasound technique was employed in the next stage of the thesis where we 
investigated parameters of body composition for the prediction of GDM. Despite BMI 
being criticised due to its inability to provide information on components of body 
composition, it is used as a risk-stratification tool in pregnancy to identify women at 
risk of developing GDM (Farah et al. 2011, Farah et al. 2012, Most et al. 2018). 
Previous studies indicate a link between maternal obesity and visceral fat thickness to 
developing GDM, insulin resistance and metabolic syndrome (Gur et al. 2014, De 
Souza et al. 2016a, Tumurbaatar et al. 2017). Therefore, we hypothesised that 
subcutaneous (SAT) and visceral adipose (VAT), as well as its distribution around the 
body may play a role in the level of risk constituted. This thesis confirmed that 
quantifying these parameters provide a more accurate risk factor than the currently used 
BMI, and therefore are useful in the identification of GDM early in pregnancy. A recent 
study by Bourdages et al. (2018) which examined the predictive effect of subcutaneous 
and visceral adiposity on development of GDM, and found that it was more suited for 
predicting GDM which advanced to requiring pharmacological management with 
insulin treatment. This study looked at measures of abdominal obesity forgoing 
adiposity distribution around the whole body. Maternal body composition parameters 
in conjunction with known risk factors for GDM measured at the end of first trimester 
were very predictive of subsequent development of GDM at 28 weeks gestation 
(n=188). Measures of BMI (24.7 kg/m2 (±6.1), 29.9 kg/m2 (±7.8), p=.022), abdominal 
SAT (1.32cm (CI 1.31-1.53), 1.99cm (CI 1.64-2.31), p=.027), abdominal VAT (.78cm 
(CI .8-.96), 1.41cm (CI 1.11-1.65), p=.002),  truncal SFT  (84.8mm (CI 88.2-101.6), 
130.4mm (CI 105.1-140.1), p=.010), waist (79.8cm (CI 80.3-84.1), 90.3cm (CI 85.9-
96.2), p=.006) and gluteal hip (94.3cm (93.9-98.0), 108.6cm (99.9-111.6), p=.023) 
were all higher in GDM vs. non-GDM groups.  When used alone, the most predictive 
variables were visceral adiposity, total abdominal adiposity and truncal subcutaneous 




predictive. The model included family history of diabetes, previous perinatal death, 
overall insulin resistant condition, abdominal SAT and VAT, 8-point SFT, MUAC and 
weight. The combined multivariate prediction model achieved an excellent level of 
discrimination, with an AUC of 0.860 (CI 0.774–0.945) for early GDM.  
A limitation of this study is that there were a limited number of events per predictor 
variable (EPV).  When the number of predictors is much larger than the number of 
outcome events, there is a risk of overestimating/overfitting the predictive performance 
of the model. Overfitting is considered a serious concern in statistics/model building 
and should be avoided at all costs (Menard 2010, Osborne 2015). To avoid this we 
explored the relationship of the variables using various steps, initially with correlation 
tests, followed by testing group differences generating p values for each variables. 
These variables were screened at a cut-off of p <.200 and a minimum of four cases 
(Song and Lu 2015, Lever et al. 2016, Zhang 2016). This strategy avoids overfitting 
the statistical model, thus avoiding developing a model based too closely on the sample 
data, resulting in a model fitting the population well. Further work to externally validate 
the prediction model for patients, other than those in the derivative cohort, is essential 
to support generalizability of the prediction model. External validation can be achieved 
by evaluating the model performance in data other than that used for the model 
development. Therefore, it is performed after developing a prediction model. This 
strategy would test how applicable this predictive model is to a new cohort, weather 
this be based on time (temporal), or ethnicity (Han et al. 2016), in the case of a future 
study were to be undertaken within a validation cohort. In order to externally validate 
a predictor model to be reliable and accurate, it is suggested that a minimum of 100 
events and/or 100 non-events are required (Han et al. 2016).  
In terms of clinical impact, effective predictors and early detection of GDM could lead 
to preventative interventions in high-risk pregnancies. These predictive interventions 
could be tested once an effective screening algorithm is defined and validated include 
dietary intervention, oral hypoglycaemic agents (Syngelaki et al. 2016) and probiotic 
(Thangaratinam et al. 2012, Koivusalo et al. 2016). This would follow in the steps of 
recent such successes with pre-eclampsia as postulated by Poon et al. (2018), where 
early identification of pregnancies at high risk of pre-eclampsia was identified 




The economic impact of such gains would have to be studied too. It is known that in 
Ireland, the total aggregated healthcare cost of GDM was estimated at €12 433 320 
(95% CI €9 298 228–16 778 193). The average cost per case detected was €1621 (95% 
CI €524–2603) and the average total cost per case detected and treated was €11 903 
(95% CI €7645–16 121) (Gillespie et al. 2011). Danyliv et al. (2016) found universal 
screening within a primary healthcare setting in Ireland would be more cost-effective 
than the current model of screening based on risk-stratification. They reported quality-
adjusted life years (QALY’s) gains of 0.0006 and a saving of €21.43 per screened case. 
These findings were contrary to findings from other countries (Fitria et al. 2019). In 
addition to the economic and QALY gains specifically in an Irish context (Danyliv et 
al. 2016), from a research point of view, a shift to universal screening would expand 
opportunities for research into algorithms to predict GDM, as well as effectiveness of 
interventions. Effective screening algorithms could reduce the costs of later screening, 
and may reduce the incidence of established type II diabetes in subsequent pregnancies. 
Studies that took place in an American (Ohno et al. 2011)  and an Australian (Moss et 
al. 2007) context, found that treating mild GDM was cost-effective in terms of 
improving maternal and neonatal outcomes including decreased rates of preeclampsia, 
caesarean sections, macrosomia, shoulder dystocia, permanent and transient brachial 
plexus injury, neonatal hypoglycaemia, neonatal hyperbilirubinemia, and neonatal 
intensive care unit admissions. These models did not consider further complications, 
which could amass indirect costs such as time off from work, or economic losses from 
a child with a permanent brachial plexus injury. This type of economic impact study is 
yet to be determined within an Irish context, and can only be undertaken if universal 
screening is introduced. Either way, an early prediction algorithm of GDM would have 
to be cost-effective in order for it to be clinically applicable within a healthcare system. 
Finally, the end of the first trimester (12 weeks gestation) is a clinically 
significant clinical time-point, at which women attend routine antenatal appointments 
to the maternity hospital to undertake an ultrasound scan to determine gestation, foetal 
number and to out-rule major foetal abnormalities. Following the scan the patient is 
booked in the Antenatal Clinic; medical and pregnancy history and any comorbidities 
are recorded and antenatal bloods are drawn. This 'booking visit' therefore presents a 
special opportunity of contact with healthcare staff, which should be utilized effectively 






 Exercising three times per week for 40-60 min at 65-75% age predicted 
HRmax using cycling, walking or circuit training as a modality is an effective 
lifestyle intervention for improving glycaemic control in patients diagnosed 
with GDM, and reduces incidence of GDM in pregnant women with obesity.  
 Both modalities and combination of modalities of exercise are effective at 
improving blood-glucose control in already diagnosed patients, and pregnant 
women with obesity. 
 Women at risk of GDM due to high BMI (>28 kg/m2) would benefit from 
similar intervention; however those at high risk of GDM due to previous 
exposure to GDM without obesity do not seem to improve glycaemic control 
with such interventions. 
 Maternal BMI during the first trimester of pregnancy exhibits a strong 
influence on neonatal hypoglycaemia but not neonatal birthweight in a cohort 
of pregnancies affected by GDM.  
 In a GDM cohort born in UMHL, women with high parity are three times 
likely to have an infant born LGA. 
 Ultrasound is a non-invasive, safe, quick and available tool for quantifying 
adiposity in both clinical practice as a research tool. 
 Measurement of abdominal adiposity via ultrasound produces reliable, 
repeatable and accurate measures of SAT and VAT during pregnancy. 
 Quantification of body composition provides a more accurate warning sign 
than BMI to indicate higher risk stratification of development of diabetes 
during pregnancy. 
 An early gestation risk prediction model, which incorporates known risk 
factors, and parameters of body composition accurately identify pregnant 





7.3 Recommendations for future work  
Further research on the effectiveness of exercise interventions needs to take place in a 
standardized manner, in order to compare results and answer what is the most effective 
exercise intervention in this population. This includes; timing and duration of 
intervention, as well as methods of measuring glucose control and indices of insulin 
sensitivity. It is recommended that dietary intake and physical activity be measured as 
confounding factors, in order to isolate and observe the effects of specific exercise 
interventions. Future studies should also focus on measurements of hyperglycaemia, as 
confirmed by the large HAPO study, that small degrees of hyperglycaemia have a 
significant effect on pregnancy and neonatal outcomes. The clinical significance of the 
outcome measures used should be considered. Interventions should aim to follow-up 
participants postpartum to understand longer-term benefits of antenatal exercise 
intervention. Acute studies looking at exercise strategies to maximise non-insulin 
stimulated uptake of glucose through are needed to counteract the increase in insulin 
resistance observed during pregnancy, and especially of GDM. Future studies in this 
field should strive for consistency in design and delivery of exercise-only interventions 
in order to make recommendation on suitable exercise prescription in this population. 
In practice, adherence to consensus in diagnostic cut-offs for GDM diagnosis is 
fundamental for standardising future research. 
As described in detail in chapter 2, methods of quantification of body composition are 
limited in pregnancy.  Indirect techniques of measuring body composition are based on 
assumptions of various tissue properties relative to each other (Heymsfield et al. 1990). 
In pregnancy, these tissue properties changes are very dynamic throughout pregnancy 
(Most, 2018). The main limitation of application of these techniques is the large 
proportion of water accumulation relative to the gestational weight gain, which leads 
to an increase in relative hydration of the FFM throughout pregnancy (Taggart et al. 
1967, van Raaij et al. 1988). This accumulation of fluid is highly variable throughout 
gestation and amongst individual women, ranging from 67-80% of FFM. Limitations 
of other methods include exposure to radiation, which has known teratogenic effects, 
such as in CT scan and DXA; cost and use of specialist equipment for MRI, and 
technique for TBW and TBK methodology; difficult procedure such as UWW; and 




definitive validation of skinfolds, ADP or bio impedance should be validated against 
MRI. 
The link between metabolic health and adiposity in pregnancy is currently a fertile 
ground of research (Tumurbaatar et al. 2017, Bi et al. 2018, Selovic and Belci 2018, 
Svensson et al. 2018). Excessive accumulation of adipose tissue into the viscera has 
been implicated in increased risk of cardio-metabolic risk (Ribeiro-Filho et al. 2001, 
Bartha et al. 2007, Vlachos et al. 2007) and diabetes mellitus (Bartha et al. 2007, 
Vlachos et al. 2007, Bray et al. 2008, Neeland et al. 2012). Further to this, some studies 
have investigated measures of abdominal adipose tissue in early pregnancy, and 
established its ability to predict glucose intolerance and gestational diabetes in later 
pregnancy (Martin et al. 2009, De Souza et al. 2014, Gur et al. 2014, Yang et al. 2017, 
Bourdages et al. 2018, D'Ambrosi et al. 2018). These research investigations give 
insight into how measures in early pregnancy can play an important role in earlier 
diagnosis and/or intervention, at a time when there is established contact with 
healthcare professional (Poon et al. 2018). Further to this, early detection of risk or 
diagnosis of GDM, has been found to be critical in improving outcomes of various 
types of interventions. Dietary (Thangaratinam et al. 2012); exercise (Cremona et al. 
2018); pharmacological (Syngelaki et al. 2016) intervention, as well a combination of 
these (Koivusalo et al. 2016), showed improved outcomes when applied for a longer 
time-span. 
Future studies investigating the role of body composition in predicting GDM should 
endeavour to use measures of insulin sensitivity which capture metabolic clearance rate 
during OGTT with the use of plasma insulin measures, such as the Matsuda index or 
HOMA-IR which are validated in pregnancy against the euglycaemic-clamp (Antuna-
Puente et al. 2011, Zhang et al. 2013). Future studies should also note the actual 
continuous neonatal hypoglycaemia rather than binary values due to controversy 
around classification of neonatal hypoglycaemia (Stanescu and Stoicescu 2014).  
Universal screening of GDM is not in place in Ireland despite a study finding the true 
prevalence in Ireland to be 12.4% (O'Sullivan et al. 2012). This screening method has 
shown poor detection rate of 60% for GDM. The nature of the test in picking up 
excursions of blood glucose response to 75g glucose ingestion taking place so late in 
pregnancy significantly delays the diagnosis and treatment of GDM. This is a limitation 




has very good analytical coefficient of variations (<2%) however variability due to pre-
analytical handling of glucose sampling and lack of standardized patient preparation 
prior to OGTT has been criticised in the literature to account for up to 62% of 
variability (Bruns and Knowler 2009, Daly et al. 2016, Chai et al. 2017). Therefore, 
future studies should strive to achieve tightly standardised pre- analytical protocols 
where monitoring of adherence takes place. 
Accurate quantification of muscle tissue should be strived for in order to understand if 
it has protective metabolic effects. The ultrasound technique investigated in this thesis 
offers a technique, which when replicated, is a highly reliable and practical tool that 
does not require demanding operator training. Therefore, researchers and clinicians can 
implement it during routine antenatal ultrasonography. Measurement of intra-
abdominal adipose via ultrasound is suitable for use in prospective observational or 
interventional studies in pregnant women. 
Accurate early risk prediction for gestational diabetes mellitus (GDM) would target 
intervention and prevention in women at the highest risk. Despite many studies 
investigating early identification of GDM, the role of early measurement of adiposity 
in clinical practice is yet be defined. Multivariate models including multiple blood-
borne biomarkers in first trimester achieved excellent discrimination in recent studies 
(Nanda et al. 2011, Corcoran et al. 2018, Correa et al. 2019). There is currently a rise 
in research into blood biomarkers as predictors of GDM, such as cholesterol, low 
density lipoproteins, triglycerides, insulin, tissue plasminogen activator (t-PA) and 
homeostatic model assessment (HOMA) which showed a combined strong 
discrimination (AUC .870), as well as adiponectin (OR 3.3) and 1,5 anhydroglucitol 
(OR 1.2) (Corcoran et al. 2018, Correa et al. 2019). A study by Nanda et al. (2011) 
showed promising results for blood biomarkers sex hormone binding globulin (SHBG) 
and adiponectin. Future studies should look to combine known risk factors for GDM, 
measures of body composition and blood borne biomarkers to devise a clinical tool for 
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To:   
 




My name is Alexandra, I am a research student at the University of 
Limerick under the supervision of Prof. Amanda Cotter.  
We are writing to you about a research project  taking place at  University 
Maternity Hospital , Limerick (UMHL). This project is seeking to recruit  
pregnant women will ing to take part  in research where you will fil l  out 
a questionnaire and take a few measurements today.  
 
The project is entitled:  
Body composition as a tool for early detection of Gestational Diabetes Mellitus. 
 
As a thank you for your time, we offer you a developed photo of your 
ultrasound scan as a little keepsake. By taking part in this study, you 
will be helping me answer research questions in pregnant women.  
 
If  you would be interested in taking part  please read the available 
participant information sheet.  Should you wish to take part,  please sign 
the consent form prior to going in for your ultrasound and give th is to 
Dr Khadijah Ismail or Prof. Amanda Cotter.  
 



















This research study has received Ethics approval from the HSE Research Ethics 
Committee (REC Ref: 082/17). If you have any concerns about this study and wish to 
contact someone independent, you may contact:  
 
Name of Committee: HSE Mid-Western Regional Hospital Research Ethics 
Committee 
Contact Person: Ms. Joanne O’Connor. 
Position: Secretary 
Address:  Patient Safety & Quality Directorate, 3rd Floor Nurses Home, University 
Hospital Limerick, Dooradoyle, Limerick. 
Tel: 061 482519 












Appendix B: Study Information Sheet 
 
 
VOLUNTEER INFORMATION SHEET 
 
Body composition as a tool for early detection of Gestational 
Diabetes Mellitus  
 
What is the study about?  
At 28 weeks of your pregnancy, you will be undergoing a routine test to check if you 
have developed diabetes during your pregnancy. This type of diabetes is known as 
gestational diabetes mellitus and in most cases resolves after the pregnancy. Roughly, 
9% of all pregnant women who attend University Maternity Hospital Limerick develop 
this type of diabetes, identifying if you have it is of important in order for it to be 
managed appropriately. At the moment, there is no way to identify this disease earlier 
in pregnancy, however if it was possible to identify this disease earlier in pregnancy it 
would be of benefit for women and infants so that it can be managed from as early as 
possible. In this study, we are interested in understanding if your body composition can 
predict the development of this disorder. 
 
Why me? 
We are looking to recruit women in their first trimester at the date of their first 
ultrasound scan. This takes place approximately 12 weeks into your pregnancy. We are 







What is involved? 
This study will take about 20 minutes of your time in total. If you do decide to 
participate, you will be asked to sign a consent form. During your first ultrasound scan, 
an additional measure will be taken by the person doing the scan. After your scan you 
will be asked to proceed to a room nearby where I will give you a short questionnaire 
regarding your current physical activity level, this takes a few minutes. You will then 
enter a private room where you will be given privacy to undress to light clothing 
(underwear). There will be a screen in the room for your additional privacy. Once you 
are ready only the PhD student (Alexandra Cremona) will be present to take few 
measurements. These measurements include weight and height, and some 
measurements from a few places around your body (arm, shoulder, back and belly) 
which I will mark slightly with an eyeliner and measure with the use of a measuring 
tape and skinfold calliper. This is a little device used to measure how thick your skin 
is. These measures do not hurt to take, all is involved is a gentle pinch as I fold the skin. 
The measuring tape may feel cold to touch, but that is about it! This part takes about 
12 minutes of your time, you will then be able to put your clothes back on and nothing 
else will be asked of you. I will then be able to collect other necessary information from 
your medical notes at a later date including the results of the routine test at 28 weeks. 
Do I have to take Part? 
No. This information sheet has been written to help you decide if you would like to 
take part. It is up to you and you alone whether or not to take part. If you do decide to 
take part, you will be free to withdraw at any time without providing a reason.  
 
How do I participate or withdraw from this research? 
If you would like to take part in this research, you can sign the consent form attached 
and hand it to the person taking your ultrasound scan (this will be Khadijah or Prof. 
Cotter). Should you wish to withdraw from the study, you can do so at any point by 
emailing Alexandra Cremona at the address at the end of this leaflet.  
 
Are there any advantages from participation? 
An ultrasound photo will be developed for you for keepsake, this will left at reception 
for you to pick up on the day of you appointment at around week 28 of your pregnancy. 
In addition, by taking part you will be assisting the PhD researcher by actively being 




A report of the findings at the end of the study can be sent to you if you are interested. 
You can request this at alexandra.cremona@ul.ie. 
 
Are there any disadvantages from participation? 
No. 
 
Will participation or lack of participation affect the treatment I receive as a 
patient? 
Your care will not be affected in any way. 
 
Will my participation be Anonymous and Confidential?  
Only the researchers and supervisor will have access to the data, which will be kept 
strictly confidential. The data provided will be anonymised when used for any scholarly 
purposes. 
 
Storage and Destruction of Data Collected 
The data we collect will be accessible by the researcher and supervisor involved in this 
study only, unless explicit consent for wider access is given by means of the consent 
form. Audio recordings will be stored on a password-protected computer. Any 
additional notes taken will be stored in a locked storage cupboard and then transferred 
to anonymised computer files (on a password-protected computer). The data will not 
be identifiable to the participant when the study results are written or in any 
publications or presentations that result from this work. The data will be held securely 
for a period of 7 years and then securely destroyed. 
 
What will happen to the results of the research study? 




You will have the opportunity to ask any questions in relation to this project before 
completing a Consent Form prior to the commencement of the study.  
 




This research proposal has been reviewed and has been granted ethical approval 
through the HSE research ethics committee. 
 
What should I do if I have concerns about this study? 
Please contact us using the details overleaf. 
 
Contact Details  




University of Limerick 
Limerick. 
 
+353 (0)61 204779 
Alexandra.cremona@ul.ie 
 
Prof. Amanda Cotter 
Clinical Academic Liaison 








This research study has received Ethics approval from the HSE Research Ethics 
Committee (REC Ref: 082/17). If you have any concerns about this study and wish to 
contact someone independent, you may contact:  
 
Name of Committee: HSE Mid-Western Regional Hospital Research Ethics Committee 
Contact Person: Ms. Joanne O’Connor. 
Position: Secretary 
Address:  Patient Safety & Quality Directorate, 3rd Floor Nurses Home, University 
Hospital Limerick, Dooradoyle, Limerick. 
Tel: 061 482519 














PARTICIPANT CONSENT FORM 
 




The purpose of this form is to ensure that you are willing to take part in this study and 
to let you understand what it entails. Signing this form does not commit you to anything 
you do not wish to do. 
 
Material gathered during this research will be securely stored. Audio recordings will 
be stored on a password-protected computer. Any notes taken will be coded to ensure 
anonymity and stored in a locked cabinet. An electronic copy of these notes will also 
be anonymised and stored on a password protected computer. The study data will be 
held for a period of 7 years after which it will be destroyed. 
 















I understand that I can withdraw from the study without having to give 





I understand that my data once processed will be anonymous and that 
only the researcher(s) (and supervisors) will have access to the raw 





I understand that my data will be stored for a period of 7 years before 















This study requires the clinical researcher to access your medical notes for 
information relevant to the study, such as outcomes of the diagnostic test done in 
week 28 of your pregnancy, as well as some basic information, such as age, your 
pregnancy history, as well as you and your infant’s outcomes at birth. 
 
I agree that the research dietitian can access my medical notes for  
the above information.  
 
 
I DO NOT agree that the research dietitian can access my medical notes  
for the above information.  
 
 
Your signature confirms that you are happy to participate in the study. 
 













Researchers names and contacts should you require clarification on 
any issue relating to the research:  
 
Ms Alexandra Cremona 
Room 3-026 
GEMS 
University of Limerick 
Limerick. 
+353 (0)61 204779 
Alexandra.cremona@ul.ie 
 
Prof. Amanda Cotter 
Clinical Academic Liaison 
Building, Dooradoyle,  
Limerick 
+353 61 593239 
Amanda.cotter@ul.ie 
  
This research study has received Ethics approval from the HSE Research Ethics 
Committee (REC Ref: 082/17). If you have any concerns about this study and wish to 
contact someone independent, you may contact:  
 
Name of Committee: HSE Mid-Western Regional Hospital Research Ethics Committee 
Contact Person: Ms. Joanne O’Connor. 
Position: Secretary 
Address:  Patient Safety & Quality Directorate, 3rd Floor Nurses Home, University 
Hospital Limerick, Dooradoyle, Limerick. 
Tel: 061 482519 

















































Appendix E: Instructions on interpretation of PPAQ 
Pregnancy Physical Activity Questionnaire 
 
Component(s) assessed: 
 Total activity, Total activity of light intensity and above 
Sedentary activity, light-intensity, moderate-intensity, vigorous-intensity 
activity 
Household/caregiving, occupational, sports/exercise, transportation, inactivity  
Time frame of recall: 
 Current trimester of pregnancy 
Original mode of administration: 
 Self-administered. 
Primary source of information: 
 Dr. Lisa Chasan-Taber, Sc.D. 
Biostatistics & Epidemiology  
School of Public Health & Health Sciences  
405 Arnold House  
715 North Pleasant Street  
University of Massachusetts  
Amherst, MA 01003-9304 
 
Primary reference: 
Chasan-Taber L, Schmidt MD, Roberts DE, Hosmer D, Markenson G, Freedson PS. 
Development and Validation of a Pregnancy Physical Activity Questionnaire. Med Sci 
Sports Exer 2004 36(10):1750-1760. 
 
RELIABILITY AND VALIDITY STUDIES 
 
Table 1. Reliability studies of the Pregnancy Physical Activity Questionnaire. 
Reference Methods Sample Summary Results 
Chasan-Taber et 
al. (1) 
1 week test-retest. 
Consistency of 
estimates for total 
activity, activity 










































































   














Total activity  0.32  0.43  0.08 0.27 
  Sedentary   -0.17  -0.34  0.12 -0.10 
  Light   0.10  0.22  -0.08 0.03 
  Moderate  0.42  0.49  0.20 0.38 
  Vigorous  0.27  0.25  0.34 0.37 
  Household/Caregiving  -0.01  0.14  -0.12 -0.04 
  Occupational  0.31  0.42      -0.10 0.16 
  Sports/Exercise  0.35  0.30  0.44 0.48 
 
 
aActivity of moderate-intensity and greater. Count cut points were as follows: >574 (Swartz et al. (2)), >191 (Hendelman et al. 




Instructions are listed on the questionnaire which is self-administered. Individuals 
are asked to select the category that best approximates the amount of time spent in 33 
activities including household/caregiving, occupational, sports/exercise, 
transportation, and sedentary behavior during the current trimester.  At the end of the 
sports/exercise section of the PPAQ, an open-ended section allows the respondent to 
add activities not already listed.  
 
CACULATIONS 
The duration of time spent in each activity is multiplied by its intensity to arrive at 
a measure of average weekly energy expenditure (MET-h∙week-1) attributable to each 
activity.  
 
Scoring of the questionnaire is as follows: 
To calculate duration the lowest bound of each response option is used due to the 
tendency for over-reporting of physical activity:  
For questions #4, 5, 6, 7, 8, 9, 10, 11, 14, 15, 16, 20, 21, 22 the following 
duration scores correspond to the duration categories:  0, 0.12, 0.50, 1.0, 2.0, 
3.0. Multiply values by 7 days per week. 
For questions #12, 13, 32, 33, 34, 35, 36 the following duration scores 
correspond to the duration categories: 0, 0.12, 0.50, 2.0, 4.0, 6.0. Multiply 
values by 7 days per week. 
For questions #17, 18, 19, 23, 24, 25, 26, 27, 28, 29, 30, 31 the following 
duration scores correspond to the duration categories 0, 0.12, 0.50, 1.0, 2.0, 
3.0. These values are already in weekly form. 
 
To calculate intensity:  
Field-based measurements in pregnant women (5) are used to represent activity 
intensity for walking and light- to moderate-intensity household tasks, and 




remainder of the PPAQ activities. The specific MET values assigned to each 
question follow (question number:MET value): 4:2.5, 5:2.0, 6:3.0, 7:2.7, 8:4.0, 
9:3.0, 10:4.0, 11:1.8, 12:1.0, 13:1.1, 14:3.2, 15:2.3, 16:2.3, 17:2.8, 18:2.8, 19:4.4, 
20:2.5, 21:4.0, 22:1.5, 23:3.2, 24:4.6, 25:6.5, 26:7.0, 27:3.5, 28:6.0, 29:4.5, 30:see 
Compendium (6), 31:see Compendium (6), 32:1.6, 33:3.0, 34:2.2, 35:4.0, 36:3.3. 
For the open ended activities only (questions #30 and 31), activity was classified 
using the following cut-points as sedentary (<1.5 METS), light (1.5-<3.0 METS), 
moderate (>3.0 - <6.0 METs METS), or vigorous (>6.0 METS).   
 
Total activity = sum of (duration * intensity) for questions #4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 
34, 35, 36. Total activity is the sum of all activities.    
 
Total activity of light intensity and above= sum of (duration * intensity) for 
questions #4, 5, 6, 7, 8, 9, 10, 11, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26, 27, 28, 29, 32, 33, 34, 35, 36, and the open-ended activities in 30 and 31 if 
>1.5 METS.   
 
Each activity is classified by intensity: sedentary, light, moderate or vigorous.   
 
Sedentary activity (n=2+2 open ended) = sum of (duration * intensity) for 
questions 12, 13 and questions #30, 31 (if open-ended activities are <1.5 METs). 
 
Light-intensity activity (n=12+2 open ended) = sum of (duration * intensity) for 
questions #4, 5, 7, 11, 15, 16, 17, 18, 20, 22, 32, 34, and questions #30, 31 (if 
open-ended activities are 1.5- <3.0 METs.) 
 
Moderate-intensity activity (n=15+2 open ended) = sum of (duration * intensity) 
for questions #6, 8, 9, 10, 14, 19, 21, 23, 24, 27, 28, 29, 33, 35, 36, and questions 
#30, 31 (if open-ended activities are >3.0 - <6.0 METs). 
 
Vigorous-intensity activity (n=2+2 open ended) = sum of (duration * intensity) 
for questions #25, 26, and questions #30, 31 (if open-ended activities are >6.0 
METs). 
 
Each activity is classified by type: household/caregiving, occupational, 
sports/exercise, transportation, inactivity.   
 
Household/caregiving activity (n=13) = sum of (duration * intensity) for 
questions #4, 5, 6, 7, 8, 9, 10, 14, 15, 16, 17, 18, 19. 
 
Occupational activity (n=5) = sum of (duration * intensity) for questions #32, 33, 
34, 35, 36. 
 
Sports/exercise activity (n=7+2 open-ended) = sum of (duration * intensity) for 
questions #23, 24, 25, 26, 27, 28, 29, 30, 31. 
 
Transportation activity (n=3) = sum of (duration * intensity) for questions #20, 
21, 22. 
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Appendix H: Tests for distribution of data 
a) All variables 
 
Tests of Normality 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statisti
c 
df Sig. Statistic df Sig. 
Age_booking .053 153 .200* .984 153 .077 
Gravida .220 153 .000 .804 153 .000 
Parity .240 153 .000 .820 153 .000 
OGTT_days .275 153 .000 .448 153 .000 
OGTT_weeks .278 153 .000 .447 153 .000 
OGTT_0 .163 153 .000 .651 153 .000 
OGTT_1 .049 153 .200* .990 153 .366 
OGTT_2 .054 153 .200* .992 153 .546 
PGAUC .054 153 .200* .986 153 .128 
Birth_weight .067 153 .091 .969 153 .002 
percentile_birthw
eight 
.074 153 .040 .954 153 .000 
APGAR@1 .485 153 .000 .295 153 .000 
APGAR@5 .507 153 .000 .380 153 .000 
GA_days .142 153 .000 .870 153 .000 
Ultra_SUB .082 153 .013 .965 153 .001 
Ultra_VISC .103 153 .000 .946 153 .000 
Ultra_total .080 153 .018 .962 153 .000 
Height .060 153 .200* .994 153 .820 
Weight .127 153 .000 .940 153 .000 
BMI .106 153 .000 .944 153 .000 
BICEP .130 153 .000 .932 153 .000 
TRICEP .090 153 .004 .959 153 .000 
SUBSCAP .142 153 .000 .903 153 .000 
ILIAC .098 153 .001 .969 153 .002 
SUPRA .096 153 .002 .922 153 .000 
ABDO .068 153 .078 .943 153 .000 
THIGH .095 153 .002 .959 153 .000 
CALF .086 153 .008 .936 153 .000 
TOTAL .096 153 .001 .955 153 .000 
APPENDICULAR .111 153 .000 .952 153 .000 
TRUNK .111 153 .000 .951 153 .000 
MUAC .106 153 .000 .950 153 .000 
MAMC .091 153 .004 .935 153 .000 
WST .104 153 .000 .940 153 .000 
HIP .093 153 .002 .953 153 .000 
TOTAL_ACTIVITY .099 153 .001 .932 153 .000 
SEDENTARY .334 153 .000 .678 153 .000 




MODERATE .161 153 .000 .825 153 .000 
VIGOROUS .384 153 .000 .411 153 .000 
Total_lightplus .081 153 .015 .943 153 .000 
household .154 153 .000 .862 153 .000 
occupational .139 153 .000 .897 153 .000 
sports .163 153 .000 .842 153 .000 
transport .201 153 .000 .817 153 .000 
inactive .236 153 .000 .697 153 .000 
% body fat .087 212 .001 .944 212 .000 
*. This is a lower bound of the true significance. 






b) All continuous data split into GDM and non-GDM 










no .046 137 .200* .986 137 .189 
yes .140 16 .200* .950 16 .495 
Gravida no .218 137 .000 .791 137 .000 
yes .237 16 .016 .867 16 .024 
Parity no .240 137 .000 .821 137 .000 
yes .236 16 .018 .809 16 .004 
OGTT_da
ys 
no .188 137 .000 .873 137 .000 
yes .467 16 .000 .401 16 .000 
OGTT_w
eeks 
no .194 137 .000 .873 137 .000 
yes .467 16 .000 .401 16 .000 
OGTT_0 no .117 137 .000 .979 137 .035 
yes .316 16 .000 .623 16 .000 
OGTT_1 no .073 137 .074 .975 137 .014 
yes .297 16 .001 .765 16 .001 
OGTT_2 no .053 137 .200* .991 137 .536 
yes .144 16 .200* .940 16 .345 
PGAUC no .062 137 .200* .985 137 .131 
yes .253 16 .007 .843 16 .011 
Birth_we
ight 
no .068 137 .200* .963 137 .001 




no .079 137 .034 .954 137 .000 
yes .151 16 .200* .933 16 .268 
APGAR@
1 
no .485 137 .000 .290 137 .000 
yes .510 16 .000 .405 16 .000 
APGAR@
5 
no .504 137 .000 .393 137 .000 
yes .536 16 .000 .273 16 .000 
GA_days no .164 137 .000 .855 137 .000 
yes .123 16 .200* .968 16 .803 
Ultra_SU
B 
no .081 137 .029 .953 137 .000 
yes .138 16 .200* .962 16 .705 
Ultra_VIS
C 
no .113 137 .000 .939 137 .000 
yes .139 16 .200* .958 16 .621 
Ultra_tot
al 
no .086 137 .015 .956 137 .000 
yes .124 16 .200* .970 16 .835 
Height no .077 137 .044 .993 137 .706 
yes .158 16 .200* .955 16 .573 
Weight no .136 137 .000 .922 137 .000 
yes .101 16 .200* .983 16 .981 
BMI no .109 137 .000 .932 137 .000 




BICEP no .140 137 .000 .917 137 .000 
yes .209 16 .059 .923 16 .188 
TRICEP no .091 137 .008 .951 137 .000 
yes .091 16 .200* .979 16 .958 
SUBSCAP no .150 137 .000 .880 137 .000 
yes .157 16 .200* .965 16 .750 
ILIAC no .108 137 .001 .961 137 .001 
yes .167 16 .200* .916 16 .146 
SUPRA no .107 137 .001 .898 137 .000 
yes .147 16 .200* .931 16 .255 
ABDO no .081 137 .027 .928 137 .000 
yes .151 16 .200* .951 16 .498 
THIGH no .100 137 .002 .953 137 .000 
yes .239 16 .015 .923 16 .186 
CALF no .104 137 .001 .916 137 .000 
yes .219 16 .039 .925 16 .205 
TOTAL no .108 137 .000 .941 137 .000 
yes .154 16 .200* .947 16 .437 
APPENDI
CULAR 
no .114 137 .000 .939 137 .000 
yes .103 16 .200* .970 16 .834 
TRUNK no .120 137 .000 .934 137 .000 
yes .191 16 .122 .892 16 .061 
MUAC no .102 137 .001 .961 137 .001 
yes .188 16 .133 .852 16 .015 
MAMC no .093 137 .006 .970 137 .004 
yes .246 16 .011 .744 16 .001 
WST no .122 137 .000 .919 137 .000 
yes .138 16 .200* .942 16 .377 
HIP no .104 137 .001 .935 137 .000 
yes .144 16 .200* .936 16 .302 
TOTAL_A
CTIVITY 
no .094 137 .005 .936 137 .000 
yes .167 16 .200* .881 16 .040 
SEDENTA
RY 
no .342 137 .000 .664 137 .000 
yes .287 16 .001 .839 16 .010 
LIGHT no .042 137 .200* .995 137 .929 
yes .093 16 .200* .973 16 .885 
MODERA
TE 
no .163 137 .000 .816 137 .000 
yes .174 16 .200* .855 16 .016 
VIGORO
US 
no .383 137 .000 .428 137 .000 
yes .332 16 .000 .585 16 .000 
Total_lig
htplus 
no .071 137 .087 .945 137 .000 
yes .165 16 .200* .891 16 .058 
househol
d 
no .163 137 .000 .867 137 .000 
yes .173 16 .200* .866 16 .024 
occupati
onal 
no .145 137 .000 .897 137 .000 







sports no .160 137 .000 .852 137 .000 
yes .173 16 .200* .873 16 .031 
transport no .189 137 .000 .856 137 .000 
yes .321 16 .000 .533 16 .000 
inactive no .243 137 .000 .684 137 .000 
yes .293 16 .001 .797 16 .002 
%body fat no .105 152 .000 .921 152 .000 
 yes .145 18 .200 .978 18 .921 
*. This is a lower bound of the true significance. 




c) All continuous data split into LGA and non-LGA 






df Sig. Statistic df Sig. 
Age_bo
oking 
normal .048 130 .200* .986 130 .201 
LGA .119 23 .200* .958 23 .431 
Gravida normal .216 130 .000 .794 130 .000 
LGA .248 23 .001 .836 23 .002 
Parity normal .234 130 .000 .824 130 .000 
LGA .272 23 .000 .787 23 .000 
OGTT_d
ays 
normal .275 130 .000 .450 130 .000 
LGA .135 23 .200* .844 23 .002 
OGTT_
weeks 
normal .277 130 .000 .450 130 .000 
LGA .140 23 .200* .845 23 .002 
OGTT_0 normal .175 130 .000 .631 130 .000 
LGA .195 23 .023 .929 23 .102 
OGTT_1 normal .066 130 .200* .984 130 .139 
LGA .170 23 .084 .954 23 .358 
OGTT_2 normal .069 130 .200* .991 130 .612 
LGA .123 23 .200* .964 23 .538 
PGAUC normal .060 130 .200* .983 130 .103 
LGA .168 23 .092 .958 23 .415 
Birth_w
eight 
normal .089 130 .013 .948 130 .000 




normal .070 130 .200* .960 130 .001 
LGA .177 23 .058 .961 23 .494 
APGAR
@1 
normal .510 130 .000 .317 130 .000 
LGA .385 23 .000 .429 23 .000 
APGAR
@5 
normal .521 130 .000 .320 130 .000 
LGA .405 23 .000 .618 23 .000 
GA_day
s 
normal .158 130 .000 .838 130 .000 
LGA .096 23 .200* .976 23 .827 
Ultra_S
UB 
normal .084 130 .025 .960 130 .001 
LGA .096 23 .200* .974 23 .786 
Ultra_V
ISC 
normal .110 130 .001 .940 130 .000 
LGA .123 23 .200* .956 23 .390 
Ultra_t
otal 
normal .094 130 .007 .957 130 .000 
LGA .082 23 .200* .960 23 .454 
Height normal .051 130 .200* .994 130 .844 
LGA .156 23 .153 .885 23 .013 
Weight normal .110 130 .001 .945 130 .000 




BMI normal .096 130 .005 .952 130 .000 
LGA .243 23 .001 .883 23 .011 
BICEP normal .121 130 .000 .931 130 .000 
LGA .204 23 .014 .884 23 .012 
TRICEP normal .086 130 .019 .956 130 .000 
LGA .124 23 .200* .961 23 .488 
SUBSCA
P 
normal .135 130 .000 .906 130 .000 
LGA .185 23 .039 .863 23 .005 
ILIAC normal .106 130 .001 .963 130 .001 
LGA .087 23 .200* .976 23 .838 
SUPRA normal .110 130 .001 .908 130 .000 
LGA .097 23 .200* .965 23 .571 
ABDO normal .076 130 .063 .932 130 .000 
LGA .086 23 .200* .978 23 .877 
THIGH normal .089 130 .014 .962 130 .001 
LGA .136 23 .200* .938 23 .163 
CALF normal .097 130 .004 .928 130 .000 
LGA .110 23 .200* .942 23 .203 
TOTAL normal .097 130 .004 .950 130 .000 




normal .113 130 .000 .950 130 .000 
LGA .118 23 .200* .954 23 .352 
TRUNK normal .113 130 .000 .944 130 .000 
LGA .131 23 .200* .962 23 .499 
MUAC normal .100 130 .003 .939 130 .000 
LGA .150 23 .198 .981 23 .928 
MAMC normal .102 130 .002 .917 130 .000 
LGA .100 23 .200* .981 23 .915 
WST normal .103 130 .002 .934 130 .000 
LGA .153 23 .175 .947 23 .255 
HIP normal .088 130 .015 .955 130 .000 




normal .100 130 .003 .932 130 .000 
LGA .196 23 .022 .915 23 .052 
SEDENT
ARY 
normal .332 130 .000 .683 130 .000 
LGA .319 23 .000 .785 23 .000 
LIGHT normal .038 130 .200* .993 130 .794 
LGA .124 23 .200* .949 23 .285 
MODER
ATE 
normal .167 130 .000 .812 130 .000 
LGA .217 23 .006 .868 23 .006 
VIGOR
OUS 
normal .384 130 .000 .395 130 .000 
LGA .383 23 .000 .505 23 .000 
Total_li
ghtplus 
normal .070 130 .200* .944 130 .000 






normal .152 130 .000 .867 130 .000 
LGA .214 23 .008 .822 23 .001 
occupat
ional 
normal .137 130 .000 .887 130 .000 
LGA .167 23 .097 .898 23 .023 
sports normal .175 130 .000 .819 130 .000 
LGA .149 23 .200* .934 23 .130 
transpo
rt 
normal .192 130 .000 .817 130 .000 
LGA .254 23 .000 .794 23 .000 
inactive normal .237 130 .000 .699 130 .000 
LGA .211 23 .009 .826 23 .001 
% body 
fat 
normal .088 175 .002 .944 175 .000 
 LGA .152 25 .142 .931 25 .091 
*. This is a lower bound of the true significance. 












Table showing inspection of multicollinearity for independent variables included in binomial regression model presented in section 6.4.5.1. There 













B Std. Error Beta Lower Bound Upper Bound 
Zero-
order Partial Part Tolerance VIF 
1 (Constant) -.124 .173  -.714 .476 -.466 .218      
Abdominal SAT .088 .067 .206 1.307 .193 -.045 .220 .257 .106 .100 .233 4.292 
Abdominal VAT .179 .070 .295 2.543 .012 .040 .318 .295 .203 .194 .431 2.319 
Bicep SFT .000 .007 .011 .060 .952 -.014 .014 .171 .005 .005 .183 5.478 
Tricep SFT -.002 .007 -.064 -.344 .731 -.016 .011 .131 -.028 -
.026 
.167 5.996 
Subscapular SFT .004 .005 .124 .729 .467 -.006 .013 .217 .059 .056 .200 5.011 





-.003 .006 -.124 -.544 .587 -.016 .009 .189 -.044 -
.041 
.112 8.934 
Abdominal SFT .000 .005 .008 .050 .960 -.009 .009 .186 .004 .004 .222 4.501 
Thigh SFT .000 .003 .021 .125 .901 -.006 .007 .158 .010 .010 .197 5.067 
Calf SFT -.005 .005 -.197 -
1.163 
.247 -.014 .004 .067 -.094 -
.089 
.203 4.927 




Weight .000 .003 .009 .053 .958 -.006 .006 .205 .004 .004 .213 4.685 
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